30618165	Positive_Correlation|chemicalD007501|diseaseD006527; Positive_Correlation|chemicalD007501|diseaseD005355; Positive_Correlation|chemicalD003300|diseaseD005355; Positive_Correlation|chemicalD003300|diseaseD006323; Association|chemicalD003300|diseaseD006527	diseaseD006323 in diseaseD006527 after curative liver transplantation: a life-threatening complication of myocardial chemicalD003300 excess?We report the case of a 38-year-old man who presented with diseaseD006323 1 year after curative liver transplantation for diseaseD006527. Clinical work-up proofed myocardial chemicalD003300 and chemicalD007501 accumulation using mass spectrometry, which led most likely to diseaseD005355 as visualized by cardiovascular magnetic resonance (unprecedented delayed enhancement pattern) and endomyocardial biopsy. Consequently, diseaseD006323 due to diseaseD014693 and subsequent episodes of sustained diseaseD017180 were considered as primary cardiac manifestation of diseaseD006527. This can, as illustrated by our case, occur even late after curative liver transplantation, which is an important fact that treating physicians should be aware of during clinical follow-up of these 9606.
31570646		Teaching Video NeuroImages: Slow diseaseD009207 in subacute diseaseD013344 and fulminant diseaseD006527.
33443665	Negative_Correlation|chemicalD003300|diseaseD009336; Association|diseaseD009336|ncbi847; Association|diseaseD006527|ncbi847; Association|chemicalD003300|diseaseD006527; Positive_Correlation|diseaseD009336|ncbi3552; Positive_Correlation|diseaseD009336|ncbi7124	Study on different pathogenic factors in different disease stages of 9606 with diseaseD006527.OBJECTIVE: To investigate in different stages of 9606 with diseaseD006527 (diseaseD006527), there are different pathogenic factors such as diseaseD013651 deposition, oxidative stress, and diseaseD007249 response in the brain. METHODS: A total of 32 untreated diseaseD006527 9606 and 10 normal controls were enrolled in the study. The diseaseD009461 were evaluated using the modified Young scale. Liver function, diseaseD013651 metabolism, susceptibility-weighted imaging (SWI), diffusion tensor imaging (DTI), and magnetic resonance spectroscopy (MRS) examination were done. The clinical disease stages were divided into chemicalD008670 deposition period, fiber damage period, and diseaseD009336 period according to the imaging results. The content of 24-h urine chemicalD003300, serum chemicalD003300, and serum chemicalD007501; and the levels of ncbi847 (ncbi847), glutathione peroxidase (GSH-PX), chemicalD008315 (chemicalD008315), chemicalD009569 (NO), ncbi4843 (NOS), ncbi6647 (ncbi6647), interleukin (ncbi3552), and ncbi7124 (ncbi7124) were detected. RESULTS: The contents of urinary chemicalD003300 in diseaseD006527 9606 at diseaseD009336 stage were lower than those in 9606 at the diseaseD013651 deposition stage (P = 0.011) and diseaseD000071075 stage (P = 0.023). The contents of NOS (P = 0.039) and NO (P = 0.047) in diseaseD006527 9606 at the stage of diseaseD000071075 were higher than those of the normal control, while GSH-PX (P = 0.025) and ncbi847 (P = 0.041) were lower in the diseaseD009336 stage. In the stage of diseaseD009336, the levels of ncbi3552 (P = 0.030) and ncbi7124 were higher than those of the normal control (P = 0.042). The neurological symptom scores in 9606 with diseaseD000071075 (P = 0.013) and diseaseD009410 were higher than those with diseaseD013651 deposition (P = 0.026). CONCLUSION: There are different pathogenic factors in different stages of diseaseD006527. At the diseaseD009336 stage, chemicalD003300 deposition was decreased in diseaseD006527 9606. In the stage of diseaseD000071075 and diseaseD009336, there is oxidative stress injury in diseaseD006527 9606. In the diseaseD009336 phase, diseaseD006527 9606 have an diseaseD007249 response.
29340742	Association|chemicalD003300|diseaseD006527; Association|chemicalD003300|diseaseD009386; Association|chemicalD003300|ncbi540; Association|diseaseD006527|ncbi540	[diseaseD006527].diseaseD006527 is a rare diseaseD009386 of chemicalD003300 metabolism. The diseaseD030342 is caused by various mutations in the chemicalD003300-transporting enzyme ncbi540, located mainly in the liver and brain. Clinical symptoms are highly variable, with any combination of hepatic and/or neurological diseaseD001523 manifestations. The age of onset varies from early childhood to young adults and can even be manifested in later ages. The clinical diagnosis is based on a combination of clinical, biochemical and molecular markers. Treatment using chelating agents and zinc salts is effective when started early or even better at presymptomatic stages of the disease.
28433106	Negative_Correlation|chemicalC020809|diseaseD006527; Association|chemicalD003300|diseaseD006527	Novel perspectives on diseaseD006527 treatment.diseaseD006527 is an autosomal-recessive diseaseC566858 causing diseaseD009461. Commonly used medical therapy shows satisfactory results with regard to diseaseD056486 but only limited effects in neurologically affected 9606. In recent years several new therapy options have been developed, showing promising results that might improve the management of diseaseD006527 in the near future. Optimization of treatment regimens depending on biochemical response pattern seems worthwhile, especially in the decoppering phase of therapy. The chelator chemicalC020809 (TTM) is a promising therapy option, currently under clinical investigation. TTM is a fast-acting and very potent chelator and appears to be associated with early diseaseD009422 after initiation of therapy to a lower extent than the drugs currently used. Treatment with nonchelating drugs characterized by alternative modes of action is under investigation, but restricted to animal or in vitro studies to date. This includes basic research studies demonstrating proof of principle for successful cell or gene therapy in diseaseD006527 in order to restore sufficient biliary chemicalD003300 excretion, even before the onset of disease.
31992405	Association|chemicalD003300|diseaseD030342; Association|chemicalD003300|diseaseD006527	diseaseD012893 in diseaseD006527: a systematic review and meta-analysis.STUDY OBJECTIVES: diseaseD006527 (diseaseD006527) is an diseaseD030342 of chemicalD003300 metabolism resulting in pathologic accumulation of chemicalD003300 in many organs and tissues. diseaseD012893 are highly prevalent in 9606 with diseaseD006527. However, both prevalence rates and severity of different diseaseD012893 in 9606 with diseaseD006527 vary widely. The aims of the current study were to systematically review and perform a meta-analysis of the association between diseaseD006527 and prevalent diseaseD012893, including diseaseD007319, diseaseD020187 (RBD), diseaseD006970 (diseaseD006970), diseaseD012891 (diseaseD012891), diseaseD012148 (diseaseD012148), diseaseD020189 (PLM), diseaseD002385 (diseaseD002385) and diseaseD020188, and objective sleep characteristics. METHODS: We performed a systematic search of PubMed, EMBase, the Cochrane Library, PsycINFO and ISI Web of Science for case-control studies. A total of 7 studies with 501 participants were included. RESULTS: We found that 54.1% of 9606 with diseaseD006527 experience diseaseD012893 and up to 7.65-fold higher odds compared to control 9606. Specifically, 9606 with diseaseD006527 had higher rates of RBD, diseaseD007319, and diseaseD006970 based on self-reported questionnaires. No differences were observed in terms of diseaseD012148, PLM, or diseaseD012891 between 9606 with diseaseD006527 and control 9606. Furthermore, objective diseaseD019958 based on polysomnographic studies included prolonged sleep onset latency and REM sleep onset latency, reduced total sleep time and sleep efficiency, higher percentage of stage N1 sleep and lower percentage of stage N2 sleep were observed in 9606 with diseaseD006527. CONCLUSIONS: Our study indicates that diseaseD012893 are frequent in 9606 with diseaseD006527. Future studies should examine the longitudinal association of diseaseD006527 with diseaseD012893.
30426382	Association|diseaseD006527|variant#540#p.C271*; Association|diseaseD056486|ncbi540; Positive_Correlation|variant#540#p.C271*|diseaseD006527; Association|variantrs572147914##|diseaseD006527; Association|diseaseD006527|ncbi540; Association|diseaseD006527|ncbi540	Molecular genetic diagnosis of diseaseD006527 by ARMS-PCR in a Pakistani family.diseaseD006527 is a rare diseaseD030342 caused by mutations in the ncbi540 gene causing diseaseD056486 due to copper accumulation. Early diagnosis and treatment could lead to improved survival of 9606. 9606 are best treated at pre-symptomatic stages but early diagnosis of diseaseD006527 is challenging owing to complex diagnosis. Evidence based genetic counseling requires characterization of underlying mutations in diseaseD006527 families. The aim was to characterize the causative mutation(s) in a Pakistani diseaseD006527 family by custom developed ARMS-PCR assay. A proband (19 years old boy) having diseaseD006527 with evidence of disease102510 ring, severe diseaseD001523 manifestations and clinical findings supported by biochemical abnormalities was followed. Following screening for 12 putative mutations in ncbi540, we identified a homozygous mutation (variant#540#p.C271*, variantrs572147914##) in proband by T-ARMS-PCR assay and validated by Sanger DNA sequencing. Furthermore, on screening of his family members, a younger sister (aged 9 years) was found to have the same homozygous mutation even though she was clinically asymptomatic except for a light disease102510 ring. Parents were heterozygous for this mutation and an elder brother was homozygous normal. Molecular diagnosis by PCR based assays (M-ARMS-PCR and T-ARMS-PCR) is cost effective, reliable, and efficient for preliminary screening of mutations in the ncbi540 gene in developing countries like Pakistan, which can be successfully applied to diseaseD006527 families for genetic testing and follow-up evidence based genetic counseling.
33275388		A New Onset of diseaseD001714 in a 49-Year-Old Man: An Interesting Case of diseaseD006527.diseaseD006527 is a rare diseaseC535468 that generally occurs in individuals between 5 and 35 years of age. Common clinical manifestations are diseaseD001523. Roughly, 4% of all cases occur in 9606 over 40 years of age and, among these 9606, the presenting symptoms are generally diseaseC000631768, which often leads to misdiagnosis as a diseaseD001523 and a delay in correct diagnosis. This report presents the case of a 49-year-old man with no formal diseaseD001523 history who presented with a new onset of diseaseD001714. We outline the distinctive characteristics that appeared inconsistent with a diseaseD001523 and pointed toward secondary diseaseD001714. Despite low serum ncbi1356, the absence of diseaseD001927 more typical of diseaseD006527 on magnetic resonance imaging led a neurology consultant to advise that the diagnosis was likely primarily diseaseD001523. Due to atypical components of the 9606's presentation, such as his late age of onset for diseaseD001714 and acute diseaseD003072, the diseaseD001523 team advocated for further diagnostic workup. The subsequent evaluation confirmed diseaseD006527 based on specific diseaseD056486 and further chemicalD003300 studies. In addition, once diagnosed, the management of diseaseD006527 involves distinct clinical considerations given 9606' presumed vulnerability to neurological side effects. This case illustrates the role diseaseD001523 providers play in advocating for diagnostic workup in 9606 with atypical presentations of primary diseaseD001523 and the distinct diagnostic and treatment considerations associated with diseaseD006527.
29274796		[Compliance with treatment in diseaseD006527: On the interest of a multidisciplinary closer follow-up].BACKGROUND: Compliance with treatment is very important for 9606 who suffer from diseaseD006527, a rare diseaseD030342. They can benefit a long-life and effective treatment. The purpose of our study is to identify the level of compliance in diseaseD006527 9606 and features associated with compliance as well. METHODS: This is a prospective study carried out in the National Reference Center for diseaseD006527 (based in Paris and Lyon) over a 8 months period. 9606 were evaluated on the first (M0) and last month (M8) with a questionnaire evaluating the number of missed treatment doses, a self-questionnaire collecting the reasons for non-compliance, and analogic scales analyzing the doctor-9606 relationship and their behavior towards the treatment. The severity of diseaseD003866 symptoms was investigated by the Beck diseaseD003866 Inventory (BDI). A detailed phone call interview was conducted by a psychologist every two months to evaluate their compliance and feeling. RESULTS: Thirty-nine 9606 were included. The mean age of 9606 was 34 years (+-9.9). At M0, 84.6% had a poor compliance with treatment. They were diagnosed more recently (P=0.049) with a higher proportion involving diseaseD009461 (P=0.007). Age, the type of treatment and the quality of the doctor-9606 relationship were not associated with the outcome; 38.5% suffered from diseaseD003866. At M8, 56.8% of 9606 were poor compliants and 21.6% presented diseaseD003866. CONCLUSION: diseaseD006527 9606 have important problems with compliance, without necessary being diseaseD003866. A close follow-up may help them become compliant, particularly those with diseaseD009461.
31277686		Social and demographic characteristics of a Polish cohort with diseaseD006527 and the impact of treatment persistence.BACKGROUND: diseaseD006527 (diseaseD006527) is a diseaseD030342 involving diseaseC535468, which presents with hepatic, diseaseD009461, and/or diseaseD001523 manifestations. diseaseD006527 requires lifelong pharmacotherapy and treatment persistence may be problematic. We studied social characteristics, education, and work-related activities and how they are affected by diseaseD006527 symptoms and treatment persistence. METHODS: In a cross-sectional study, data on demographic characteristics, achieved education level, household and marital status, plus a primary source of income were collected from 202 Polish subjects (mean +- standard deviation age of 36.4 +- 9.9 years at assessment) with diseaseD006527. RESULTS: Overall, diseaseD006527 appeared to have a negative impact on achieved level of education and influenced the ability to work as compared with the general Polish population. 9606 with diseaseD009461 manifestations less often achieved upper-secondary/post-secondary or higher education compared with those with diseaseD012877 (65.5% vs. 83.6%; p = 0.003). They also significantly less frequently stated salary (19.6% vs. 56.2%; p < 0.0001) as the primary income and more often were on diseaseD009069 pension (53.3% vs. 26.0%; p = 0.0003). The percentage of married 9606 with diseaseD006527 appeared lower than in the general population (47.0% vs. 54.6%), although the difference was not significant (p = 0.2). The 27.6% of 9606 who were non-persistent with diseaseD006527 treatment less frequently achieved upper/post-secondary or higher education compared with persistent 9606 (66.0% vs. 76.3%; NS) and their primary source of outcome was significantly less often a salary (18.9% vs. 40.3%; p = 0.001). CONCLUSIONS: diseaseD009461 manifestations had an adverse effect on education level and work ability. Treatment non-persistence had a further negative impact regardless of the disease form. 9606 with diseaseD006527 should receive appropriate treatment, with the need for persistence emphasized and monitored to avoid a detrimental effect on their lives.
37028691		Vascular Changes in Macula, Optic Disc, and diseaseD002833 in diseaseD006527: A Cross-sectional Optical Coherence Tomography Angiography Study.
32520831		Pediatric diseaseD006527 Presenting as diseaseD017114: An Individual 9606 Data Meta-analysis.OBJECTIVES: diseaseD006527 (diseaseD006527) presenting as diseaseD017114 (diseaseD017114) is rare and typically fatal without liver transplantation (LT). Its rarity has hindered comprehensive studies. We undertook an individual 9606 data meta-analysis to characterize a cohort of pediatric 9606 presenting with diseaseD017114 whose final diagnosis was diseaseD006527 to examine outcomes and identify predictors of poor outcomes. METHODS: Database searches were conducted in PubMed, ScienceDirect, and Google Scholar, restricted to English-language articles published between January 1984 and May 2018. Articles were excluded if pediatric (<18 years old) data were not extractable or if LT was not readily available at reporting institutions. Extracted data included clinical and biochemical characteristics, genotype, treatment, and outcome. RESULTS: Data were available on 249 subjects from 52 articles, plus 7 additional subjects identified from our institution's diseaseD006527 database (N = 256). Females represented 69% (n = 170/245). Median age at presentation was 13.4 years (n = 204, range 4.0-17.9). Of the total 256 subjects, 87% underwent LT, 11% achieved spontaneous recovery and 2% diseaseD003643 before LT. International normalized ratio >2.0 at presentation was a predictor of LT/diseaseD003643 (odds ratio 7.6, 95% confidence interval 1.5-28), with a trend observed for diseaseD006501 (diseaseD006501) (odds ratio 4.18, 95% confidence interval 0.99-18). Arithmetic diagnostic scores proved inferior in the pediatric age-bracket compared to adults. CONCLUSIONS: This large international pediatric cohort has permitted an individual 9606 data analysis of diseaseD006527 presenting as diseaseD017114. Notably, 11% of subjects achieved spontaneous survival; the rest required LT. diseaseD001778 (international normalized ratio >2:0) and diseaseD006501 at presentation heralded poor outcomes. Further prospective studies may identify additional early predictors of outcomes.
31246682		diseaseD006527 in a Child With Mild Neuropsychiatric and diseaseD056486: A Challenging Diagnosis for a diseaseD009358.
34627751	Positive_Correlation|chemicalD003300|diseaseD006527; Association|diseaseD006527|ncbi11979; Positive_Correlation|chemicalD002784|ncbi11979; Association|chemicalD003300|ncbi11979	diseaseD005234 in the 10090 Model of diseaseD006527 Coincides with a Muted diseaseD007249 Response.diseaseD006527 (diseaseD006527) is caused by inactivation of the copper transporter ncbi11979 and chemicalD003300 accumulation in tissues. diseaseD006527 presentations vary from diseaseD005234 to diseaseD007249, diseaseD005355, and diseaseD017093. Diets influence the liver phenotype in diseaseD006527, but findings are inconsistent. To better understand the impact of excess calories on liver phenotype in diseaseD006527, the study compared C57BL/6J ncbi11979-/- and C57BL/6J 10090 fed for 12 weeks with Western diet or normal chow. Serum and liver metabolites, body fat content, liver histology, hepatic proteome, and chemicalD003300 content were analyzed. Wild-type and ncbi11979-/- livers showed striking similarities in their responses to Western diet, most notably down-regulation of chemicalD002784 biosynthesis, altered nuclear receptor signaling, and changes in cytoskeleton. Western diet increased body fat content and induced diseaseD005234 in males and females regardless of genotype; however, the effects were less pronounced in ncbi11979-/- 10090 compared with those in the wild type 10090. Although hepatic chemicalD003300 remained elevated in ncbi11979-/- 10090, diseaseD007249 was reduced. The diet diminished signaling by Rho GTPases, integrin, ncbi20309, and reversed changes in cell cycle machinery and cytoskeleton. Overall, high calories decreased diseaseD007249 response in favor of diseaseD005234 without improving markers of cell viability. Similar changes of cellular pathways during diseaseD005234 development in wild-type and ncbi11979-/- 10090 explain histologic overlap between diseaseD006527 and diseaseD065626 despite opposite chemicalD003300 changes in these disorders.
28193762		Teaching NeuroImages: Ocular findings in a 9606 with diseaseD006527 and diseaseD012851.
31345362	Association|chemicalD003300|diseaseD006527; Association|chemicalD007501|diseaseD006527; Association|chemicalD015032|diseaseD006527; Negative_Correlation|chemicalD013311|diseaseD006527	The effects of chemicalD007501 and zinc status on prognosis in pediatric diseaseD006527.OBJECTIVES: diseaseD006527 (diseaseD006527) is a diseaseD008659 leading to hepatic and extrahepatic chemicalD003300 deposition. Several studies have reported that besides chemicalD003300 (chemicalD003300), chemicalD007501 (chemicalD007501) and zinc (chemicalD015032) are also accumulated at varying levels in various tissues in diseaseD006527. However, there is not an adequate number of studies investigating the effects of chemicalD007501 and chemicalD015032 status on diseaseD006527 presentation and prognosis. We aimed to evaluate serum levels of ferritin (SFr), chemicalD003300 (SCu), and zinc (chemicalD013311) in diseaseD006527 and determine their role in disease presentation and prognosis. MATERIALS-METHOD: We retrospectively reviewed the medical records of 97 pediatric 9606 with diseaseD006527 who were diagnosed and followed at Inonu University Pediatric Gastroenterology, Hepatology and Nutrition Department between January 2006 and May 2017. Serum chemicalD003300 and chemicalD015032 levels were analyzed by using flame atomic absorption spectrophotometer. Ferritin was analyzed by chemiluminescence immunoassay method. RESULTS: Analysis of serum levels of the elements according to the type of presentation, there was no significant difference between the groups for ncbi1356. However, SCU, FSCu, SFr and 24 h urinary chemicalD003300 levels were significantly higher (p = 0.002, p = 0.003, p = 0.023 and p < 0.001, respectively) and chemicalD013311 and CSZn levels were significantly lower (fulminant diseaseD006527). p < 0.001, p < 0.001). There was a positive correlation between SFr, SCu serum levels and mortality scores (respectively, r: 0.501, 0.564 for disease615924, r:0.490, 0.504 for MELD, r: 0.345, 0.374 for Dhwan), and a negative correlation between chemicalD013311 level and mortality scores. (r:-0.650 for disease615924, r:-0.703 for MELD, r:-0.642 for Dhwan) We used the ROC curves to determine the worst prognosis for fulminant diseaseD006527. According to these limit values, we found that the sensitivity and specificity of FWD development was significantly higher. (for SZn sensitivity of 91.5%, a specificity of 100%, p=<0,001, for SCu predicted FWD development with a sensitivity of 100%, a specificity of 73.7%, p=<0,001, for SFr predicted FWD development with a sensitivity of 92.9%, a specificity of 66.2%, p < 0,001) CONCLUSION: Our study suggests that SFr, SCu, SZn levels might have prognostic importance for diseaseD006527.
32008504	Association|chemicalD003300|diseaseD006527	Effect of Liver Transplant on diseaseD009461 Manifestations and Brain Magnetic Resonance Imaging Findings in diseaseD006527.OBJECTIVES: diseaseD006527 is an diseaseD002869 recessive diseaseD009358 of chemicalD003300 metabolism. It leads to chemicalD003300 accumulation in various organs (liver, eye, brain) and deteriorates their functions. Symptoms usually appear in the second and third decades of life. diseaseD009461 symptoms and manifestations may appear 2 to 5 years after diseaseD017093, and diseaseD009461 symptoms are usually diseaseD009069. The main treatment objective is to decrease accumulation of chemicalD003300 by increasing urinary chemicalD003300 excretion. With early diagnosis and treatment, the quality of life of 9606 with diseaseD006527 evolves. In this study, we aimed to evaluate the effects of liver transplant on diseaseD009461 manifestations and radiologic findings in 9606 with diseaseD006527. MATERIALS AND METHODS: Since 1988, our center has performed 642 liver transplant procedures. Fifty-three 9606 with diseaseD006527 received a liver transplant during this period, with 15 adults 9606 included in our study. All study 9606 were evaluated by the same neurologist and radiologist. diseaseD014202 was scored by the glass scale test. Radiologic evaluations were made by cranial magnetic resonance imaging. RESULTS: Before liver transplant, 4/15 study 9606 had diseaseD014202. In 1 9606, diseaseD014202 was accompanied by diseaseD004421; the 9606's imaging findings and diseaseD009461 manifestations had regressed posttransplant. In the other 3 study 9606 with diseaseD014202, diseaseD014202 decreased without any change in imaging findings. New-onset diseaseD014202 was seen in 1 9606 after liver transplant, but this 9606 had no observed imaging changes. This situation was correlated with immunosuppressive therapy. CONCLUSIONS: diseaseD009461 recovery can be achieved in 9606 with diseaseD006527 with early diagnosis and treatment. Radiologic findings can be improved after therapy.
34091542	Positive_Correlation|diseaseD006527|variant##p.H1069Q; Negative_Correlation|chemicalD014266|diseaseD006527; Negative_Correlation|chemicalD010396|diseaseD006527	Pediatric diseaseD006527: Phenotypic, Genetic Characterization and Outcome of 182 Children in France.OBJECTIVES: To describe a cohort of diseaseD006527 (diseaseD006527) pediatric cases, and to point out the diagnostic particularities of this age group and the long-term outcome. METHODS: Clinical data of 182 pediatric 9606 included in the French diseaseD006527 national registry from 01/03/1995 to 01/06/2019 were gathered. RESULTS: Diagnosis of diseaseD006527 was made at a mean age of 10.7 +- 4.2 years (range 1-18 years). At diagnosis, 154 9606 (84.6%) had diseaseD012877, 19 (10.4%) had diseaseD009461, and 9 9606 (4.9%) were asymptomatic. The variant##p.H1069Q mutation was the most frequently encountered (14% of 9606).Neurological 9606 were diagnosed at least 1 year after they presented their first symptoms. At diagnosis, the median urinary chemicalD003300 excretion (UCE) was 4.2 mumol/24 hours (0.2-253). The first-line treatment was chemicalD010396 (chemicalD010396) for 131 (72%) 9606, zinc salts for 24 (13%) 9606, and chemicalD014266 for 17 (9%) 9606. Liver transplantation was performed in 39 (21.4%) 9606, for hepatic indications in 33 of 39 9606 or for diseaseD009422 in 6 of 39 9606, mean Unified diseaseD006527 Rating Scale of the latter went from 90 +- 23.1 before liver transplantation (LT) to 26.8 +- 14.1 (P < 0.01) after a mean follow-up of 4.3 +- 2.5 years. Overall survival rate at 20 years of follow-up was 98%, 9606 and transplant-free combined survival was 84% at 20 years. CONCLUSION: Diagnosis of diseaseD006527 can be challenging in children, particularly at the early stages of diseaseD008107 and in case of neurological presentation; hence the support of clinical scores and genetic testing is essential. Diagnosis at early stages and proper treatment ensure excellent outcomes, subject to good long-term treatment compliance. LT is a valid option for diseaseD058625 not responding to treatment and can be discussed for selected cases of diseaseD009422.
32618564	Association|chemicalD003300|diseaseC535468; Association|diseaseD006527|ncbi540; Positive_Correlation|chemicalD003300|diseaseD006527	[Acute diseaseD006461 crisis revealed a diseaseD006527].diseaseD006527 is a rare diseaseD030342 of diseaseC535468 metabolism that affects liver and brain due to chemicalD003300 tissue accumulation. The mechanism involved is based on mutations of the ncbi540 gene. Children have predominant hepatic manifestations while adult are more often diagnosed by diseaseD001523. However, others features are diseaseC557674, diseaseD012213 and diseaseD000743. We report the diagnostic of diseaseD006527 in a 14 years old girl and her sibling after investigation of diseaseD000743, diseaseD048550, and diseaseD017674.
38385422	Positive_Correlation|chemicalD016559|diseaseD056486; Positive_Correlation|chemicalD016559|diseaseD002779; Positive_Correlation|chemicalD016559|diseaseD017093	Management of chemicalD016559-Induced diseaseD064420 With Normal Serum Levels After Liver Transplant.diseaseD056486 after liver transplant occurs in 1.7% of 9606. chemicalD016559 is an effective immunosuppressant that is used to treat acute rejection. Although rare, it can cause diseaseD064420, which is demonstrated by diseaseD017093. Here, we present a case of a young male 9606 who was diagnosed with diseaseD006527, had penicillaminechelating therapy, and underwent living related liver transplant. Within 1 month posttransplant, he developed deranged, predominantly diseaseD002779 pattern liver function tests. Laboratory parameters showed total chemicalD001663 of 1.12 mg/ dL, alanine aminotransferase of 553 IU/L, ncbi2678 of 624 IU/L, and chemicalD016559 level of 10.2 ng/mL. After thorough evaluation, a liver biopsy was performed. Liver biopsy showed hepatocellular diseaseD009336 with centrilobular diseaseD002779 without any evidence of graft rejection. However, with normal level of chemicalD016559, the biopsy was suggestive of diseaseD056486. Thus, chemicalD016559 dose was reduced, resulting in improved liver function tests and 9606 discharge from the hospital. chemicalD016559 is an effective immunosuppressant after liver transplant and has the ability to treat early acute rejection. The 9606's liver biopsy showed hepatocellular diseaseD009336 with centrilobular diseaseD002779 without any evidence of graft rejection. diseaseD017093 after chemicalD016559 usually resolves after dose reduction or by switching to another agent. With demonstrated chemicalD016559-induced diseaseD064420 in liver transplant recipients, despite normal serum levels, transplant physicians should keep high index of suspicion regarding diseaseD064420 in the posttransplant setting.
32662046	Association|diseaseD006527|ncbi3569; Positive_Correlation|chemicalD018698|diseaseD006527; Association|diseaseD006527|ncbi3586; Association|diseaseD006527|ncbi3576; Association|diseaseD006527|ncbi7124; Negative_Correlation|chemicalD005978|diseaseD006527; Positive_Correlation|chemicalD008315|diseaseD006527	diseaseD009069 in diseaseD006527: Correlation with MRI and Biomarkers of diseaseD002280.To report the phenomenology of diseaseD009069 (MD) in neurological diseaseD006527 (diseaseD006527), and correlate these with MRI, and biomarkers of oxidative stress, excitotoxicity, and diseaseD007249. Eighty-two 9606 were included, and their phenomenology of MD was categorized. The severity of diseaseD004421 was assessed using the Burke-Fahn-Marsden score, and diseaseD002819, diseaseD001264, diseaseD009207, and diseaseD014202 on a 0-4 scale. The MRI changes were noted. Serum chemicalD018698, cytokines, and oxidative stress markers were measured. diseaseD009069 were noted in 78/82 (95.1%) 9606 and included diseaseD004421 in 69 (84.1%), diseaseD002819 in 31 (37.8%), diseaseD014202 in 24 (29.3%), diseaseD010302 in 19 (23.2%), diseaseD001264 in 13 (15.9%), and diseaseD009207 in 9 (11.0%) 9606. diseaseD004421 was more frequently observed in the 9606 with thalamic (76.8 vs 23.2%), globus pallidus (72.0 vs 28.0%), putamen (69.5 vs 30.5%), caudate (68.3 vs 31.7%) and brainstem (61.0 vs 39.0%) involvement, and diseaseD014202 with cerebellar involvement (37.5 vs 5.2%). The median age of onset of diseaseD009461 was 12 (5-50) years. diseaseD006527 9606 had higher levels of chemicalD008315 (chemicalD008315), chemicalD018698, and cytokines (ncbi3569, ncbi3576, ncbi3586, and ncbi7124) and lower levels of chemicalD005978 and total antioxidant capacity (TAC) compared with the controls. Serum chemicalD018698, ncbi3569, ncbi3576, and plasma chemicalD008315 levels were increased with increasing neurological severity, while chemicalD005978 and TAC levels decreased. The severity of diseaseD004421 related to the number of MRI lesions. MD is the commonest diseaseD009461 in diseaseD006527. Oxidative stress, chemicalD018698, and cytokine levels are increased in diseaseD006527 and correlate with neurological severity.
30028785	Association|diseaseD065290|ncbi213	Transplant-free Survival in diseaseD008107 Presenting as diseaseD017114 in Childhood.BACKGROUND: In adults, the absence of a preexisting diseaseD008107 (diseaseD008107) is required to diagnose diseaseD017114 (diseaseD017114). The pediatric classification does not consider this aspect, thus previous studies pooled together children with diseaseD017114 and children with unknown diseaseD008107 presenting with diseaseD017114 (diseaseD065290). We aimed to compare prevalence, features, and outcome of children with diseaseD065290 to those with a proper diseaseD017114. METHODS: 9606 admitted between 1996 and 2017 because of diseaseD017114 defined by diseaseD017114 criteria (raised transaminases, International Normal Ratio >=2.0, no history of diseaseD008107) were classified as diseaseD065290 if diagnosed with diseaseD019693, diseaseD006527, diseaseD006502, 10407 reactivation, diseaseD008661. The others were classified as diseaseD017114. RESULTS: Seventy-four children (median age, 4 years; 1.0-8.8; male/female, 36/38] with diseaseD017114 were found; 18 of <1 year of age were excluded. Fifty-six (median age, 6.6 years; 2.7-11.7; male/female, 23/33], 22 with diseaseD065290 (diseaseD019693, n = 14; diseaseD006527, n = 6; diseaseD008661, n = 2) and 34 with diseaseD017114 (paracetamol overdose, n = 6; diseaseD014777, n = 3; diseaseD009145, n = 5; indeterminate, n = 20) were compared. In diseaseD065290, the median age at onset was higher, ncbi2875, ncbi213, and International Normal Ratio levels were lower, diseaseD013163, diseaseD001201, and diseaseD005355 were more common (all P < 0.01). On multivariate analysis, the diagnosis of diseaseD065290 was an independent predictor of transplant-free survival (P = 0.006). CONCLUSIONS: In children, diseaseD065290 is common, has peculiar features, and is associated with a favorable outcome. This study suggests the need to distinguish this entity from other forms of diseaseD017114 in children.
34934154		Metallothionein immunohistochemistry has high sensitivity and specificity for detection of diseaseD006527.Diagnosis of diseaseD006527 (diseaseD006527) can be difficult because of its protean clinical presentations, but early diagnosis is important because effective treatment is available and can prevent disease progression. Similarly, diagnosis of diseaseD006527 on liver biopsy specimens is difficult due to the wide range of histologic appearances. A stain that could help identify diseaseD006527 9606 would be of great value. The goal of this study was to use mass spectrometry-based proteomics to identify potential proteins that are differentially expressed in diseaseD006527 compared to controls, and could serve as potential immunohistochemical markers for screening. Several proteins were differentially expressed in diseaseD006527 and immunohistochemical stains for two (metallothionein (MT) and cytochrome C oxidase chemicalD003300 chaperone (ncbi10063)) were tested and compared to other methods of diagnosis in diseaseD006527 including chemicalD003300 staining and quantitative chemicalD003300 assays. We found diffuse metallothionein immunoreactivity in all liver specimens from 9606 with diseaseD006527 (n = 20); the intensity of the staining was moderate to strong. This staining pattern was distinct from that seen in specimens from the control groups (none of which showed strong, diffuse staining), which included diseases that may be in the clinical or histologic differential of diseaseD006527 (diseaseD005234 (n = 51), diseaseD006525 (n = 40), diseaseD019693 (n = 50), diseaseD001660 (n = 42), and normal liver (n = 20)). ncbi10063 immunostain showed no significant difference in expression between the diseaseD006527 and control groups. MT had higher sensitivity than chemicalD012236 for diagnosis of diseaseD006527. While the quantitative liver chemicalD003300 assays also had high sensitivity, they require more tissue, have a higher cost, longer turnaround time, and are less widely available than an immunohistochemical stain. We conclude that MT IHC is a sensitive immunohistochemical stain for the diagnosis of diseaseD006527 that could be widely deployed as a screening tool for liver biopsies in which diseaseD006527 is in the clinical or histologic differential diagnosis.
31582009	Association|diseaseC531854|ncbi3077; Positive_Correlation|diseaseD006432|variantrs1800562##; Positive_Correlation|diseaseC531854|variantrs1800562##; Association|diseaseD006432|ncbi3077; Association|diseaseD006432|ncbi3077; Association|diseaseC531854|ncbi3077	Genetic Causes of diseaseD008107: When to Suspect a Genetic Etiology, Initial Lab Testing, and the Basics of Management.Genetic causes of diseaseD008107 lead to a wide range of presentations. This article describes diseaseD006432, diseaseD005878, diseaseD019896, diseaseD006527, diseaseC535933, BRIC, and diseaseC531854 The most common cause of diseaseD006432 is a variantrs1800562## mutation in the ncbi3077 gene. diseaseD005878 is a benign cause of indirect diseaseD006932. diseaseD019896 causes both diseaseD008171. diseaseD006527 can cause diseaseD020271 and diseaseD008107. Progressive diseaseC535932 and diseaseC535933 are rare causes of diseaseD002779. diseaseC531854 is a rare disease that can appear similar to diseaseD065626 in adults.
31077787	Association|chemicalD003300|diseaseD006527	Assessment of corneal and lens clarity in children with diseaseD006527.PURPOSE: To investigate the effect of chemicalD003300 accumulation on corneal and lens clarity in children with diseaseD006527 (diseaseD006527) compared to healthy children. METHODS: This multicenter cross-sectional study included 24 subjects with diseaseD006527 and 25 age-matched controls. Clinical and laboratory characteristics of the diseaseD006527 subjects were recorded. The Pentacam HR imaging system was used both for lens densitometry and corneal densitometry. RESULTS: Corneal densitometry values were higher in the posterior 6-10 mm (P = 0.021), posterior 10-12 mm (P < 0.001), posterior total diameter (P = 0.037), total thickness 10-12 mm (P = 0.032), and total thickness 6-10 mm zones and layers (P = 0.040) in the diseaseD006527 eyes than in control eyes. The lens densitometry values of zone 1 were higher in diseaseD006527 eyes (P < 0.001). There was a significant relationship between corneal densitometry values in the posterior 10-12 mm zones (P = 0.012; r = 0.527) and the duration of diseaseD006527 and liver chemicalD003300 content (P = 0.016; r = 0.507). A statistically significant correlation was also detected between lens densitometry values in zone 1 and diseaseD006527 duration (P = 0.018; r = 0.426). CONCLUSION: In this study cohort, children with diseaseD006527 had decreased corneal and lens clarity even in cases without Kayser-Fleischer rings and diseaseD002386. Densitometry measurements using Scheimpflug imaging provided detection of corneal and lens involvement in the early stages of diseaseD006527.
30691663	Negative_Correlation|chemicalD002794|diseaseD006527; Negative_Correlation|chemicalC000179|diseaseD006527; Association|chemicalD002794|diseaseD009461; Negative_Correlation|chemicalD003401|diseaseD006527; Association|chemicalC000179|diseaseD009461; Association|chemicalD003401|diseaseD009461	Brain magnetic resonance spectroscopy (MRS) as a diagnostic tool for detecting early neurological changes in children with diseaseD006527.PURPOSE: Although brain magnetic resonance spectroscopy (MRS) imaging findings in adult diseaseD006527 (diseaseD006527) have been explained in extensive details, a paucity of information currently exists regarding brain MRS imaging findings in pediatric diseaseD006527. The purpose of this study was to clarify the role of brain MRS in detecting early metabolite abnormalities in children with diseaseD006527. 9606 AND METHODS: A case-controlled prospective study included 26 children with diseaseD006527 and 26 healthy controls. All children were subjected to examination on a 1.5 T MRI scanner. The spectra of chemicalC000179 (chemicalC000179), chemicalD002794 (chemicalD002794), and chemicalD003401 (chemicalD003401), as well as the metabolite ratios of chemicalC000179/chemicalD002794, chemicalC000179/chemicalD003401, and chemicalD002794/chemicalD003401, were measured and compared between two groups. RESULTS: Eight 9606 revealed increased signal intensity in the basal ganglia at T1-weighted images. When compared with healthy controls, diseaseD006527 9606 showed a significant decrease (p <  0.05) in chemicalC000179 (63.8 +- 9.6 vs 97.6 +- 3.8), chemicalD002794 (46.7 +- 8.9 vs 87.3 +- 4.7), chemicalD003401 (44 +- 10.1 vs 81.9 +- 4.05), chemicalC000179/chemicalD002794 (1.92 +- 1.2 vs 3.34 +- 0.55), chemicalC000179/chemicalD003401 (1.29 +- 0.7 vs 2.46 +- 0.34), and chemicalD002794/chemicalD003401 (0.78 +- 0.4 vs 2 +- 0.13). 9606 complicated with diseaseD017093 showed a significant decrease in all previous parameters (p <  0.05) than 9606 without complications. 9606 with mixed diseaseD009461 showed a severe reduction in chemicalC000179, chemicalC000179/chemicalD003401, and chemicalC000179/chemicalD002794 compared with 9606 with diseaseD056486 only. CONCLUSION: MRS in pediatric diseaseD006527 detects early neurological changes even with normal MRI.
28578978	Negative_Correlation|chemicalD010396|diseaseD006527; Negative_Correlation|chemicalD010396|diseaseD008103; Negative_Correlation|chemicalD014266|diseaseD006527	Modality of treatment and potential outcome of diseaseD006527 in Taiwan: A population-based longitudinal study.BACKGROUND/PURPOSE: This study aimed to investigate the epidemiology, the preference of medication, and the potential outcome of diseaseD006527 in Taiwan. We aimed to provide better therapeutic options for 9606 with diseaseD006527 based on the data generated from this study. METHODS: We utilized the National Health Insurance Research Database (NHIRD), which stores clinical records of nearly 99% of Taiwan's residents. The database used is a random sample of two-million out of 23-million beneficiaries in Taiwan's NHIRD in 2005. The integrated medical records of these two-million cases were collected from 2000 to 2011. Subjects of diseaseD006527 were identified as those with International Classification of Diseases, Ninth Revision (ICD-9) code 275.1 and the specific prescription drugs (including chemicalD010396, zinc, and chemicalD014266) in either 9606 clinic or inpatient records. RESULTS: During the study period, 66 cases of diseaseD006527 were identified. The male to female ratio was 1.75. The average prevalence rate was 1.81 per 100,000 and the average annual diagnosis rate was 0.22 per 100,000. The diagnosis was mostly established at 20-24 and 10-14 years of age, followed by 25-29 years. Fifty four of all subjects (81.8%) started the treatment with chemicalD010396, compared with zinc (12.1%) and chemicalD014266 (6.1%). Among these 66 cases, 27 (40.9%) had diseaseD008103 and three (4.5%) underwent liver transplantation due to diseaseD017093. CONCLUSION: chemicalD010396 is still the most popular prescription of diseaseD006527, followed by zinc monotherapy. Although diseaseD056487 cannot be avoided, a favorable potential outcome is well demonstrated in this population-based study.
31167735	Positive_Correlation|chemicalD003300|diseaseD007249; Positive_Correlation|chemicalD003300|diseaseD005355; Association|chemicalD003300|diseaseD006527	diseaseD018281 in a 9606 with undiagnosed diseaseD006527.diseaseD018281 (diseaseD018281) is the second most common primary diseaseD009369. Although the frequency of diseaseD009369 is generally increased in diseaseD008107, diseaseD018281 rarely presents in diseaseD006527 (diseaseD006527). The incidence of diseaseD009369 in diseaseD006527 is only 1.2%, with diseaseD018281 accounting for 0.5%. A 66 year old male with history of diseaseD006973, diseaseD003920, and compensated cryptogenic diseaseD005355 presented with acute onset diseaseD004417 and pleuritic diseaseD002637. He was incidentally found to have a sizeable mass in the right hepatic lobe. Ultimately, a liver biopsy revealed dense demoplasia and increased mucin production, consistent with diagnosis of diseaseD018281. Biopsy also demonstrated increased chemicalD003300 deposition consistent with diseaseD006527, explaining the 9606's underlying diseaseD005355. Unlike other forms of diseaseD008107 where incidence of diseaseD006528 is increased, the lower rate of diseaseD009369 seen in diseaseD006527 may be explained by a protective effect of chemicalD003300 in diseaseD006527. chemicalD003300 acts to both directly stabilize DNA and inhibit angiogenesis. In this case, it is possible that the degree of chemicalD003300 deposition in his liver was mild, causing diseaseD005355 and the diseaseD007249 that caused his diseaseD018281. However, it may not have been sufficient to "protect" against development of diseaseD018281.
35443488	Association|diseaseD000086382|ncbi213; Association|chemicalD001663|diseaseD008103; Association|diseaseD008103|ncbi213	Comparison of diseaseD000086382 Index (NFI) with Aspartate aminotransferase to platelet ratio index (APRI) in diseaseD003924 9606 with diseaseD065626 (diseaseD065626).With India being the "diseaseD003920 capital of the world", diseaseD065626 (diseaseD065626) is becoming the most common cause of diseaseD017093. Varied prevalence of this disease in diseaseD003924 indicate variability in diseaseD065626 risk factors along with the particular diagnostic methods used. Investigations like liver biopsy and ultrasound abdomen have their limitations. Liver biopsy is invasive on the other hand ultrasound has less sensitivity. Several others are in the list, but are cost ineffective. Among the several non-invasive biomarkers, recently developed diseaseD000086382 Index (NFI) is a new addition. Newly developed NFI was developed by observing the various relationships and variations of serum chemicalD001663, alkaline phosphatase, platelet count and serum ncbi213 in diseaseD008103. MATERIAL: This hospital based observational cross section study was conducted from June 2020 to May 2021in 76 study population of Assam Medical College and Hospital. diseaseD003924 9606 having more than 18 years were included after consent. Alcoholics, pregnant 9606 and 9606 with secondary cause of diseaseD005234 [diseaseD006509, diseaseD019698, diseaseD006527, diseaseD019693, diseaseD007037, diseaseD013217, Parenteral nutrition, On medications like (chemicalD014635, corticosteroids, antivirals)] were excluded. diseaseD000086382 Index (NFI) were calculated by [Bilirubinx(ncbi250)2/Platelet count(ncbi213)2] in study population. Fibroscan 402 is used for diseaseD005355 stage assessment. Ziol transient elastography breaking point were used for staging of diseaseD005355 in study population according to Metavir system of diseaseD005355. Area under the curves of NFI and APRI for different diseaseD005355 stages were obtained by ROC curves using SPSS software edition 21.0. OBSERVATION: NFI and APRI where able to predict diseaseD005355 stage with correlation coefficient indices 0.5174 and 0.5369 respectively. Area under the ROC curve for NFI and APRI were 0.807 and 0.793 respectively for discriminating F0-F1 and above. Area under the ROC curve for discriminating F0-F2 and above for NFI and APRI were 0.814 and 0.810. Area under the ROC curve for discriminating F0-F3 and above for NFI and APRI were 0.935 and 0.913. CONCLUSION: Aggregate measures of performance across all possible classification threshold for NFI is better then APRI.
28162166	Association|chemicalD008670|diseaseD006527; Positive_Correlation|chemicalD007501|diseaseD006527; Positive_Correlation|chemicalD007501|diseaseD056486; Association|chemicalD008670|diseaseD056486	[Difference in imaging and chemicalD008670 metabolism between diseaseD056486 and cerebral type diseaseD006527].Objective: To evaluate the difference of chemicalD008670 metabolism, damage to structure and functional activity in brains between diseaseD056486 and cerebral type diseaseD006527 (diseaseD006527). Methods: Forty 9606 with diseaseD006527, including 20 with cerebral type and 20 with diseaseD056486 type, and 20 age-matched healthy controls in the First Affiliated Hospital, Sun Yat-sen University between Jul 2013 and May 2016 were enrolled.All study subjects underwent diffusion tensor imaging (DTI), resting state functional MRI (rs-fMRI) and susceptibility weighted imaging (SWI) of the brain.Six regions of interest (ROIs) were chosen.The values of fractional anisotropy (FA), lambda in ROIs were determined on DTI, FA and fiber volumes between ROIs were also determined on DTI.The values of amplitude of low frequency fluctuation (ALFF) and regional homogeneity (REHO) in ROIs were determined on rs-fMRI.The values of corrected phase (CP) were calculated on SWI.The chemicalD003300 and chemicalD007501 content were measured.The difference of imaging and chemicalD008670 metrics between cerebral type and diseaseD056486 type diseaseD006527 were evaluated. Results: DTI metrics differed between 9606 with the cerebral and diseaseD056486 types of diseaseD006527 values in the caudate nucleus, and thalamus were lower (P=0.037, 0.040), and REHO values in the caudate nucleus were lower (P=0.029), in 9606 of cerebral type than in diseaseD056486 type 9606.CP values of the right caudate nucleus and left putamen in cerebral type diseaseD006527 9606 were lower than in diseaseD056486 type 9606 (P=0.020, 0.23). The serum chemicalD007501 content of diseaseD056486 type diseaseD006527 9606 was higher than the normal (P=0.013), and the urine chemicalD003300 content was higher than the cerebral type 9606 (P=0.021). Conclusions: chemicalD008670 deposition and damage to the structure and functional activity in the brain may occur in diseaseD056486 type diseaseD006527 9606.The structural and functional activity diseaseD001925 in diseaseD056486 type is less severe than that in cerebral type 9606, while the chemicalD008670 deposition is not significant different between diseaseD056486 and cerebral type.
31113589	Negative_Correlation|chemicalD010396|diseaseD005355; Negative_Correlation|chemicalD010396|diseaseD017114	diseaseD017114 due to diseaseD006527: Eight Years of the National Liver Transplant Program in Uruguay.INTRODUCTION AND AIM: diseaseD006527 (diseaseD006527) is an uncommon cause of diseaseD017114 (diseaseD017114). Our aim was to describe clinical features, diagnostic findings, treatments, and outcomes of 9606 with diseaseD017114 due to diseaseD006527. MATERIAL AND METHODS: Retrospective medical record reviews of all 9606 with diseaseD017114 due to diseaseD006527 in eight years in Uruguay. RESULTS: diseaseD006527 was the cause of six (15%) of thirty-nine diseaseD017114 cases. All 9606 were females, with a mean age of 18 years. Four 9606 presented with hyperacute diseaseD017093 and two with diseaseD058186. diseaseD007565 was the main complaint of all 9606. Mean total chemicalD001663 (chemicalD001663), alkaline phosphatase (AP), ncbi26503, and ALT were 27.5 mg/dL, 45.5 lU/l, 156 IU/L, and 51 IU/L, respectively. ncbi1356 levels were low in four 9606, urinary cooper was high in four, and two had Kayser-Fleischer rings. All 9606 had Coombs-negative diseaseD000743, diseaseD058186, histochemical identifiable chemicalD003300, and advanced diseaseD005355 on liver histology. The average MELD score was 36. All 9606 were treated with chemicalD010396 and listed for urgent liver transplantation (LT). Prometheus  was performed in one 9606. Three 9606 diseaseD003643: two without LT and one after LT. Three 9606 survived: one without LT (New Wilson Index<11) and two with LT. The referral time to the program and the total time (referral plus waiting list time) were longer for non-survivors than for survivors (14 vs. 3 days and 23 vs. 8 respectively). CONCLUSION: All cases had typical clinical, analytical and histopathology characteristics. Early referral was determinant of prognosis.
30452922	Association|chemicalD003300|diseaseD017093; Association|chemicalD003300|diseaseD006527; Association|chemicalD003300|ncbi84557; Association|ncbi540|ncbi84557; Association|chemicalD003300|diseaseD030342; Association|diseaseD006527|ncbi2475; Association|diseaseD006527|ncbi540; Association|chemicalD003300|ncbi540; Association|diseaseC535468|ncbi540; Association|ncbi2475|ncbi540; Association|ncbi540|ncbi9776	Activation of Autophagy, Observed in diseaseD017093 Tissues From 9606 With diseaseD006527 and From ncbi540-Deficient Animals, Protects Hepatocytes From chemicalD003300-Induced Apoptosis.BACKGROUND & AIMS: diseaseD006527 (diseaseD006527) is an diseaseD030342 of chemicalD003300 metabolism that leads to copper accumulation and diseaseD064420 in the diseaseD017093 and brain. It is caused by mutations in the adenosine triphosphatase copper transporting beta gene (ncbi540), which encodes a protein that transports chemicalD003300 from hepatocytes into the bile. We studied ncbi540-deficient cells and animals to identify strategies to decrease diseaseC535468 in 9606 with diseaseD006527. METHODS: We used RNA-seq to compare gene expression patterns between wild-type and ncbi540-knockout 0027 cells exposed to chemicalD003300. We collected blood and diseaseD017093 tissues from ncbi11979-/- and ncbi11979+/- (control) 10116 (LPP) and 10090; some 10090 were given 5 daily injections of an autophagy inhibitor (spautin-1) or vehicle. We obtained diseaseD017093 biopsies from 2 9606 with diseaseD006527 in Italy and diseaseD017093 tissues from 9606 without diseaseD006527 (control). diseaseD017093 tissues were analyzed by immunohistochemistry, immunofluorescence, cell viability, apoptosis assays, and electron and confocal microscopy. Proteins were knocked down in cell lines using small interfering RNAs. Levels of chemicalD003300 were measured in cell lysates, blood samples, diseaseD017093 homogenates, and subcellular fractions by spectroscopy. RESULTS: After exposure to chemicalD003300, ncbi540-knockout cells had significant increases in the expression of 103 genes that regulate autophagy (including ncbi84557, known as ncbi84557) compared with wild-type cells. Electron and confocal microscopy visualized more autophagic structures in the cytoplasm of ncbi540-knockout cells than wild-type cells after chemicalD003300 exposure. Hepatocytes in diseaseD017093 tissues from 9606 with diseaseD006527 and from ncbi11979-/- 10090 and 10116 (but not controls) had multiple autophagosomes. In ncbi540-knockout cells, ncbi2475 (ncbi2475) had decreased activity and was dissociated from lysosomes; this resulted in translocation of the ncbi2475 substrate transcription factor EB to the nucleus and activation of autophagy-related genes. In wild-type 0027 cells (but not ncbi540-knockout cells), exposure to chemicalD003300 and amino acids induced recruitment of ncbi2475 to lysosomes. Pharmacologic inhibitors of autophagy or knockdown of autophagy proteins ncbi10533 and ncbi9776 induced and accelerated the death of ncbi540-knockout 0027 cells compared with wild-type cells. Autophagy protected ncbi540-knockout cells from chemicalD003300-induced death. CONCLUSION: ncbi540-deficient hepatocytes, such as in those in 9606 with diseaseD006527, activate autophagy in response to chemicalD003300 overload to prevent chemicalD003300-induced apoptosis. Agents designed to activate this autophagic pathway might decrease diseaseC535468 in 9606 with diseaseD006527.
33547549	Positive_Correlation|chemicalD003300|diseaseD006527	diseaseD006527 tissue classification and characterization using seven artificial intelligence models embedded with 3D optimization paradigm on a weak training brain magnetic resonance imaging datasets: a supercomputer application.diseaseD006527 (diseaseD006527) is caused by chemicalD003300 accumulation in the brain and liver, and if not treated early, can lead to severe disability and diseaseD003643. diseaseD006527 has shown diseaseD056784 (diseaseD056784) in the brain magnetic resonance scans (MRI) scans, but the diagnosis is challenging due to (i) subtle intensity changes and (ii) weak training MRI when using artificial intelligence (AI). Design and validate seven types of high-performing AI-based computer-aided design (CADx) systems consisting of 3D optimized classification, and characterization of diseaseD006527 against controls. We propose a "conventional deep convolution neural network" (cDCNN) and an "improved DCNN" (iDCNN) where rectified linear unit (ReLU) activation function was modified ensuring "differentiable at zero." Three-dimensional optimization was achieved by recording accuracy while changing the CNN layers and augmentation by several folds. diseaseD006527 was characterized using (i) CNN-based feature map strength and (ii) Bispectrum strengths of pixels having higher probabilities of diseaseD006527. We further computed the (a) area under the curve (AUC), (b) diagnostic odds ratio (DOR), (c) reliability, and (d) stability and (e) benchmarking. Optimal results were achieved using 9 layers of CNN, with 4-fold augmentation. iDCNN yields superior performance compared to cDCNN with accuracy and AUC of 98.28 +- 1.55, 0.99 (p < 0.0001), and 97.19 +- 2.53%, 0.984 (p < 0.0001), respectively. DOR of iDCNN outperformed cDCNN fourfold. iDCNN also outperformed (a) transfer learning-based "Inception V3" paradigm by 11.92% and (b) four types of "conventional machine learning-based systems": k-NN, decision tree, support vector machine, and random forest by 55.13%, 28.36%, 15.35%, and 14.11%, respectively. The AI-based systems can potentially be useful in the early diseaseD006527 diagnosis. Graphical Abstract.
28836933		diseaseD002543 Related With 5073 Species Following Deceased-Donor Liver Transplant.Early or late posttransplant diseaseD009894 are among the leading complications after liver transplant. The source of early posttransplant diseaseD009894 is usually the 9606, the implantation of an diseaseD007239 graft, contamination during a surgical procedure, or invasive interventions performed at the intensive care unit. A 10-year-old male 9606 with diseaseD006527 (Pediatric diseaseD058625 Score of 42, Child-Pugh score of 12, total chemicalD001663 40 mg/dL, platelet count 55000/mL, hemoglobin level 6.3 g/dL, albumin level 1.7 g/dL, urinary chemicalD003300 level 4305 mu/24 h) was closely monitored in the pediatric intensive care unit of our liver transplantation center for care of a worsened general status. A deceased-donor liver transplant was performed using a right lobe liver graft (ex vivo split) obtained through the national organ sharing network. The 9606 developed rightward diseaseD010262 and diseaseD003244 after the procedure and underwent cranial magnetic resonance imaging and computerized tomography examinations. The cranial magnetic resonance image, taken on the third postoperative day, revealed lesions consistent with diseaseD007238, and the computed tomography scan, taken on the eighth day, showed diseaseD002543. Decompressive craniotomy, which included diseaseD006406 drainage and catheter placement, was performed. Culture and histopathologic examinations of the diseaseD006406 material revealed a 5073 species of fungi. However, the 9606 diseaseD003643 before a definitive diagnosis was made. The aim of this report is to raise awareness on early posttransplant diseaseD009894 presenting with diseaseD020300 following liver transplant.
31611120		diseaseD006527 With Giant diseaseD013158 Caused by diseaseD005352 During Living Donor Liver Transplantation: A Case Report.diseaseD008103 can cause diseaseD013158 (diseaseD013158) that pose a threat to 9606 undergoing liver transplantation. However, liver transplantation with multiple diseaseD002532 including giant diseaseD013158 caused by arterial fragility has never been reported. We describe a 36-year-old man with decompensated diseaseD008103 due to diseaseD006527 that was complicated by giant diseaseD013158 and multiple diseaseD000783 in the bilateral renal arteries caused by diseaseD005352 (diseaseD005352). The maximal diameter of the triple snowball-shaped diseaseD013158 was 11 cm. We planned a 2-stage strategy consisting of a splenectomy with distal pancreatectomy to treat the diseaseD013158 and subsequent living donor liver transplantation (LDLT) to address the diseaseD008103. This strategy was selected to prevent fatal postoperative infectious diseaseD008107 caused by the potential development of diseaseD010185 during simultaneous procedures and to histopathologically diagnose the diseaseD020765 before LDLT to promote safe hepatic artery reconstruction. However, a postoperative diseaseD010185 did not develop after a splenectomy with distal pancreatectomy, and the pathologic findings of the artery indicated diseaseD005352. The 9606 underwent ABO-identical LDLT with a right lobe graft donated by his brother. Other than postoperative diseaseD017542 the left renal artery requiring emergency interventional radiology, the 9606 has remained free of any other diseaseD008107 and continues to do well at 2 years after LDLT.
29759592	Association|diseaseD018981|ncbi84317; Association|diseaseD018981|ncbi147007; Association|diseaseD008107|ncbi84317; Association|diseaseD052556|ncbi84317; Association|diseaseD006527|ncbi84317; Association|diseaseD018981|ncbi23545	ncbi84317-diseaseD018981: A new rare and misleading inherited cause of diseaseD008107.diseaseD018981 (diseaseD018981) linked to defects in Golgi apparatus homeostasis constitute an increasing part of these rare diseaseD030342. Among them, COG-diseaseD018981, ncbi23545-diseaseD018981, ncbi147007-diseaseD018981 and ncbi84317-diseaseD018981 have been shown to disturb Golgi vesicular trafficking and/or lumen pH acidification. Here, we report 3 new unrelated cases of ncbi84317-diseaseD018981 with emphasis on diagnosis difficulties related to strong phenotypic similarities with mitochondriopathies, diseaseD052556 and diseaseD006527. Indeed, while two individuals clinically presented with early and severe diseaseD008103 and diseaseD005355 associated with diseaseD009461, the other one "only" showed isolated and late severe diseaseD017093. Biological results were similar to previously described 9606, including diseaseD006937, elevated alkaline phosphatases and defects in chemicalD003300 metabolism. diseaseD018981 screening and glycosylation study finally led to the molecular diagnosis of ncbi84317-diseaseD018981. Besides pointing to the importance of diseaseD018981 screening in 9606 with unexplained and severe diseaseD008107, these reports expand the clinical and molecular phenotypes of ncbi84317-diseaseD018981. The hepatic involvement is particularly addressed. Furthermore, hypothesis concerning the pathogenesis of the diseaseD008107 and of major biological abnormalities are proposed.
28987261		diseaseD006527: Diagnosis, Treatment, and Follow-up.Consideration of a diagnosis of diseaseD006527 is still the critical factor in testing for and establishing disease diagnosis. In association with other clinical and biochemical tests, liver biopsy results and molecular genetic testing can also be used to generate a score for diagnosing diseaseD006527. Medical therapy is effective for most 9606; liver transplant can rescue those with diseaseD017114 or those with advanced diseaseD008107 who fail to respond to or discontinue medical therapy. Treatment monitoring must be done at regular intervals and includes clinical evaluation, liver tests and blood counts, and chemicalD003300 metabolic parameters.
32060651	Negative_Correlation|chemicalD004113|diseaseD006527; Negative_Correlation|chemicalD008670|diseaseD006527; Negative_Correlation|chemicalD010396|diseaseD006527	A study of susceptibility-weighted imaging in 9606 with diseaseD006527 during the treatment of chemicalD008670 chelator.OBJECTIVE: A randomized-controlled trial comparing study of the changes in brain sensitive-weighted imaging (SWI) of diseaseD006527 (diseaseD006527) 9606 during the treatment with chemicalD008670 chelator was done. METHODS: 100 untreated diseaseD006527 9606 (80 cases of cerebral type, 20 cases of hepatic type, age 20.13 +- 9.12 years old) and 20 normal controls were selected. diseaseD009461 were scored using the modified Young scale. Liver function tests and chemicalD003300 indices were collected. All study objects received SWI test of the brain. The values of corrected phase (CP) were calculated on SWI. diseaseD006527 9606 were treated with chemicalD010396 (chemicalD010396) (group 1) or Dimercaptopropane Sulfonate (DMPS) + chemicalD004113 (chemicalD004113) (group 2). Hepatic-type diseaseD006527 9606 were treated with chemicalD010396 (group 3). All 9606 received annual diseaseD009461 score, liver function, chemicalD003300 indices, and SWI examination. RESULTS: At the first year of treatment, score of the modified Young scale in group 2 was lower than that in group 1 (P = 0.023) and lower than that before treatment (P = 0.040). After 2 years of treatment, the score of the modified Young scale in group 1 was lower than that before treatment (P = 0.012). At the second year after treatment, the urinary chemicalD003300 in group 2 was higher than that in group 1 (P = 0.014). Urinary chemicalD003300 was maintained at 200 microg/day in group 1 and 300 microg/day in group 2 after 3 years of treatment. At the first year of treatment, serum chemicalD003300 in group 1 was lower than that in group 2 (P = 0.032). At the first year of treatment, CP values of the pallidum and substantia nigra in group 2 were higher than those in group 1 (P = 0.026, 0.040). At the second year of treatment, CP value of substantia nigra in group 2 was higher than that in group 1 (P = 0.037). After 3 years of treatment, there was no difference in CP values between diseaseD006527 9606 and normal controls. CONCLUSIONS: Therapy with DMPS and chemicalD004113 improves diseaseD009461 of diseaseD006527 9606 more quickly and leads to less aggravation, compared with therapy with chemicalD010396. The chemicalD008670 content in the brain of diseaseD006527 9606 was at a low level after 3 years of treatment. DMPS and chemicalD004113 can remove chemicalD008670 from brain tissue faster than chemicalD010396.
32804913		Fulminant diseaseD006527 in Children: Recovery After Plasma Exchange Without Transplantation.OBJECTIVES: Since 2005, a New diseaseD006527 Index (NWI) >=11 is used as a predictor of diseaseD003643 without transplantation in fulminant diseaseD006527 (diseaseD006527). Plasma exchange is advocated as a new treatment modality. METHODS: We present a 9606 with fulminant diseaseD006527 treated with plasma exchange. All published cases applying plasma exchange for fulminant diseaseD006527 were reviewed systematically. RESULTS: A 14-year-old girl presented with diseaseD006461 and diseaseD017114. She had no diseaseD001927; NWI was 14. As a bridge to transplantation plasma exchange was started immediately. Complete remission was achieved with plasma exchange and later chelation therapy with chemicalD010396. She is now at 3-year transplant-free survival. Literature review identified 37 9606 presenting with fulminant diseaseD006527 and NWI >=11 who were treated with plasma exchange. Seventeen of these 9606 (ie, 46%) recovered without transplantation. CONCLUSIONS: Multiple case reports and case series demonstrate transplant free survival after plasma exchange and subsequent chelation therapy, despite a NWI >=11. Plasma exchange affects the clinical course and is a therapeutic option in children and young adults presenting with fulminant diseaseD006527.
33275389		Commentary on "A New Onset of diseaseD001714 in a 49-Year-Old Man: An Interesting Case of diseaseD006527".diseaseD006527 is a rare diseaseC535468 that generally occurs in individuals between 5 and 35 years of age. Common clinical manifestations are diseaseD001523. Roughly, 4% of all cases occur in 9606 over 40 years of age and, among these 9606, the presenting symptoms are generally diseaseC000631768, which often leads to misdiagnosis as a diseaseD001523 and a delay in correct diagnosis. This report presents the case of a 49-year-old man with no formal diseaseD001523 history who presented with a new onset of diseaseD001714. We outline the distinctive characteristics that appeared inconsistent with a diseaseD001523 and pointed toward secondary diseaseD001714. Despite low serum ncbi1356, the absence of diseaseD001927 more typical of diseaseD006527 on magnetic resonance imaging led a neurology consultant to advise that the diagnosis was likely primarily diseaseD001523. Due to atypical components of the 9606's presentation, such as his late age of onset for diseaseD001714 and acute diseaseD003072, the diseaseD001523 team advocated for further diagnostic workup. The subsequent evaluation confirmed diseaseD006527 based on specific diseaseD056486 and further chemicalD003300 studies. In addition, once diagnosed, the management of diseaseD006527 involves distinct clinical considerations given 9606' presumed vulnerability to neurological side effects. This case illustrates the role diseaseD001523 providers play in advocating for diagnostic workup in 9606 with atypical presentations of primary diseaseD001523 and the distinct diagnostic and treatment considerations associated with diseaseD006527.
32485301	Association|diseaseD006527|ncbi540; Association|chemicalD003300|diseaseD006527; Association|diseaseD009461|ncbi1356; Association|diseaseD006527|ncbi1356	Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of diseaseD006527.BACKGROUND & AIMS: diseaseD006527 is an diseaseD030342 that impairs chemicalD003300 homeostasis and is caused by homozygous or compound heterozygous mutations in ncbi540, which encodes a copper-transporting P-type ATPase. 9606 have variable clinical manifestations and laboratory test results, resulting in diagnostic dilemmas. We aimed to identify factors associated with symptoms and features of diseaseD006527 from a large cohort, over 15 years. METHODS: We collected data from 715 9606 (529 with symptoms, 146 without symptoms, and 40 uncategorized) and a genetic confirmation of diseaseD006527 (mean age of diagnosis, 18.84 years), recruited from 3 hospitals in China from 2004 through 2019. We analyzed clinical data along with serum levels of ncbi1356 (available from 636 9606), 24-hr urinary chemicalD003300 excretion (collected from 131 9606), diseaseC537149 (diseaseC535468, with neurologic data from 355 9606), and diseaseC564543. Differences among the groups were analyzed using 1-way analysis of variance followed by Tukey multiple comparison test. RESULTS: Of the 529 9606 with symptoms, 121 had hepatic features, 355 had neurologic features, 28 had osteomuscular features (premature diseaseD010003, diseaseD009140, and diseaseD050723), and 25 had diseaseD001523. Age of onset was significantly younger in 9606 with hepatic (16.94 +- 1.03 years; P = .0105) or osteomuscular features (13 +- 1.33 years; P = .0001) than 9606 with neurological features (19.48 +- 0.46 years). Serum levels of ncbi1356 differed among asymptomatic 9606 and 9606 with diseaseD009461 of diseaseD006527. Serum levels of ncbi1356 ranged from 18.93 mg/L to approximately 120.00 mg/L (quantiles of 0.025 to approximately 0.975). Fifty-one of 131 9606 (39%) had urinary chemicalD003300 excretion levels below 100 mug/24 hr; there was significant variation in levels of urinary chemicalD003300 excretion between 9606 older than 14 years vs 14 years or younger. Of the 355 9606 with neurologic features, 244 9606 (69%) had abnormal findings from MRI and diseaseC537149; only 1 9606 with abnormal findings from brain MRI was negative for diseaseC537149. CONCLUSIONS: Serum level of ncbi1356, 24-hour urinary chemicalD003300 excretion, and diseaseC537149 can be used to identify 9606 who might have diseaseD006527. 9606 with serum levels of ncbi1356 below 120 mg/L and children with urinary chemicalD003300 excretion above 40 mug should undergo genetic testing for diseaseD006527. 9606 with diseaseD009069 and brain diseaseC564543 without diseaseC537149 are not likely to have diseaseD006527.
34857647	Negative_Correlation|chemicalC020809|chemicalD003300; Negative_Correlation|chemicalD003300|chemicalD010396; Negative_Correlation|chemicalC020809|diseaseD064420; Negative_Correlation|chemicalC020809|diseaseD009422; Association|chemicalD003300|ncbi213; Association|chemicalD003300|diseaseD006527; Positive_Correlation|chemicalD010396|diseaseD009422; Negative_Correlation|chemicalD010396|diseaseD006527; Comparison|chemicalC020809|chemicalD010396	chemicalC020809 prevents chemicalD003300-induced blood-brain barrier damage.In diseaseD006527, excessive chemicalD003300 accumulates in 9606' livers and may, upon serum leakage, severely affect the brain according to current viewpoints. Present remedies aim at avoiding chemicalD003300 diseaseD064420 by chelation, for example, by chemicalD010396 (chemicalD010396) or chemicalC020809 (chemicalC020809), the latter with a very high chemicalD003300 affinity. Hence, chemicalC020809 may potentially avoid diseaseD009422 that frequently occurs upon chemicalD010396 treatment. As the etiology of such worsening is unclear, we reasoned that chemicalD003300 loosely bound to ncbi213, that is, mimicking a potential liver chemicalD003300 leakage into blood, may damage cells that constitute the blood-brain barrier, which was found to be the case in an in vitro model using primary porcine brain capillary endothelial cells. Such blood-brain barrier damage was avoided by chemicalC020809, plausibly due to firm protein embedding of the chelator bound chemicalD003300, but not by chemicalD010396. Mitochondrial protection was observed, a prerequisite for blood-brain barrier integrity. Thus, high-affinity chemicalD003300 chelators may minimize such deterioration in the treatment of neurologic diseaseD006527.
32493955	Positive_Correlation|chemicalD003300|diseaseD006527; Association|diseaseD006527|ncbi540	WilsonGen a comprehensive clinically annotated genomic variant resource for diseaseD006527.diseaseD006527 (diseaseD006527) is one of the most prevalent diseaseD030342 with an estimated global carrier frequency of 1 in 90 and a prevalence of 1 in 30,000. The disease owes its genesis to Kinnier Wilson who described the disease, and is caused by accumulation of chemicalD003300 (chemicalD003300) in various organs including the liver, central nervous system, cornea, kidney, joints and cardiac muscle which contribute to the characteristic clinical features of diseaseD006527. A number of studies have reported genetic variants in the ncbi540 gene from diverse ethnic and geographical origins. The recent advent of next-generation sequencing approaches has also enabled the discovery of a large number of novel variants in the gene associated with the disease. Previous attempts have been made to compile the knowledgebase and spectrum of genetic variants from across the multitude of publications, but have been limited by the utility due to the significant differences in approaches used to qualify pathogenicity of variants in each of the publications. The recent formulation of guidelines and algorithms for assessment of the pathogenicity of variants jointly put forward by the American College of Medical Genetics and the Association of Molecular Pathologists (ACMG &AMP) has provided a framework for evidence based and systematic assessment of pathogenicity of variants. In this paper, we describe a comprehensive resource of genetic variants in ncbi540 gene manually curated from literature and data resources and systematically annotated using the ACMG & AMP guidelines for assessing pathogenicity. The resource therefore serves as a central point for clinicians and geneticists working on diseaseD006527 and to the best of our knowledge is the most comprehensive and only clinically annotated resource for diseaseD006527. The resource is available at URL http://clingen.igib.res.in/WilsonGen/. We compiled a total of 3662 genetic variants from publications and databases associated with diseaseD006527. Of these variants compiled, a total of 1458 were found to be unique entries. This is the largest diseaseD006527 database comprising 656 pathogenic/likely pathogenic variants reported classified according to ACMG & AMP guidelines. We also mapped all the pathogenic variants corresponding to ncbi540 protein from literature and other databases. In addition, geographical origin and distribution of ncbi540 pathogenic variants reported are also mapped in the database.
37491953	Positive_Correlation|chemicalD008670|diseaseD009461; Negative_Correlation|chemicalD008670|diseaseD017093; Positive_Correlation|chemicalD008670|diseaseD000080902; Negative_Correlation|chemicalD008670|diseaseD006527	Symptom aggravation after withdrawal of chemicalD008670 chelating agent therapy in patients with diseaseD006527.OBJECTIVE: To study the aggravation of clinical symptoms after discontinuation of chemicalD008670 chelating agent therapy in diseaseD006527 (diseaseD006527) patients, analyze the causes of aggravation, and observe the prognosis. METHODS: 40 diseaseD006527 patients (cerebral type 30 cases and hepatic type 10 cases) who stopped using chemicalD008670 chelating agent were selected, 40 diseaseD006527 patients with normal therapy, and 10 normal control cases were selected. All patients underwent diseaseD009461 evaluation using modified Young scale, Child-Pugh liver function grading, chemicalD008670 metabolism, and disease typing. Magnetic sensitivity imaging (SWI), diffusion tensor imaging (DTI), and magnetic resonance spectroscopy imaging (MRS) were performed. According to the imaging results, diseaseD006527 patients were divided into chemicalD008670 deposition stage, fiber damage stage, and diseaseD009336 stage. All patients were treated with chemicalD008670 chelating agent for 6 months. RESULTS: The score of modified Young scale in drug withdrawal group was lower than that in normal treatment group before drug withdrawal (p = .032). The score of modified Young scale was higher after drug withdrawal than before (p = .011). The number of Child-Pugh B-grade patients after drug withdrawal was more than that before drug withdrawal and in normal treatment group. The proportion of patients in the stage of diseaseD009336 after drug withdrawal (25%) was higher than that before drug withdrawal (10%) (p = .025). After drug withdrawal, urine chemicalD003300 was significantly higher than that before drug withdrawal and in the normal treatment group (p = .032, .039). After the withdrawal group resumed chemicalD008670 chelating agent treatment, 34.2% of diseaseD009461 worsened. CONCLUSIONS: diseaseD006527 patients showed diseaseD009461 aggravation and increased diseaseD017093 after chemicalD008670 chelating agent withdrawal. Increased chemicalD008670 deposition and new diseaseD000080902 occurred in the brain. After re-treatment, the aggravated diseaseD009461 of diseaseD006527 patients are difficult to reverse.
29325287	Negative_Correlation|chemicalD010396|diseaseD006527; Association|chemicalD003300|diseaseD006527; Association|chemicalD003300|diseaseD008107	[The diagnostic value and limits of diagnostic parameters for diseaseD006527].diseaseD006527 (diseaseD006527) is a rare and treatable diseaseD030342. This paper describes the new advances and author's long-term experiences in the diagnosis of diseaseD006527. The characteristics in clinical and routine tests are: the age of presentation can be quite broad, the diseaseD006527 could not be excluded based on age only; the 9606 usually have mild digestive symptoms but obvious chronic diseaseD008107 signs; liver function tests may reveal normal or a mild elevation in chemicalD001663, ALT and ncbi26503, but quite abnormal in serum albumin and prothrombin time in most 9606; Coombs-negative diseaseD000743, normal or markedly subnormal serum alkaline phosphatase (typically < 40 IU/L) are useful for the diagnosis of fulminant diseaseD006527. In china, Kayser-Fleischer rings are present in 72.2% of 9606 at the time of diagnosis, the positive rate is significantly higher in 9606 with a neurological presentation (93.4%) than 9606 presenting with diseaseD008107 (63.3%), however, they are usually absent in 9606 under 6 years old, occasionly present in 9606 with chronic diseaseD008107. The mean serum ceruloplamin level in diseaseD006527 9606 is 71.1 +- 48.7 mg/L, the level is < 200 mg/L in 98.9% of 9606, < 100 mg/L in about three fourths 9606, < 50 mg/L in about half 9606, but it may be low in 50% of 9606 with severe diseaseD058625 of any etiology too, and even lower than 50 mg/L in 9606 with diseaseD013577. Basal 24-hour urinary chemicalD003300 excretion may be>=100 g at presentation in 86.7% of 9606 with diseaseD006527, but also in 22% of 9606 with certain chronic diseaseD008107, the sensitivity of chemicalD010396 challenge test is lower than basal urinary chemicalD003300 excretion, however, the specificity is significantly higher than former (97% versus 78%). Hepatic chemicalD003300 determination remains the gold standard for the diagnosis of diseaseD006527. We have designed a standard method for hepatic chemicalD003300 determination. The most useful cut-off value is 209 g/g dry wt using our method, with the sensitivity of 99.4%, and specificity of 96.1%. However, long-standing diseaseD017093 and or obstruction can cause heptic chemicalD003300 elevations into the diseaseD006527 area. In recent years, direct complete DNA sequencing has become easy, rapid, less expensive and commercially available. Currently reported mutation detection rate is 90%, the specificity is almost 100%. The limitation to the method has been the ability to identify all the affected alleles in suspected individuals. If no mutation is identified, the diagnosis of diseaseD006527 could not be excluded. None of the laboratory parameters alone allows a definite diagnosis of diseaseD006527. The diseaseD006527 diagnostic scoring system based on a composite of key parameters helps clinicians to gauge the degree of certainty of the diagnosis: diseaseD006527 scores greater than 4, the diagnosis of diseaseD006527 is highly likely; score 0 or 1, the diagnosis is unlikely. However, the diseaseD006527 diagnosis could not be excluded in suspected 9606 who do not perform genetic test and hepatic chemicalD003300 determination. 9606 with chronic diseaseD008107 may have scores more than 4.
37226184		Medical care of 9606 with diseaseD006527 in Germany: a multidisciplinary survey among university centers.BACKGROUND: diseaseD006527 (diseaseD006527) is a rare, diseaseD009386 of diseaseC535468 metabolism. Due to its variable symptoms and manifestations, diagnosis remains challenging. Affected 9606 must obtain lifelong medical treatment, as the disease is fatal if untreated. 9606 require continuous monitoring, but little is known about the care of these 9606 in Germany. Therefore, we analyzed the medical care of diseaseD006527 9606 at German university centers. We sent a questionnaire containing 20 questions to a total of 108 departments of pediatrics, neurology and gastroenterology in 36 university hospitals. Our questions referred to the characteristics of diseaseD006527 9606 at the different sites and internal procedures regarding diagnosis, therapy and follow-up. A descriptive statistical analysis was performed. RESULTS: Sixty-three departments (58%) returned our questionnaire. In total, approximately one-third of the estimated diseaseD006527 9606 in Germany are seen annually in the 9606 clinics of these departments (approx. 950 9606). There are only a few departments which treat 9606 in a multidisciplinary setting (12%). Our survey revealed that for diagnosis, 51% of all departments used an algorithm based on the Leipzig score as recommended by international guidelines. Most departments apply essential parameters recommended by diseaseD006527 guidelines. Routine monitoring is performed at least biannually by 84% of the departments, and standard investigations for monitoring are regularly applied. A routine family screening is performed by 84% of all departments. A reduction in medical therapy during pregnancy is recommended by 46% of the departments. Only 14% suggested that diseaseD006527 9606 should not breastfeed. Liver transplantation (LT) due to diseaseD006527 is a rare but repeatedly occurring event. Most departments of gastroenterology (72%) reported at least one 9606 with LT within the last decade. CONCLUSIONS: Medical care of diseaseD006527 9606 at German university centers follows the recommendations set forth by international guidelines, but only a few centers treat significant numbers of 9606. The surveillance of 9606 does not follow specified standards, but most departments adhere to the accepted guidelines. The formation of central units and networks in a multidisciplinary setting should be evaluated to improve the care of diseaseD006527 9606.
32539308		Late Diagnosis of diseaseD006527, Initially Presenting as diseaseD002526 Mimicking diseaseD020754, by Multigene Panel Testing.
34666712	Negative_Correlation|chemicalD010396|diseaseD006527; Negative_Correlation|chemicalD010396|diseaseD007674; Negative_Correlation|chemicalD019287|diseaseD006527; Negative_Correlation|chemicalD019808|diseaseD006527; Negative_Correlation|chemicalD019808|diseaseD007674; Association|chemicalD003300|diseaseD006527; Association|diseaseD030342|ncbi540; Negative_Correlation|chemicalD019287|diseaseD007674; Association|chemicalD003300|diseaseD030342; Association|diseaseD006527|ncbi540	Immunoglobulin a diseaseD007674 as the first clinical presentation of diseaseD006527: a case report and literature review.BACKGROUND: diseaseD006527 (diseaseD006527) is a rare diseaseD030342 of chemicalD003300 metabolism. Differences in chemicalD003300 tissue accumulation lead to various clinical manifestations, including some atypical presentations. The complex clinical features of diseaseD006527 make diagnosis challenging, delaying the best chance for treatment. CASE PRESENTATION: We report a case of a 26-year-old man with diseaseD009393-range diseaseD011507 and elevated serum chemicalD003404. The renal pathology indicated diseaseD005922 and diseaseD000230, which was inconsistent with diseaseD007674. diseaseD005355 was also detected by imaging examination. Considering both diseaseD007674 and diseaseD056486, diseaseD006527 was suspected. Based on results showing abnormal chemicalD003300 metabolism, corneal Kayser-Fleischer rings, and diseaseD030342 in the ncbi540 gene, the 9606 was finally diagnosed with diseaseD006527. After treatment with oral chemicalD010396, chemicalD019287 and chemicalD019808, the 9606 showed alleviation of both diseaseD006527 and diseaseD007674 after 3 years of follow-up. He maintained a good quality of daily life. CONCLUSION: This case highlights that unexplained diseaseD017093 in 9606 with diseaseD005922 can be clues for diseaseD006527.
36872503		Motor Evoked Potentials in Newly Diagnosed and Treated 9606 With diseaseD006527.PURPOSE: To investigate whether 9606 with diseaseD006527 have abnormal motor evoked potentials (MEPs) elicited by transcranial magnetic stimulation. METHODS: In a prospective, observational, single-center study, transcranial magnetic stimulation was used to examine MEPs recorded from the abductor digiti minimi in 24 newly diagnosed treatment-naive 9606 and 21 treated 9606 with diseaseD006527. RESULTS: Motor evoked potentials were recorded in 22 (91.7%) newly diagnosed treatment-naive 9606 and in 20 (95.2%) treated 9606. Abnormal MEP parameters were found in a similar proportion of newly diagnosed and treated 9606: MEP latency (38% vs. 29%), MEP amplitude (21% vs. 24%), central motor conduction time (29% vs. 29%), and resting motor threshold (68% vs. 52%). Abnormal MEP amplitude (P = 0.044) and resting motor threshold (P = 0.011) were more frequent in treated 9606 with diseaseD001927 but not in newly diagnosed 9606. We did not observe significant improvement in MEPs parameters after 1 year of treatment introduction in eight examined 9606. However, in one 9606 where MEPs were initially nondetectable, they were present 1 year after treatment introduction with chemicalD019287, although MEPs were not in the normal range. CONCLUSIONS: Motor evoked potential parameters did not differ between newly diagnosed and treated 9606. There was no significant improvement in MEP parameters one year after treatment introduction. Further studies conducted on large cohorts are necessary to determine the usefulness of MEPs in detecting diseaseC531847 and improvement after anticopper treatment introduction in diseaseD006527.
37121747		Late-onset diseaseD006527 in a 9606 Followed-up for diseaseD065626.A 73-year-old 9606 was referred to our hospital for persistent diseaseD017093. When the 9606 was 45 years old, her youngest sister had been diagnosed with diseaseD006527 (diseaseD006527). The 9606 therefore underwent several family screening tests, all of which were unremarkable. She had an annual medical checkup and was diagnosed with diseaseD017093 and diseaseD005234 at 68 years old. A liver biopsy and genetic testing were performed, and she was diagnosed with diseaseD006527; chelation therapy was then initiated. In 9606 with diseaseD008107 and a family history of diseaseD006527, multiple medical examinations should be conducted, as the development of diseaseD006527 is possible regardless of age.
29504323	Positive_Correlation|chemicalD003300|diseaseD009202	Electrocardiographic Manifestations In Paediatric diseaseD006527.BACKGROUND: diseaseD006527 (diseaseD006527) is one of the most common diseaseD008107 in older children. It has a strong genetic background with autosomal recessive inheritance. diseaseD006527 is a multisystem disorder with predominant hepatic and neurological manifestations and variable age of presentation. The data on cardiac manifestations in children is very limited and only few adult studies are available in the literature. This study was planned to determine the frequency and spectrum of Electrocardiographic (ECG) changes in pediatric diseaseD006527. METHODS: This was an observational cross-sectional study conducted at The Children Hospital & the Institute of 9606 Health, Lahore, from January 2015 to January 2017. The children diagnosed as diseaseD006527 were enrolled for the recording of resting ECG. The ECG changes were seen and discussed with an experienced pediatric cardiologist who was involved and explained about the objectives of study. RESULTS: Total 55 9606 were enrolled but record of ECG was missing for 4 9606 and excluded from the study. Out of 51 9606 22 had at least one ECG abnormality. Most frequent findings seen were diseaseD001260 in 18 9606 (35.2%) followed by diseaseD013616 and diseaseD012804 in 12 and 8 9606 respectively. Other diseaseD000014 included bifid P waves, ST segment changes each of 2 9606, and one diseaseD018879. QRS details including axis, complex, amplitude ratio and QT interval was normal in all the 9606. There was no mortality during the study period due to cardiac cause. CONCLUSIONS: ECG diseaseD000014 are not uncommon in pediatric diseaseD006527 but of mild nature. These are presumably related to underlying diseaseD009202 due to deposition of chemicalD003300 in heart which can be quantified by cardiac magnetic resonance imaging (MRI) and echocardiography is required to confirm ECG diseaseD000014 detected.
28619500		Was diseaseC535562 the Cause of Intractable diseaseD012640 in a 17-Year-Old Boy with diseaseD006527?BACKGROUND: diseaseC535562 (diseaseC535562), which is often found incidentally in a few populations, occasionally becomes symptomatic if enlarged significantly. diseaseD006527 (diseaseD006527) is an uncommon diseaseD030342 in diseaseC535468 metabolism characterized by abnormal accumulation of chemicalD003300 in various tissues, particularly in the liver and the brain. diseaseD004827, although rare both in diseaseC535562 and diseaseD006527, may happen in a few 9606 with either of the conditions. CASE DESCRIPTION: We report a case of 17-year-old boy, a 9606 with known diseaseD006527, who developed intractable diseaseD012640 for a year, which was not controlled with a large amount of antiepileptics. Magnetic resonance imaging showed enlargement of his preexisting diseaseC535562, which was small and asymptomatic at the time of diagnosis of diseaseD006527. His diseaseD006527 was in a state of remission when he developed the diseaseD004827. On endoscopic diseaseD003560 fenestration, he was relieved of the diseaseD012640. CONCLUSIONS: Symptomatic diseaseC535562 is a rare disorder, but the coexistence of diseaseD006527 is even rarer. Endoscopic diseaseD003560 fenestration is a novel procedure that can be successful in properly selected cases. To the best of our knowledge, diseaseC535562 associated with diseaseD006527 has not been reported in any English literature. We present this case for its rarity along with a relevant literature review.
34608110	Negative_Correlation|chemicalD010396|diseaseD003643	diseaseD006527 in Children; Chelation Therapy or Liver Transplantation? A 10-Year Experience from Pakistan.BACKGROUND diseaseD006527 (diseaseD006527) is a rare diseaseD030342 with vast clinical presentations and a higher incidence in areas where consanguinity is common. Most 9606 can be treated with oral chelation, but some require advanced surgical intervention, like liver transplantation (LT). This study aims to review outcomes of diseaseD006527 9606 presenting to a tertiary care center over a period of 10 years. MATERIAL AND METHODS This retrospective analysis was conducted at Shifa International Hospital, Islamabad, Pakistan. 9606 <18 years who were diagnosed with diseaseD006527 per ESPAGHAN guidelines from 2010 to 2020 were included. Presentation, diagnosis, treatment, and LT and its complications were recorded. Follow-ups were recorded, and 9606 were contacted by phone in cases of interrupted follow-up. Frequencies and percentages of variables were calculated. RESULTS A total of 48 9606 with diseaseD006527 were identified. Symptomatic disease was seen in 45 9606, with 3 diagnosed on screening. The hepatic form was common (62.2%). Mean age at diagnosis was 9.74 (range 5-17) years, 28 (58.3%) were male, while 17 (35.4%) were female. Urinary chemicalD003300 was increased in all 9606 (645.82+-528.40). Oral treatment with chemicalD010396 was given to 34 (75.5%) 9606; 4 (8.9%) diseaseD003643 while on oral treatment. Living donor LT was performed in 11 (22.9%) 9606, who had a mean King's Wilson index of 11 (range, 6-14). Currently, all LT 9606 are alive, with maximum graft survival of 7 years. CONCLUSIONS LT offers a promising treatment with good outcomes in pediatric diseaseD006527. However, timely diagnosis and management with oral chelation therapy can prolong survival without LT.
34627038	Association|diseaseD007249|ncbi14063; Association|chemicalD005557|chemicalD010232	Delineation of the healthy 9986 liver by immunohistochemistry - A technical note.diseaseD008107 pose a big global health problem and diseaseD017093 may result from diseaseD014777, diseaseD044343 or diseaseD009369. Studying pathologic liver tissue demands for accurate and specific histological stainings and immunohistochemical labellings, including chromogenic and fluorescent approaches. Moreover, a reliable set of healthy liver stainings and labellings are required, to provide a baseline or reference for the pathological situation. Here, we used the liver tissue of a healthy 9986 and compared different histological key steps, such as chemicalD010232 embedding after chemicalD005557 fixation versus cryopreservation; or an antigen retrieval (AR) step in processing chemicalD010232 sections versus the same procedure without AR; or chromogenic with fluorescent detection system, respectively. Moreover, we provide images of serial sections, where we stained the same morphological structure with different markers, including collagen I, collagen III, ncbi14268, ncbi11475, ncbi13717, ncbi14063 (ncbi14063) which is an diseaseD007249-related marker, ncbi17345 for proliferating cells, and chemicalC002313 (as negative control for pathological aberrations like diseaseD006527). Differences between conditions were quantitatively assessed by measuring the colour intensity. Generally, we observed that cryosections exhibited a stronger signal intensity in immunohistochemically labelled sections than in chemicalD010232 sections; however, the strong staining got slurred, which sometimes hampered proper identification of morphological structures at higher magnifications. Moreover, there was a clear increase in signal intensity for chemicalD010232 sections when an AR step was performed compared to condition without AR. Results for 10090 isotype staining as a negative control clearly supported those findings. Different stainings of the portal triad, the central vein and the bile ducts revealed a clear-cut distribution of extracellular matrix components, with prominent ncbi14268 and ncbi13717 around the lumen of the central vein as well as a patchy ncbi14063 expression. As for the bile ducts, complete absence of ncbi11475 and ncbi14063 was found at the margins, however, collagen I expression and ncbi13717 were positive and showed a strong signal. Like this, we provide useful and valuable reference images for researchers using the 9986 liver model. It may help to decide which of the immunohistochemical protocols are valuable to reach a certain aim and which protocols lead to the best visualization of the target structure.
29085216	Positive_Correlation|diseaseD006527|variantrs1057517310##; Association|diseaseD006527|ncbi540; Association|diseaseD006527|ncbi540	diseaseD006527 in Lebanon and regional countries: Homozygosity and hepatic phenotype predominance.AIM: To determine the phenotypes and predominant disease-causing mutations in Lebanese 9606 with diseaseD006527, as compared to regional non-European data. METHODS: The clinical profile of 36 9606 diagnosed in Lebanon was studied and their mutations were determined by molecular testing. All 9606 underwent full physical exam, including ophthalmologic slit-lamp examination ultrasound imaging of the liver, as well as measurement of serum ncbi1356 and 24-h urinary-chemicalD003300 levels. In addition, genetic screening using PCR followed by sequencing to determine disease-causing mutations and polymorphisms in the ncbi540 gene was carried on extracted DNA from 9606 and immediate family members. Our phenotypic-genotypic findings were then compared to reported mutations in diseaseD006527 9606 from regional Arab and non-European countries. RESULTS: 9606 belonged to extended consanguineous families. The majority were homozygous for the disease-causing mutation, with no predominant mutation identified. The most common mutation, detected in 4 out of 13 families, involved the ncbi51761 hinge region and was present in 9606 from Lebanon, Egypt, Iran and Turkey. Otherwise, mutations in Lebanese 9606 and those of the region were scattered over 17 exons of ncbi540 While the homozygous exon 12 mutation variantrs1057517310## was only detected in 9606 from Lebanon but none from the regional countries, the worldwide common mutation variantrs76151636## was not present in the Lebanese and was rare in the region. diseaseC536289 was predominant in 9606 from both Lebanon and the region (25%-65%). Furthermore, the majority of 9606, including those who were asymptomatic, had evidence of some diseaseD008107. Pure diseaseD009461 phenotype was rare. CONCLUSION: Findings do not support presence of a founder effect. Clinical and genetic screening is recommended for family members with index 9606 and unexplained diseaseD008107.
31169307	Positive_Correlation|diseaseD006527|variantrs138427376##; Positive_Correlation|diseaseD006527|variantrs137853285##; Association|chemicalD003300|diseaseD006527; Positive_Correlation|diseaseD006527|variantrs137853285##; Association|chemicalD003300|diseaseD030342; Association|diseaseD006527|ncbi540	The dilemma to diagnose diseaseD006527 by genetic testing alone.BACKGROUND: diseaseD006527 (diseaseD006527) is an diseaseD030342 of hepatic chemicalD003300 excretion. About sixty per cent of 9606 present with diseaseD008107. diseaseD006527 is considered a fatal disease if undiagnosed and/or untreated but recent data indicate that disease penetrance may not be 100%. MATERIALS AND METHODS: All 9606 underwent liver biopsy as part of the diagnostic workup. Genetic testing for ncbi540 was performed by Sanger sequencing. RESULTS: We report on a large family with multiple affected siblings. The first 9606 (male, 31 years) underwent orthotopic liver transplantation (OLT) because of fulminant diseaseD006527. He was homozygous for variantrs137853285##. One asymptomatic brother (37 years) had the same mutation. He is doing well on chelation therapy. Fifteen years later, a second-degree sibling (female, 16 years) presented with fulminant diseaseD006527 and underwent OLT. She was compound heterozygote (variantrs137853285##/variantrs137853285##). Further family screening revealed a third mutation (variantrs138427376##) in a female (21 years) and male (16 years) compound-heterozygote sibling (variantrs137853285##/variantrs138427376##). In both, serum ncbi1356 and 24-hour urinary chemicalD003300 excretion were normal. Liver biopsy showed normal histology and a quantitative hepatic chemicalD003300 content within the normal range or only slightly elevated (19 and 75 mug/g dry weight, respectively). No decoppering treatment was initiated so far. CONCLUSION: Genetic testing alone is not always sufficient to diagnose diseaseD006527 in asymptomatic 9606, and 9606 mutation databases should be used with caution. Even 9606 carrying two disease-causing mutations do not necessarily have demonstrable alteration of chemicalD003300 metabolism. Asymptomatic siblings diagnosed by genetic screening require further testing before initiating treatment.
33244627		Structural and functional brain changes in diseaseD009461 diseaseD006527.diseaseD006527 (diseaseD006527) can manifest with diseaseD001523. Our understanding of the in vivo brain changes in diseaseD006527, particularly in the hepatic phenotype, is limited. Thirty subjects with diseaseD006527 and 30 age- and gender-matched controls participated. diseaseD006527 group underwent neuropsychiatric assessment. Unified diseaseD006527 Rating Scale neurological exam scores were used to determine neurological (diseaseD003643, score > 0) and hepatic-only (WDH, score 0) subgroups. All subjects underwent 3 Tesla anatomical and resting-state functional MRI. Diffusion tensor imaging (DTI) and susceptibility-weighted imaging (SWI) were performed only in the diseaseD006527 group. Volumetric, DTI, and functional connectivity analyses were performed to determine between-group differences. diseaseD003643 and WDH groups were matched in demographic and diseaseD001523 profiles. The entire diseaseD006527 group compared to controls showed significant thinning in the bilateral superior frontal cortex. The diseaseD003643 group compared to control and WDH groups showed prominent structural brain changes including significant striatal and thalamic diseaseD001284, more subcortical hypointense lesions on SWI, and diminished white matter integrity in the bilateral anterior corona radiata and corpus callosum. However, the WDH group also showed significant diseaseD056784 compared to controls. The functional connectivity between the frontostriatal nodes was significantly reduced in the diseaseD003643 group, whereas that of the hippocampus was significantly increased in the WDH group compared to controls. In summary, structural and functional brain changes were present even in neurologically non-manifesting diseaseD006527 9606 in this cross-sectional study. Longitudinal brain MRI scans may be useful as biomarkers for prognostication and optimization of treatment strategies in diseaseD006527.
31511488	Positive_Correlation|chemicalD003300|diseaseD017093; Negative_Correlation|chemicalD010396|diseaseD006527; Comparison|chemicalD010396|chemicalD019345	Importance of a Liver Biopsy in the Management of diseaseD006527.A 37-year-old diseaseD006527 9606 treated with chemicalD010396 visited our hospital for the evaluation of his liver function. Laboratory data showed a low serum chemicalD003300 level and ncbi1356. The ratio of urinary chemicalD003300 to urinary chemicalD003404 in a spot urinary analysis after 4 days' cessation of chemicalD010396 was under 0.1. We concluded that the chemicalD003300 chelation was excessive and changed chemicalD010396 to chemicalD019345. However, his liver function test results did not normalize. We performed a liver biopsy and discovered a high chemicalD003300 content. The diseaseD017093 was improved after resuming chelating therapy. Accurate measurement of the hepatic chemicalD003300 content via a biopsy is important for the adequate management of this disease.
30988085		Exceptional involvement of medulla oblongata in diseaseD006527.
33881171	Association|chemicalD003300|diseaseD006527	Optical coherence tomography in 9606 with diseaseD006527.OBJECTIVES: diseaseD006527 (diseaseD006527) is an diseaseD030342 that leads to chemicalD003300 accumulation and deposition in different organs, frequently affecting visual pathways. Recent studies have detected morphological changes of the retina in 9606 with diseaseD006527 using optical coherence tomography (OCT). Measuring the thickness of the retinal nerve fibre layer (RNFL) with OCT provides an objective assessment of integrity and diseaseD019572. The aim of this study was to evaluate the relationship between OCT parameters and form of the disease, therapy and symptoms duration, as well as severity of diseaseD009422. METHODS: The study comprised of 52 9606 with diseaseD006527 and 52 healthy controls (HC). All the 9606 were on a regular and stable chelation therapy and/or zinc salts. 9606 were divided into two groups, with neurological (NWD) or diseaseD006527 disease (HWD). OCT was performed to assess the RNFL thickness. RESULTS: The diseaseD006527 9606 had significantly lower intraocular pressure in both eyes and lower RNFL thickness than the HC. There were no differences between NWD and HWD in any of the ophthalmologically tested parameters. No significant correlations were found between clinical features and retinal thickness parameters. Stratification of the cohort according to the disease duration showed that disease duration did not influence the RNFL thickness. CONCLUSION: We found that involvement of the retina represented a subclinical finding in neurologically intact 9606 in the HWD group. Nevertheless, the value of OCT as a biomarker for the assessment of the clinical course and progression of diseaseD006527 still remains uncertain.
34999690	Association|chemicalD003300|diseaseD006527; Negative_Correlation|diseaseD006527|ncbi1356	Efficacy of Different Diagnostic Test for Identifying diseaseD006527.diseaseD006527 is an diseaseD030342 in which chemicalD003300 pathologically accumulates primarily within the liver, brain and other tissues. It can presents clinically as diseaseD008107, as a progressive diseaseD009461 or as diseaseD001523. The wide array of clinical manifestations of diseaseD006527 can lead to misdiagnosis with subsequent greater risk of irreversible diseaseD056486. Many tests can be used to investigate 9606 of diseaseD006527, including serum free chemicalD003300, 24 hours urine chemicalD003300 estimation, hepatic chemicalD003300 estimation and genetic mutation testing. But there is no single ideal diagnostic test that can exclude or confirm the disease with certainty. The aim of the study was to find out the efficacy of different diagnostic test for the diagnosis of diseaseD006527. This cross-sectional analytical study was conducted at department of Paediatric Gastroenterology and Nutrition of Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh from January 2016 through January 2018. A total of 56 cases of diseaseD006527 and 39 9606 with a diseaseD008107 other than diseaseD006527 were studied. diseaseD006527 was diagnosed by Leipzig score. Along with other physical findings and laboratory investigations slit lamp eye examination for KF ring, serum ncbi1356 and 24 hour urinary chemicalD003300 excretion were done. The mean age of diseaseD006527 9606 was 9.69+-2.37 years, male female ratio was 1:1. Serum ncbi1356 level was significantly lower in diseaseD006527 9606 (p<0.001). Median of 24 hour urinary chemicalD003300 in diseaseD006527 was 702.75mug/ 24 hr (range119-11210mug/24 hour) and in non diseaseD006527 group it was 77.41mug/24 hour (range 20.0-478mug/24 hour) and the difference between them is statistically significant (p=0.001). The sensitivity of KF ring was 82.1% and specificity was 100%. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of serum ncbi1356 were 98.2%, 92.3%, 94.8%, 97.2% and 95.7% respectively. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 24 hour urinary chemicalD003300 were 100%, 63%, 80% and 85.1% respectively. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy of KF ring, serum ncbi1356 and basal 24 hour urinary chemicalD003300 excretion when combined together came out to be 70.4%, 100%, 100%, 59.3% and 79.3% respectively. This study result showed that serum ncbi1356 and 24 hour urinary chemicalD003300 can be used as a screening test for the diagnosis of diseaseD006527.
33640437	Association|diseaseD006527|ncbi540	Direct Measurement of ncbi540 Peptides Is Highly Effective in the Diagnosis of diseaseD006527.BACKGROUND & AIMS: Both existing clinical criteria and genetic testing have significant limitations for the diagnosis of diseaseD006527 (diseaseD006527), often creating ambiguities in 9606 identification and leading to delayed diagnosis and ineffective management. ncbi540 protein concentration, indicated by direct measurement of surrogate peptides from 9606 dried blood spot samples, could provide primary evidence of diseaseD006527. ncbi540 concentrations were measured in 9606 samples from diverse backgrounds, diagnostic potential is determined, and results are compared with biochemical and genetic results from individual 9606. METHODS: Two hundred and sixty-four samples from biorepositories at 3 international and 2 domestic academic centers and 150 normal controls were obtained after Institutional Review Board approval. Genetically or clinically confirmed diseaseD006527 9606 with a Leipzig score >3 and obligate heterozygote (carriers) from affected family members were included. ncbi540 peptide measurements were made by immunoaffinity enrichment mass spectrometry. RESULTS: Two ncbi540 peptides were used to measure ncbi540 protein concentration. Receiver operating characteristics curve analysis generates an area under the curve of 0.98. ncbi540 peptide analysis of the sequence ncbi540 887 was found to have a sensitivity of 91.2%, specificity of 98.1%, positive predictive value of 98.0%, and a negative predictive value of 91.5%. In 9606 with normal ncbi1356 concentrations (>20 mg/dL), 14 of 16 (87.5%) were diseaseD007153. In 9606 without clear genetic results, 94% were diseaseD007153. CONCLUSIONS: Quantification of ncbi540 peptide effectively identified diseaseD006527 9606 in 92.1% of presented cases and reduced ambiguities resulting from ncbi1356 and genetic analysis. Clarity is brought to 9606 with ambiguous genetic results, significantly aiding in noninvasive diagnosis. A proposed diagnostic score and algorithm incorporating ncbi540 peptide concentrations can be rapidly diagnostic and supplemental to current Leipzig scoring systems.
30541745	Positive_Correlation|chemicalC000629812|diseaseD013921; Negative_Correlation|chemicalC000629812|diseaseD009402; Positive_Correlation|chemicalC000629812|diseaseD009503; Negative_Correlation|chemicalC000629812|diseaseD015470; Negative_Correlation|chemicalC000629812|disease613700	FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk diseaseD015470.On August 3, 2017, the FDA granted regular approval to chemicalC000629812 (also known as chemicalC000629812; Jazz Pharmaceuticals), a liposomal formulation of daunorubicin and cytarabine in a fixed combination, for the treatment of adults with newly diagnosed therapy-related diseaseD015470 (t-diseaseD015470) or diseaseD015470 (diseaseD015470) with diseaseD009402 (diseaseD015470). Approval was based on data from Study CLTR0310-301, a randomized, multicenter, open-label, active-controlled trial comparing chemicalC000629812 with a standard combination of daunorubicin and cytarabine ("7+3") in 309 9606 60-75 years of age with newly diagnosed t-diseaseD015470 or diseaseD015470. Because of elemental copper concerns with the chemicalC000629812 formulation, 9606 with diseaseD006527 were excluded from the study. chemicalC000629812 demonstrated an improvement in overall survival (HR 0.69; 95% confidence interval, 0.52-0.90; P = 0.005) with an estimated median overall survival of 9.6 months compared with 5.9 months for the "7+3" control arm. The diseaseD064420 profile of chemicalC000629812 was similar to that seen with standard "7+3" with the exception of more prolonged diseaseD009503 and diseaseD013921 on the chemicalC000629812 arm. Because the pharmacology of chemicalC000629812 differs from that of other formulations of daunorubicin and cytarabine, labeling includes a warning against interchanging formulations during treatment. This is the first FDA-approved treatment specifically for 9606 with disease613700-diseaseD015470 or diseaseD015470.
36571168		Nomogram for prediction of diseaseD006501 after splenectomy for diseaseD006971 in 9606 with diseaseD006527.BACKGROUND: The occurrence of diseaseD006501 (diseaseD006501) after splenectomy in 9606 with diseaseD006527 (diseaseD006527) can lead to serious complications. The early identification of high-risk 9606 can help improve 9606 prognosis. This study aimed to establish and validate a personalized nomogram for assessing the risk of diseaseD006501 after splenectomy in 9606 with diseaseD006527 and diseaseD006971. METHODS: We retrospectively collected the data from 81 9606 with diseaseD006527 and diseaseD006971 who underwent splenectomy. Based on whether diseaseD006501 occurred within a month after the operation, they were divided into the diseaseD006501 group and the non-diseaseD006501 group. The clinical data of the 2 groups were compared, and univariate analysis was used to select the statistically significant features and incorporated into the least absolute shrinkage and selection operator (LASSO) regression model for optimization. Multivariate logistic regression analysis was used to determine the independent risk factors for diseaseD006501 after splenectomy, which were then applied to establish a personalized nomogram. We calculated the concordance (C)-index and drew the receiver operating characteristic (ROC) curve, the model calibration curve, and the clinical decision analysis (DCA) curve to evaluate the accuracy, calibration, and clinical applicability of the model, respectively. We used bootstrapping for internal validation of the model. RESULTS: Univariate analysis showed that the differences in preoperative portal vein diameter and velocity of portal blood flow, postoperative mean platelet volume (MPV), mean platelet distribution width (PDW), D-dimer, prothrombin time (PT), and the increase of platelet count (PLT) were of statistical significance (P<0.05). According to the results of the LASSO and multivariate logistic regression analyses, a model including preoperative portal vein diameter, preoperative portal blood flow velocity, postoperative D-dimer, and the increase of PLT was established to predict the risk of diseaseD006501 after splenectomy. The model showed good accuracy with a C-index of 0.838 (95% CI: 0.750-0.926) and had a well-fitted calibration curve. Furthermore, internal validation showed it achieved a moderate C-index of 0.805. The DCA curve indicated that the model has clinical applicability when 9606 are treated at thresholds of 2-100%. CONCLUSIONS: Establishing a predictive model for the risk of diseaseD006501 in 9606 with diseaseD006527 and diseaseD006971 after splenectomy can help clinicians identify 9606 at high risk of diseaseD006501 who require intervention measures.
35470480	Association|variant#540#c.51+2T>G|diseaseD006527; Association|variant#540#c.3532_3535del|diseaseD006527; Association|variantrs747219377##|diseaseD006527; Association|diseaseD030342|ncbi540; Association|chemicalD003300|ncbi540; Association|diseaseD006527|ncbi540; Association|diseaseD006527|ncbi540	Genetic studies discover novel coding and non-coding mutations in 9606 with diseaseD006527 in China.OBJECTIVES: diseaseD006527 (diseaseD006527) is a rare diseaseD030342 associated with various mutations in the ncbi540 gene and leads to significant disability or diseaseD003643 if untreated. Early diagnosis and proper therapy usually predict a good prognosis, especially in pre-symptomatic diseaseD006527. Genetic testing provides an accurate and effective diagnostic method for the early diagnosis of diseaseD006527. METHODS: We recruited 18 clinically diagnosed diseaseD006527 9606 from 16 unrelated families and two independent individuals. The next-generation sequencing of the ncbi540 gene was performed. The 0063 cell lines were divided into wild-type (WT) ncbi540 and mutated ncbi540 groups. Cell proliferation was determined by Cell Counting Kit-8 (CCK-8) assay and apoptosis was detected by ncbi308/chemicalD011419 (PI) assays. RESULTS: Pedigree analysis showed that compound heterozygous variants (17/18, 94.44%) were present in the majority of diseaseD006527 9606. A total of 33 ncbi540 gene variants were identified, including three variants with uncertain significance (VUS) [two splice mutations (variant#540#c.51+2T>G, variantrs747219377##) and one frameshift mutation (variant#540#c.3532_3535del)]. The CCK-8 and apoptosis assays demonstrated that the VUS of ncbi540 could significantly affect the transportation of chemicalD003300. CONCLUSIONS: The study revealed diseaseD030342 of 16 Chinese families and two independent individuals with diseaseD006527, which enriched the mutation spectrum of the ncbi540 gene worldwide and provided valuable information for studying the mutation types of ncbi540 in the Chinese populations. Genetic testing in diseaseD006527 9606 is necessary to shorten the time to initiate therapy, reduce diseaseD056486 and improve the prognosis.
30936238		Teaching Video NeuroImages: diseaseD009207 as the presenting feature of diseaseD006527.
34320232	Association|diseaseC535468|ncbi540; Association|diseaseD006527|ncbi540	Designing Clinical Trials in diseaseD006527.BACKGROUND AND AIMS: diseaseD006527 (diseaseD006527) is an diseaseD030342 caused by ncbi540 gene mutations leading to pathological accumulation of diseaseC535468 in the liver and brain. Adoption of initial treatments for diseaseD006527 was based on empirical observations. These therapies are effective, but there are still unmet needs for which treatment modalities are being developed. An increase of therapeutical trials is anticipated. APPROACH AND RESULTS: The first diseaseD006527 Aarhus Symposium (May 2019) included a workshop on randomized clinical trial design. The authors of the article were organizers or presented during this workshop, and this article presents their consensus on the design of clinical trials for diseaseD006527, addressing trial population, treatment comparators, inclusion and exclusion criteria, and treatment endpoints. To achieve adequate recruitment of 9606 with this rare disorder, the study groups should include all clinical phenotypes and treatment-experienced as well as treatment-naive 9606. CONCLUSIONS: The primary study endpoint should be clinical or a composite endpoint until appropriate surrogate endpoints are validated. Standardization of clinical trials will permit pooling of data and allow for better treatment comparisons, as well as reduce the future numbers of 9606 needed per trial.
29358698	Association|diseaseD006527|variant#540#p.R778L; Positive_Correlation|chemicalD003300|diseaseD006527; Association|diseaseD006527|ncbi100344865; Association|diseaseD006527|ncbi540	Production of diseaseD006527 Model 9986 with Homology-Directed Precision Point Mutations in the ncbi100344865 Gene Using the CRISPR/Cas9 System.CRISPR/Cas9 has recently been developed as an efficient genome engineering tool. The 9986 is a suitable animal model for studies of diseaseD008659. In this study, we generated ncbi100344865 site-directed point mutation 9986 to simulate a major mutation type in Asians (variant#540#p.R778L) with diseaseD006527 (diseaseD006527) by using the CRISPR/Cas9 system combined with single-strand DNA oligonucleotides (ssODNs). The efficiency of the precision point mutation was 52.94% when zygotes were injected 14 hours after HCG treatment and was significantly higher than that of zygotes injected 19 hours after HCG treatment (14.29%). The 9986 carrying the allele with mutant ncbi100344865 died at approximately three months of age. Additionally, the chemicalD003300 content in the livers of 9986 at the onset of diseaseD006527 increased nine-fold, a level similar to the five-fold increase observed in 9606 with diseaseD006527. Thus, the efficiency of precision point mutations increases when RNAs are injected into zygotes at earlier stages, and the ncbi100344865 mutant 9986 are a potential model for 9606 diseaseD006527 with applications in pathological analysis, clinical treatment and gene therapy research.
29449431	Association|chemicalD003300|diseaseD006527; Association|chemicalD003300|diseaseC535468	diseaseD006527: more than meets the eye.diseaseD006527 is a rare but important disorder of diseaseC535468 metabolism, with a failure to excrete chemicalD003300 appropriately into bile. It is a multisystem condition with presentations across all branches of medicine. Diagnosis can be difficult and requires a high index of suspicion. It should be considered in unexplained diseaseD008107 particularly where diseaseC564678 are also present. Treatments are available for all stages of disease. A particularly important presentation not to overlook is diseaseD017114 which carries a high mortality risk and may require urgent liver transplantation. Here, we provide an overview of this complex condition.
32291276	Association|variantrs72552255##|variantrs72552255##; Association|variantrs72552255##|variantrs72552255##; Positive_Correlation|diseaseD003920|variantrs758115611##; Association|chemicalD005947|ncbi3630; Association|variantrs72552255##|diseaseD006527; Association|variantrs758115611##|variantrs758115611##; Association|variantrs72552255##|variantrs72552255##; Negative_Correlation|chemicalD004113|diseaseD012871; Association|chemicalD005947|ncbi540; Association|diseaseD006527|variantrs758115611##; Association|variantrs72552255##|variantrs758115611##; Association|diseaseD006527|variantrs72552255##; Association|diseaseD006527|variantrs72552255##; Positive_Correlation|variantrs758115611##|diseaseD003920; Negative_Correlation|chemicalD004113|chemicalD005947; Association|variantrs758115611##|diseaseD006527; Association|diseaseD006527|variantrs758115611##; Positive_Correlation|diseaseD003920|variantrs758115611##; Association|chemicalD010396|ncbi540; Positive_Correlation|diseaseD003920|variantrs72552255##; Negative_Correlation|chemicalD010396|diseaseD012871; Positive_Correlation|variantrs72552255##|diseaseD003920; Association|diseaseD006527|ncbi540; Positive_Correlation|chemicalD005947|chemicalD010396; Positive_Correlation|diseaseD003920|variantrs72552255##; Negative_Correlation|chemicalD010396|diseaseD006527; Association|chemicalD004113|ncbi3630; Association|variantrs758115611##|variantrs758115611##; Negative_Correlation|chemicalD010396|variantrs758115611##; Association|diseaseD003920|ncbi540; Negative_Correlation|chemicalD004113|diseaseD006527; Association|diseaseD003920|ncbi540; Association|diseaseD006527|ncbi540	diseaseD006527 With Novel Compound Heterozygote Mutations in the ncbi540 Gene Presenting With Severe diseaseD003920.OBJECTIVE: To determine the relationship between ncbi540 mutations and diseaseD003920 in diseaseD006527 (diseaseD006527). RESEARCH DESIGN AND METHODS: A total of 21 exons and exon-intron boundaries of ncbi540 were identified by Sanger sequencing. RESULTS: Two novel compound heterozygous mutations (variantrs758115611##/ variantrs758115611## and variantrs72552255##/ variantrs72552255##) were detected in ncbi540 After chemicalD010396 (chemicalD010396) therapy, serum aminotransferase and ceruloplasmin levels in this 9606 were normalized and levels of HbA1c decreased. However, when the 9606 ceased to use chemicalD010396 due to an diseaseD012871, serum levels of fasting blood chemicalD005947 increased. chemicalD004113 capsules were prescribed and memory recovered to some extent, which was accompanied by decreased ncbi3630 dosage for chemicalD005947 control by 5 units. CONCLUSIONS: This is the first report of diseaseD003920 caused by diseaseD006527.
32886541	Positive_Correlation|chemicalD003300|diseaseD004487; Positive_Correlation|chemicalD003300|diseaseD009135	Skeletal Muscle Involvement in diseaseD006527: Clinical and Magnetic Resonance Imaging (MRI) Observations in 2 Families.OBJECTIVE: Skeletal muscle involvement in diseaseD006527 is rare. Calf diseaseD063806 might be attributed as growing diseaseD010146 in children. We report calf muscle involvement in diseaseD006527 and describe the magnetic resonance imaging (MRI) findings of leg, differential diagnosis with literature review. 9606 AND METHODS: Our observations describe calf muscle diseaseC564543 in 5 cases of diseaseD006527 from 2 families. The clinical presentations were neurologic in 3, hepatic in 1, and asymptomatic in 1 9606. We systematically describe the clinical characteristics and their calf muscle MRI findings. RESULTS: Three 9606 had bilateral diseaseD010146 and intermittent diseaseD009120. The diseaseD010146 was of mild to moderate intensity and managed symptomatically. Serum alkaline phosphatase, creatinine phosphokinase, and needle electromyography were normal. Turbo inversion recovery magnitude sequence MRI of calf muscle revealed hyperintensity in bilateral gastrocnemii muscles. These muscles appear hyperintense in diffusion-weighted imaging. CONCLUSION: The calf muscle involvement could be attributed to diseaseD004487 due to chemicalD003300-induced diseaseD009135 mediated by inhibition of Na+/K+-ATPase on cellular membranes of fast-twitch gastrocnemii muscles which contain predominant type II myofiber. In diseaseD006527 9606 with diseaseD010146 or diseaseD009120, muscle MRI may show nonspecific gastrocnemius hyperintensity. Further evaluation may give insight into its pathophysiology.
31878905	Negative_Correlation|chemicalD003300|diseaseD006527	The study of diseaseD006527 in pregnancy management.INTRODUCTION: Pregnancy management in 9606 with diseaseD006527 (diseaseD006527) remains an important clinical problem. This research was conducted to investigate how to avoid worsening of diseaseD006527 symptoms during pregnancy and increase pregnancy success in 9606 with diseaseD006527 by identifying the best pregnancy management approaches in these 9606. 9606 AND METHODS: The clinical data of 117 pregnancies among 75 9606 with diseaseD006527 were retrospectively analyzed. Related information of the fetus was also recorded and analyzed. At the same time, regression analysis was performed for data of 22 pregnant 9606 without diseaseD006527, as normal controls. RESULTS: Of a total of 117 pregnancies among the 75 9606 with diseaseD006527 and 31 pregnancies among the 22 control womenincluded in this study, there were 108 successful pregnancies and 9 spontaneous abortions. Among the 108 successful pregnancies, 97 9606 a history of chemicalD003300 chelation therapy before pregnancy; all 97 9606 stopped anti-chemicalD003300 therapy during pregnancy. The nine 9606 with diseaseD000022 had no pre-pregnancy history of chemicalD003300 displacement therapy. The incidence of lower diseaseD004487 was higher in the diseaseD006527 group than in normal controls (P = 0.036). Compared with the control group, there was a higher proportion in the diseaseD006527 group of male infants (P = 0.022) and lower average infant birth weight (t = 3.514, P = 0.001). CONCLUSION: It is relatively safe for 9606 with diseaseD006527 9606 to become pregnant. The best management method for pregnancy in 9606 with diseaseD006527 may be intensive pre-pregnancy chemicalD003300 chelation therapy and no anti-chemicalD003300 treatment during pregnancy.
28433100		Diagnosis of diseaseD006527.Clinical presentation of diseaseD006527 can vary widely; therefore diagnosis is not always straightforward. diseaseD006527 is not just a disease of children and young adults, but may present at any age. The key features of diseaseD006527 are diseaseD008107 and diseaseD005355, diseaseD001523, diseaseD012303, and acute episodes of diseaseD006461, often in association with diseaseD017114. Diagnosis is particularly difficult in children and in adults presenting with active diseaseD008107. None of the available laboratory tests is perfect and may not be specific for diseaseD006527. A detailed neurologic examination is required for all cases. Neuroimaging and electrophysiologic methods are helpful. To overcome the diagnostic challenge, several clinical signs (diseaseD012303, diseaseD009461) and laboratory features (chemicalD003300 in serum, urine, liver; serum ncbi1356; genetic testing) are scored 0 (absent) to 2 (present) and the Leipzig score is calculated. If the score is >=4, the diagnosis of diseaseD006527 is very likely. For asymptomatic siblings of index 9606, mutation analysis is the most reliable approach.
34405819		Evaluation of Validity and Efficiency of Diagnostic Criteria in diseaseD019693 in Children.BACKGROUND: diseaseD019693 (diseaseD019693) is a progressive diseaseD008107 with various clinical symptoms, but treatment and prevention of diseaseD017093 and diseaseD005355 is possible with early diagnosis. However, no specific test has been approved for the diagnosis of diseaseD019693. In 2008, the International diseaseD019693 Group (IAIHG) developed a simplified diagnostic scoring system that has been widely used in practice. Nevertheless, it cannot distinguish diseaseD019693 from diseaseD015209 (diseaseD015209) and consensus is lacking with respect to its validity, sensitivity, and applicability for children 9606. The newer 2018 version also requires validation. The present study intends to evaluate the validity and efficiency of the IAIHG simplified scoring system and new scoring system in children with diseaseD019693. METHODS: The present study is a non-interventional case-control study covering 152 9606 with diseaseD056486 (83 9606 with diseaseD019693 and 69 9606 with diseaseD006527 (diseaseD006527)). Titers of autoantibodies, IgG levels, hepatic histology, and absence of diseaseD014777 were scored and calculated according to IAIHG diagnostic criteria. Statistics software package (SPSS) and draft receiver operating characteristic (ROC) curves was used to analyze data and determine value of diagnostic criteria. RESULT: In our study, both scoring systems' accuracy was good in diseaseD019693 diagnosis, although new score displays higher sensitivity and specificity, suggestive of greater accuracy and predictive strength. CONCLUSION: Our study is the first validation study of the new scoring system in diagnosing diseaseD019693, and further studies require verifying this scoring system.
33368534		Ninety days transplant free survival with high volume plasma exchange in diseaseD006527 presenting as diseaseD017114.OBJECTIVE: To study the efficacy and safety of high volume plasma exchange (HVPE) in diseaseD006527 presenting as diseaseD017114 (diseaseD006527-ALF). METHODS: An analysis of prospectively collected data of consecutively admitted diseaseD006527-ALF cases was done and 9606 were divided into two groups: (i) high volume plasma exchange (HVPE) group- who received HVPE + standard medical therapy (SMT), and (ii) SMT group- received only SMT. Outcome measure was transplant free survival (TFS) at 90 days post enrollment, change in biochemical, hemodynamic parameters & incidence of diseaseD009102 in HVPE as compared to SMT group, and HVPE related complications. RESULTS: Out of the total 43 cases of diseaseD006527ALF reported in the study period, 37 were enrolled (median age 9 years, 62.2% males). All biochemical parameters and prognostic indices except blood chemicalD000641 and serum chemicalD003404 improved significantly at 72 to 96 hours after enrollment in the HVPE group. Overall, TFS at 90 days was present in 9/19 (47.3%) in HVPE group vs 3/18 (16.6%) in the SMT group (OR 2.84, 95% CI 0.91-8.8, P = .049). Kaplan Meier survival analysis revealed that HVPE group had significantly higher cumulative survival as per the Log Rank test (P = .027); median days of survival was 38 days (IQR 12-63) in HVPE group vs 14 (IQR 5-22) days in SMT group. CONCLUSIONS: The present study indicates that in children with diseaseD006527-ALF, HVPE not only acts as a bridging therapy to LT but may also improve proportion of the cases with TFS.
29417175	Negative_Correlation|chemicalD014266|diseaseD006527	The steady state pharmacokinetics of chemicalD014266 in diseaseD006527 9606.PURPOSE: To determine the steady state pharmacokinetics of chemicalD014266 in children (>= 12 years of age) and adult 9606 who had been receiving chemicalD014266 therapy prior to the study. METHODS: Twenty 9606 were exposed to chemicalD014266 (chemicalD014266 capsules supplied by Univar) after standard oral dosing as part of ongoing therapy. Plasma chemicalD014266 concentration was determined pre-dose and at 30 min, 1, 1.5, 2, 3, 4, 5, 6, 8, and 12 h post-dose. Concentrations of chemicalD014266 in plasma were determined by LC-MS/MS using a validated bioanalytical method with stable labelled chemicalD014266 as the internal standard. RESULTS: chemicalD014266 was generally absorbed fairly rapidly with a median Tmax of 1.49 h (range, 0.48-4.08 h). There was some variability in exposure, with a 10-fold range in Cmax, and a 13.8-fold range in AUC0-t. This variability was slightly lower when PK parameters were dose-normalised (6.7-fold range in Cmax/D and an 11.6-fold range in AUC0-t/D). The terminal half-life, which could be defined in 14 of the 20 9606, was broadly consistent between 9606 (range of 2.33 to 6.99 h). There was no marked difference in pharmacokinetics between adult 9606 (n = 16) and children (n = 4). The Cmax range was 506 to 3100 ng/mL in adults and 309 to 1940 ng/mL in children-the equivalent ranges for AUC0-t were 1240 to 17,100 ng/mL h and 1500 to 8060 ng/mL h. When PK parameters were normalised for administered dose, the Cmax/D and AUC0-t/D for children were contained within the ranges for the adult 9606. CONCLUSIONS: The steady state pharmacokinetics of chemicalD014266 in diseaseD006527 9606 were broadly similar to that reported in healthy subjects.
30601285		Imaging diseaseD012303 in diseaseD006527 Using In Vivo Confocal Microscopy.PURPOSE: This study analyzes images of Kayser-Fleischer (K-F) rings in 9606 with diseaseD006527 (diseaseD006527) using in vivo confocal microscopy (IVCM) and explores whether IVCM can be a useful clinical tool in facilitating the diagnosis and characterization of K-F rings. METHODS: One hundred four eyes of 52 9606 with diseaseD006527 and K-F rings (K-F group) and 52 normal eyes of 52 age- and gender-matched control subjects (control group) were enrolled in the study. Both K-F and control groups consisted of 29 male 9606 and 23 female 9606. IVCM imaging was performed, and images of the peripheral Descemet membrane were analyzed. RESULTS: All 9606 in K-F group showed abnormal patterns in the peripheral Descemet membrane from IVCM images. These abnormalities can be generally divided into 3 types: patchy, stripy, and spotty patterns. Each 9606 may have a combination of these patterns, with patchy pattern being most prevalent (100%), whereas stripy and spotty patterns are present in 30% to 40% of the K-F rings. Notably, these patterns are not correlated with other systematic symptoms of diseaseD006527. CONCLUSIONS: IVCM images can be used as an objective clinical diagnostic tool to facilitate the identification of K-F rings and the diagnosis of diseaseD006527.
31933160	Association|diseaseD019636|ncbi8398; Association|diseaseD052556|ncbi11128; Association|diseaseD052556|ncbi8398	Recessive diseaseD001259 Differential Diagnosis Algorithm (RADIAL) Versus Specific diseaseD009542 Type disease211750 Suspicion Indices: A Retrospective Algorithm Comparison.Early diagnosis of diseaseD052556 (diseaseD052556) is crucial to slow the progression of neurological manifestations. Different tools were developed to aid diagnosis of diseaseD052556, but to date, no study has compared their performance. We aimed to compare the RADIAL algorithm, intended for the differential diagnosis of diseaseD002524 (diseaseD002524) and diseaseD052556-specific suspicion indices (SIs). This study was a retrospective analysis of data from 834 9606 with molecularly confirmed diseaseD002524, including 57 diseaseD052556 cases (RADIAL cohort). We aimed to compare the algorithm performance of RADIAL (Top 1 and Top 3) with that of four SIs (Original, Refined, 2/3 and 2/7) in discriminating diseaseD052556 cases and non-diseaseD052556 cases. We also identified diseaseD002524 closely related to diseaseD052556 as those with low specificity to detect non-diseaseD052556 cases and described differential and overlapping features with diseaseD052556. Overall, excellent sensitivity and specificity (> 0.90) were achieved with both RADIAL and SI tools for diseaseD052556 cases. The highest sensitivity was attained with the 2/7 SI, Refined SI and Top 3 RADIAL algorithms. Top 1 and Top 3 RADIAL were the most specific tools, followed by the Original SI. The individual comparison of each ARCA revealed that diseaseD006527, ncbi8398-associated diseaseD019636, and diseaseC536319 (ncbi11128) are frequent diseaseD052556 false positives (ncbi8398 and POL3A only with the SIs). Both RADIAL and SI diagnostic approaches showed strong discriminatory potential and may be useful screening tools in different clinical contexts.
29527989	Negative_Correlation|chemicalD000077287|diseaseD004827; Negative_Correlation|chemicalD000077287|diseaseD012640; Association|chemicalD003300|diseaseD006527; Association|chemicalD003300|diseaseD030342	Complications of Liver Transplant in Adult 9606 With the Hepatic Form of diseaseD006527.OBJECTIVES: diseaseD006527 is an diseaseD002869, recessive, diseaseD030342 of chemicalD003300 metabolism that results in the accumulation of chemicalD003300 in many organs and tissues. This disease is mainly characterized by dysfunction due to chemicalD003300 accumulation in the liver, kidney, brain, cornea, bone, heart, and blood cells. The clinical spectrum is broad in diseaseD006527. Asymptomatic diseaseD006527 may be present, but findings related to the involvement of an individual organ or diseaseD009102 can be seen. These findings can include diseaseD002493. Our aim here was to examine the diseaseD002493 and our clinical experience in 9606 who underwent liver transplant for diseaseD006527 in our clinic. MATERIALS AND METHODS: We retrospectively reviewed the medical records of transplant 9606 with diseaseD006527 who were seen at Baskent University Faculty of Medicine Transplantation Science between 2005 and 2017. 9606 demographics, neurologic complaints, findings from neurologic examinations, and imaging findings were recorded. We also recorded the presence of the Kayser-Fleischer ring, serum ncbi1356, 24-hour chemicalD003300 urine levels, and levels of dry chemicalD003300 in liver in each 9606. RESULTS: Our study included 19 9606 who ranged in age range from 18 to 44 years (mean age of 26 years). Seven of 19 9606 (36.8%) had diseaseD009461, including diseaseD004827 in 2 9606 (10.5%), diseaseD001927 in 1 9606 (5.2%), diseaseD014202 in 3 9606 (15.7%), and diseaseD006261 in 1 9606 (5.2%). The cause of these long-term diseaseD002493 was the immunosuppressive drugs. 9606 with diseaseD004827 were provided with diseaseD012640 control medication (chemicalD000077287). diseaseD014202 did not need treatment. CONCLUSIONS: In diseaseD006527, diseaseD002493 can be severe. The most common complication seen in our 9606 was diseaseD014202. Early diagnosis and treatment may slow down diseaseD009069.
34144249		Characteristics and outcomes of hospitalized 9606 with diseaseD006527 in the United States: A national survey.INTRODUCTION AND OBJECTIVES: diseaseD006527 (diseaseD006527) is a rare diseaseD030342 characterized by excessive chemicalD003300 disposition predominantly in the liver and brain. Hospitalization data on 9606 with diseaseD006527 are scarce. Hence, we sought to examine the inpatient characteristics and outcomes of 9606 with diseaseD006527. 9606 AND METHODS: We utilized the National Inpatient Database (2006-2011) and analyzed all adult 9606 with a diagnosis of diseaseD006527. RESULTS: There were 9046 hospitalizations during the study period. The leading etiologies for admissions were diseaseD008107 (8.58%), diseaseD006527 (6.49%) and diseaseD007239 (diseaseD018805 3.10% and diseaseD011014 2.50%). The overall inpatient mortality rate for diseaseD006527 9606 was 2.58%. Independent predictors of mortality in diseaseD006527 9606 were acute diseaseD012131 (OR: 4.53; 95% CI: 2.44-8.42), diseaseD058186 (OR: 4.09; 95% CI: 2.19-7.65), decompensated diseaseD008107 or diseaseD017093 (OR: 3.37; 95% CI: 1.72-6.59), and advanced age (every 10 year increase, OR: 1.48; 95% CI: 1.25-1.75). Propensity-score matched analysis revealed better inpatient survival in diseaseD006527 9606 compared to matched non-diseaseD006527 9606 (2.84% vs. 4.67%, p = 0.01). CONCLUSIONS: Our study demonstrated the clinical characteristics and outcomes of hospitalized 9606 with diseaseD006527. These findings add important knowledge to our understanding of the healthcare utilization and outcomes of this rare disease in the United States.
30686905	Negative_Correlation|chemicalD001663|diseaseD006527; Association|chemicalD001663|diseaseD005355	Differential hepatic features presenting in diseaseD006527-associated diseaseD005355 and diseaseD006509-associated diseaseD005355.BACKGROUND: diseaseD005355 is a chronic late stage diseaseD008107 associated with hepatitis viruses, diseaseD000437, and diseaseD008659, such as diseaseD006527 (diseaseD006527). There are no clear markers or clinical features that define diseaseD005355 originating from these disparate origins. We hypothesized that diseaseD005355 is not one disease and diseaseD005355 of different etiology may have differential clinical hepatic features. AIM: To delineate the liver features between diseaseD006527-associated diseaseD005355 and diseaseD006509-associated diseaseD005355 in the Chinese population. METHODS: In this observational study, we reviewed the medical data of consecutive 9606 who had diseaseD006527-associated diseaseD005355 or diseaseD006509-associated diseaseD005355 from January 2010 to August 2018, and excluded 9606 who had diseaseD009369, severe diseaseD011660, or other diseaseD008107. According to the etiology of diseaseD005355, 9606 were divided into two groups: diseaseD006527-associated diseaseD005355 group (60 9606) and diseaseD006509-associated diseaseD005355 group (56 9606). The diseaseD008103 degree, liver function indices, and diseaseD006975 features of these 9606 were compared between the two groups. RESULTS: No inter-group differences were observed in the diagnostic diseaseD008103 markers, however, clinical features clearly defined the origin of diseaseD005355. diseaseD006527-associated diseaseD005355 9606 (16-29 years) had lower levels of alanine transaminase, aspartate transaminase, and chemicalD001663, lower prothrombin time, lower incidence of diseaseD006501, and lower portal vein diameter (P < 0.05), compared to diseaseD005355 resulting from diseaseD006509 in older 9606 (45-62 years). Importantly, they had decreased risks of progression from Child-Pugh grade A to B (odds ratio = 0.046, 95% confidence interval: 0.006-0.387, P = 0.005) and of diseaseD001201 (odds ratio = 0.08, 95% confidence interval: 0.01-0.48, P = 0.005). Conversely, diseaseD006527-associated diseaseD005355 9606 had a higher risk of diseaseD013163 (odds ratio = 4.15, 95% confidence interval: 1.38-12.45, P = 0.011). CONCLUSION: diseaseD006527-associated diseaseD005355 presents a higher risk of diseaseD013163 associated with diseaseD007970 and diseaseD013921, although revealing milder diseaseD017093 and diseaseD006975 symptoms, which recommends diseaseD006527 9606 to be monitored for associated complications.
31546533		Resolution of diseaseD012303 in diseaseD006527.
36071243	Association|diseaseD006527|ncbi540; Association|diseaseC548032|ncbi540; Association|diseaseC564835|ncbi161742; Association|diseaseC564835|ncbi540; Association|diseaseD006527|ncbi2261; Association|diseaseC548032|ncbi161742; Association|diseaseC548032|ncbi10002; Association|diseaseD006527|ncbi10002; Association|diseaseC564835|ncbi2261; Association|diseaseC564835|ncbi10002; Association|diseaseC548032|ncbi2261; Association|diseaseD006527|ncbi161742	Exome sequencing for structurally normal fetuses-yields and ethical issues.The yield of chromosomal microarray analysis (CMA) is well established in structurally normal fetuses (0.4-1.4%). We aimed to determine the incremental yield of exome sequencing (ES) in this population. From February 2017 to April 2022, 1,526 fetuses were subjected to ES; 482 of them were structurally normal (31.6%). Only pathogenic and likely pathogenic (P/LP) variants, per the American College of Medical Genetics and Genomics (ACMG) classification, were reported. Additionally, ACMG secondary findings relevant to childhood were reported. Four fetuses (4/482; 0.8%) had P/LP variants indicating a moderate to severe disease in ncbi540, ncbi10002, ncbi161742 and ncbi2261, causing diseaseD006527, Enhanced diseaseC564835, diseaseC548032, respectively. Two fetuses had secondary findings, in ncbi5979 and DSP. Our data suggest that offering only CMA for structurally normal fetuses may provide false reassurance. Prenatal ES mandates restrictive analysis and careful management combined with pre and post-test genetic counseling.
29692402		Indian childhood diseaseD005355 - down but not out: Report of a rare case with a practical clinicopathological diagnostic approach.Indian childhood diseaseD005355 is an entity believed to be on the verge of extinction. We present the case of a 13-month-old girl presenting acutely with diseaseD007565, diseaseD005334, and persistently increasing chemicalD001663. Investigations revealed direct diseaseD006932, elevated transaminases, diseaseD000740, a blood with few schistocytes, positive direct coombs test, and deranged prothrombin time. Viral, autoimmune, and metabolic workup was unremarkable. Ultrasonography showed diseaseD008107, diseaseD006975, and diseaseD001201. Due to numerous confounding factors and a low index of suspicion, the diagnosis of Indian childhood diseaseD005355 remained elusive and was clinched only on liver biopsy, albeit more than three weeks later, shortly after which the child expired. The timing and technique of the liver biopsy may have profound impact on the ultimate clinical outcome. Close coordination between the clinical and pathological teams is essential for deciphering acute presentations where the etiology is uncertain. We highlight the clinical considerations, varied morphological pointers, and offer a diagnostic algorithm facilitating the consideration of this disease.
30879594		Rendezvous Technique Using Double Balloon Endoscope for Removal of Multiple Intrahepatic Bile Duct diseaseD007669 in Hepaticojejunostomy After Living Donor Liver Transplant: A Case Report.diseaseD002761 is a major complication following transplantation. We report a living donor liver transplant (LDLT) 9606 with diseaseD002761 due to multiple diseaseD007669 in the intrahepatic bile duct during hepaticojejunostomy anastomosis, who was successfully treated with the rendezvous technique using double balloon endoscope. A 64-year-old 9606 underwent LDLT with right lobe graft and hepaticojejunostomy for diseaseD006527. There was diseaseD003763 with diseaseD010538, which was treated conservatively after transplant. Two years after surgery, she developed diseaseD016918 due to diseaseD003251 of hepaticojejunostomy anastomosis and multiple diseaseD007669 in the intrahepatic bile ducts. Percutaneous transhepatic biliary drainage was performed. The size of the drainage tube was increased, and the anastomotic area was dilated in a stepwise manner using a balloon catheter. The diseaseD007669 were crushed and lithotomy was performed using electronic hydraulic lithotripsy through cholangioscopy. Finally, lithotomy was performed for the remaining diseaseD007669 through endoscopic retrograde cholangiography with the rendezvous technique using the double balloon endoscope. Rendezvous approach with percutaneous transhepatic biliary drainage and double balloon endoscopic retrograde cholangiography was an effective treatment for the multiple diseaseD007669 in hepaticojejunostomy following LDLT with right lobe graft.
34087921		Blind liver biopsy: a 17-year experience.OBJECTIVES: Liver biopsy is the gold standard for assessing diseaseD007249, diseaseD009336 and diseaseD005355. The aim of the study is to evaluate clinical indications and histopathological results of percutaneus liver biopsy. MATERIALS AND METHODS: A total of 516 children who underwent blind liver biopsy were evaluated retrospectively. RESULTS: Blind liver biopsy was performed for diseaseD019694 in 50% of the cases (n=260), diseaseD007232 in 14% (n=68), diseaseD019693 in 7.7% (n=40), diseaseD006527 in 7.3% (n=38), isolated elevation of the liver enzymes in 5% (n=26), diseaseD019698 in 4.2% (n=22), diseaseD008659 in 3.4% (n=17), diseaseD009369 in 2.2% (n=11) and the others in 3.4% (n=17). Major complications were observed in 0.19% of the cases (n=1) and minor complications such as diseaseD010146 at the biopsy site in 13.5% of the cases (n=70), diseaseD007022 and diseaseD013610 in 1.9% (n=10). CONCLUSIONS: Blind liver biopsy is a safe method in diagnosing diseaseD008107 in childhood.
33541028	Negative_Correlation|chemicalD010396|diseaseD006527; Negative_Correlation|chemicalD014494|diseaseD006527; Negative_Correlation|chemicalC020809|diseaseD006527	[Advances in the treatment of diseaseD006527].diseaseD006527 is kind of an diseaseD030342. Early diagnosis and timely treatment are very important for prognosis. This article reviews the treatment of diseaseD006527, focusing on chemicalD010396, chemicalD014494, chemicalC020809 and zinc, liver transplantation and gene therapy. At the same time, the problems of medication adherence and follow-up evaluation in 9606 with diseaseD006527 are also discussed.
38175989		Teaching NeuroImage: Neuroimaging Features of diseaseD006527.A 13-year-old boy of nonconsanguineous parents presented with diseaseD004409, diseaseD020234, and slurring of speech for 2 years. On examination, he had diseaseD009127, diseaseD004421, diseaseD004401, and diseaseD012798. Ophthalmologic examination revealed bilateral Kayser-Fleischer rings. He had elevated serum "free" chemicalD003300 levels (41.2 mug/dL [range:10-15]), 24-hour urine chemicalD003300 levels (895.7 mug/d [range:<60]), and reduced serum ncbi1356 levels (4.3 mg/dL (range:20-40]). MRI revealed "face of 9646" appearance (Figure A), T2-fluid attenuated inversion recovery hyperintensities (Figure, B and C), and frontal cystic encephalomalacic changes (Figure D), suggestive of diseaseD006527 (diseaseD006527). Face of 9646 in diseaseD006527, first described by Hitoshi et al.,1 is due to high signal intensity in tegmentum with normal signals in red nuclei forming the eyes, normal signals of pars reticulata (lateral portion) of substantia nigra forming the ears, and hypointensity of superior colliculus forming the chin.2 Bilateral cystic changes are less commonly reported in diseaseD006527 Recognizing diverse neuroimaging signatures beyond well-known findings in diseaseD006527 enhances diagnostic accuracy.
29321352	Positive_Correlation|diseaseD006527|variantrs777629392##; Positive_Correlation|diseaseD006527|variantrs753236073##; Positive_Correlation|diseaseD006527|variantrs28942074##; Association|diseaseD006527|ncbi540; Association|diseaseD006527|ncbi540	Genetic analysis of 55 northern Vietnamese 9606 with diseaseD006527: seven novel mutations in ncbi540.diseaseD006527 (diseaseD006527) is an diseaseD030342 of diseaseC535468 metabolism. The gene responsible for diseaseD006527 was discovered in 1993 and is located on chromosome 13 at 13q14.3. It encodes a copper-specific transporting P-type ATPase. Early diagnosis can improve treatment outcome and decrease the rate of disability or even mortality.We used Sanger sequencing to identify mutation hot spots in 55 northern Vietnamese with a clinical diagnosis of diseaseD006527. Mutations were screened and detected by direct DNA sequencing. A total of 26 different ncbi540 gene mutations were identified, including seven novel mutations (five nonsense and two missense mutations). The most frequent mutations were variantrs753236073## (24.55%), variantrs28942074## (5.45%) and variantrs777629392## (4.55%). Mutation detection rate in exon 2 was 34.55% and ranked first, followed by exon 8 with 16.36%, and exon 18 with 10.91% each, thus, exons 2, 8 and 18 are the mutation hot spots for northern VietnameseWD 9606. These findings were different from previous studies in Asia. Our research established a suitable strategy for ncbi540 gene testing in northern Vietnamese diseaseD006527 9606.
29356957	Association|diseaseD006527|variant##p.V176fsX; Association|diseaseD020521|variant##p.V176fsX	Recurrent diseaseD020521-like episodes of diseaseD006527 with a novel variant##p.V176fsX mutation.
30357869	Negative_Correlation|chemicalD010396|diseaseD017114; Negative_Correlation|chemicalD010396|diseaseD006527	Reversal of diseaseD017114 Due to diseaseD006527 by a Regimen of High-Volume Plasma Exchange and chemicalD010396.
31568969	Positive_Correlation|chemicalD003300|diseaseD006527; Negative_Correlation|chemicalD008550|diseaseD006527; Negative_Correlation|chemicalD003300|chemicalD008550; Negative_Correlation|chemicalD008550|diseaseD005355	chemicalD008550: A hypothesis regarding its use to treat diseaseD006527.diseaseD006527 is associated with excessive chemicalD003300 accumulation in cells, primarily in the liver and brain. The subcellular lesions caused by an excess of this essential metal accounts for many of the signs of diseaseD006527. The drugs used to treat this disease are not always effective, and depending on dose, they may have collateral diseaseD064420. chemicalD008550 is an endogenously-produced molecule that functions as a chemicalD003300 chelator, a potent antioxidant, and as a suppressor of endoplasmic reticulum stress and the unfolded protein response in both the liver and the brain, while also reducing diseaseD005355/diseaseD005355 in the liver. chemicalD008550 is inexpensive, non-toxic and can be administered via any route. chemicalD008550 should be tested for its potential utility in experimental models of diseaseD006527 with extension to the 9606 if chemicalD008550 proves to be effective in the animal studies.
33369596		Long-Term Urinary chemicalD003300 Excretion on Chelation Therapy in Children with diseaseD006527.OBJECTIVES: In diseaseD006527 (diseaseD006527), 24-hour urinary chemicalD003300 excretion (UCE) is recommended to be used for diagnosis. It may be a useful tool to assess the efficacy of treatment during follow-up; however, there are limited data regarding the cutoff value of 24-hour UCE during follow-up in children. Therefore, we aim to evaluate the clinical use of 24-hour UCE during follow-up in children with diseaseD006527. 9606 AND METHODS: Medical records of children diagnosed with diseaseD006527 at Kings' College Hospital from 2005 to 2018 were retrospectively reviewed. The UCE, serum chemicalD003300, and ncbi1356 levels, tested during follow-up, were statistically analyzed. RESULTS: Over the median duration of 7 years (range 1.4-14.4), 28 9606 (age ranged 3.8-17.3 years) had UCE tests during follow-up. Of those, 21 9606 had at least one 24-hour UCE test and 7 children had only spot UCE tests. In comparison with the level of 24-hour UCE collected at the first visit after chemicalD010396 challenge test, the median excretion rate was significantly reduced over the follow-up period (P < 0.001), from 26.2 to 8.9 mumol/day following 1-2 years of therapy (P = 0.15), then reduced significantly to 2.2 mumol/day after 3-4 years (P = 0.009), and 5.6 mumol/day at >5 years of follow-up (P = 0.003). CONCLUSIONS: Our study suggests that within 1 year of treatment, the level of nonceruloplasmin-bound chemicalD003300 concentration (NCC) drops to <0.8 mumol/L. In the absence of progressive diseaseD008107 or signs of diseaseC535468, 24-hour UCE decreases to <=8 mumol/day and <6 mumol/day after 1 and 5 years of treatment, respectively.
28975833		The Role of Diagnosis and Treatment of diseaseD008107 for the Prognosis of diseaseD006528.diseaseD006528 (diseaseD006528) is the third leading cause of diseaseD009369-related deaths worldwide. Underlying diseaseD008107 has been associated with an increased risk of developing diseaseD006528. This study is a review of the current literature regarding the diagnosis, prognostic significance, and role of treating diseaseD008107 in 9606 who are at risk of diseaseD006528. Relevant peer review of the English literature between 1980 and 2017 within PubMed and the Cochrane library was conducted for scientific content on current advances in managing diseaseD008107 and the development of diseaseD006528. 11103, 10407 (10407), diseaseD065626, diseaseD019693, diseaseD006432, diseaseD006527, diseaseD008105, diseaseD019896, and certain drugs lead to an increased risk of developing diseaseD006528. 9606 with diseaseD008107 have an increased incidence of diseaseD006528. 11103, 10407, and diseaseD006432 can directly lead to diseaseD006528 without the presence of diseaseD005355, while diseaseD006528 related to other underlying diseaseD008107 occurs in 9606 with diseaseD005355. Treating the diseaseD008107 and reducing the progression to diseaseD005355 should lead to a decreased incidence of diseaseD006528.
30665472		Clinical Utility of Longitudinal Measurement of Motor Threshold in diseaseD006527.This study describes the longitudinal changes of resting motor threshold (RMT) and central motor conduction time (CMCT) in 18 9606 with diseaseD006527 (diseaseD006527). The RMT, CMCT, and Global Assessment Scale for diseaseD006527 (GAS-diseaseD006527) were measured at baseline and at follow-up after 12.94 +- 7.23 months. There was a significant decrease in the RMT (72.11 +- 18.62 vs. 63.7 +- 15.52%; p-value = 0.002) and GAS-diseaseD006527 scores (14.38 +- 5.35 vs. 9.77 +- 6.47 ms; p-value = 0.04). CMCT did not improve despite chelation therapy. Hence, RMT may serve as a marker of chelation efficacy in diseaseD006527.
29153911		Unusual osseous presentation of diseaseD006527 in a child.
28715695	Positive_Correlation|diseaseD019698|ncbi2475; Association|diseaseD006528|ncbi207; Association|diseaseD006528|ncbi1981; Positive_Correlation|diseaseD006528|ncbi83939; Association|diseaseD006528|ncbi1975; Positive_Correlation|diseaseD008108|ncbi2475; Positive_Correlation|diseaseD006528|ncbi2475; Positive_Correlation|diseaseD006528|ncbi5728; Association|diseaseD019694|ncbi1983; Association|diseaseD006528|ncbi1983; Association|diseaseD006528|ncbi8661; Association|diseaseD019694|ncbi1975; Association|diseaseD006527|ncbi5728; Positive_Correlation|diseaseD005235|ncbi5728; Association|diseaseD006528|ncbi8669; Association|diseaseD006528|ncbi8664; Association|diseaseD006528|ncbi8662; Association|diseaseD019694|ncbi8661; Positive_Correlation|diseaseD006527|ncbi2475; Positive_Correlation|diseaseD019694|ncbi5728; Association|diseaseD006528|ncbi3692; Association|diseaseD019694|ncbi83939	New diseaseD006528 biomarkers: PI3K/ncbi207/ncbi2475 pathway members and eukaryotic translation initiation factors.diseaseD006528 (diseaseD006528) is the third leading cause of diseaseD009369-related deaths worldwide. The initiation of protein translation is an important rate-limiting step in eukaryotes and is crucial in many diseaseD014777. Eukaryotic translation initiation factors (eIFs) are involved in the initiation step of protein translation and are linked to the phosphatidylinositol-3-kinases PI3K/ncbi207/ncbi2475 pathway. Therefore we aimed to investigate a potential role of eIFs in diseaseD006528. We herein report on the immunohistochemical expression of the various eIF subunits in 235 cases of virus-related 9606 diseaseD006528. Additionally, we used immunoblot analysis to investigate the expression of virus-related diseaseD006528 and non-virus-related diseaseD006528 in comparison to controls. ncbi2475 (or ncbi2475 as it is known now (ncbi2475) and activated ncbi2475 were significantly increased in diseaseD019698 (HCV)-associated diseaseD006528, in diseaseD006528 without a viral background, in diseaseD008108 and diseaseD006527. pPTEN, ncbi5728 (ncbi5728) and pAKT showed a significant increase in HBV- and HCV-associated diseaseD006528, diseaseD019694, diseaseD006528 without a viral background, diseaseD005235 (diseaseD005235) and diseaseD006527. Phosphorylated (p)-ncbi83939, ncbi83939, ncbi8662, ncbi8664, ncbi8669, p-ncbi1975, ncbi1981 and ncbi3692 were upregulated in HCV-associated diseaseD006528. ncbi83939, p-ncbi1975, ncbi1983 and various ncbi8661 subunits were significantly increased in diseaseD019694 (HBV)-associated diseaseD006528. diseaseD006528 without viral background displayed a significant increase for the eIF subunits p-2alpha, 3C, 3I, 4E and 4G. We noticed engraved differences in the expression pattern between diseaseD019694, HBV- and HCV-associated diseaseD006528 and non-virus-related diseaseD006528.
32276787	Association|chemicalD003300|chemicalD003404; Association|chemicalD003404|diseaseD006527; Association|chemicalD003300|diseaseD006527	Reference intervals of spot urine chemicalD003300 excretion in preschool children and potential application in pre-symptomatic screening of diseaseD006527.The objectives were to determine the reference intervals of spot urine chemicalD003300 excretion indexes in pre-school children and to evaluate their utility in screening for diseaseD006527 (diseaseD006527). With spot urine collected from a control sample of preschool children (aged 3-7 years, n=153), the reference intervals of spot urine chemicalD003300 excretion indexes and their biological variation were defined. In order to investigate their utility performance in screening for diseaseD006527 in this age group, multiple spot urine samples from six diseaseD006527 9606 who were diagnosed at presymptomatic stage were also analysed and compared. Cut-off values useful for detection of diseaseD006527 were defined by receiver operator curve (ROC) analysis. Biological (inter-individual) variation of spot urine chemicalD003300 indexes expressed as coefficient of variation (CVg) were around 60% at this age group, which was moderate and similar to other clinically useful urine tests, such as urine albumin excretion ratio. Spot urine chemicalD003300 excretion strongly correlated with both urine chemicalD003404 and osmolality. Linear regression against both chemicalD003404 and osmolality showed that ~94% of data points in healthy preschool children fell within the prediction interval, suggesting that both were useful normalisation factors. ROC showed that chemicalD003300 to osmolality ratio was the best index with an area under curve (AUC) greater than 0.98. Cut-off values of 0.5 mumol/L, 0.1 mumol/mmol and 0.00085 mumol/mOsmol (32 mug/L, 56 mug/g chemicalD003404 and 0.054 mug/mOsmol, respectively, in conventional units) for spot urine chemicalD003300 concentration, chemicalD003300 to chemicalD003404 ratio and chemicalD003300 to osmolality ratio, respectively, have potential application in the differentiation of diseaseD006527 9606. Based on the data, a new diseaseD006527 screening strategy targeting preschool children is proposed. Application of a bivariate screening strategy using spot urine chemicalD003300 concentration and urine osmolality may be useful in a population-wide screening program for diseaseD006527 among preschool children.
28126506	Negative_Correlation|chemicalD007980|diseaseD010300; Negative_Correlation|chemicalD007980|diseaseD010302	[Other causes of diseaseD010302].Numerous causes may induce diseaseD010302, and in case of diseaseD010302, chemicalD007980 resistance, associated neurological signs, early falls, early diseaseD054969 or early diseaseD003072 are the main red flags which should lead to exclude diseaseD010300. diseaseD010302 and in young people, diseaseD006527, should always be searched. Lower limbs diseaseD010302 is often due to diseaseD014652. diseaseD019578, diseaseD013494, diseaseD020961 and the rarer diseaseD000088282, each have specific clinical signs. Genetic causes are rarer.
32067425		The co-occurrence of diseaseD006527 and diseaseC537409 in one family highlights the promising diagnostic potential of proteolytic analysis.BACKGROUND: We report the first case of a family with co-occurrence of diseaseD006527 (diseaseD006527), an diseaseC535468, and diseaseC537409 (diseaseC537409), a diseaseD000081207 (diseaseD000081207) that features marked reduction in circulating B lymphocytes and serum immunoglobulins. METHODS AND RESULTS: Through utilization of a multiplexed biomarker peptide quantification method known as the immuno-SRM assay, we were able to simultaneously and independently identify which family members are affected with diseaseD006527 and which are affected with diseaseC537409 using dried blood spots (DBS). CONCLUSION: Being able to delineate multiple diagnoses using proteolytic analysis from a single DBS provides support for implementation of this methodology for clinical diagnostic use as well as large-scale population screening, such as newborn screening (NBS). This could allow for early identification and treatment of affected individuals with diseaseD006527 or diseaseC537409, which have been shown to reduce morbidity and decrease mortality in these two populations.
30368998	Positive_Correlation|chemicalD015032|diseaseD001927	Recovery of severe diseaseD017114 without transplantation in 9606 with diseaseD006527.diseaseD006527 (diseaseD006527) is a disorder of diseaseC535468 that leads to diseaseD008103. diseaseD006527 9606 with a NWIS > 11 should receive LT; however, we encountered 2 diseaseD006527 9606 with an NWIS > 11 who recovered from ALF without LT. The present report aimed to analyze cases of diseaseD006527 9606 with a high NWIS who recovered from severe ALF and to discuss the clinical manifestations of the 9606 and the effects of treatments, including zinc (chemicalD015032) therapy, chelator therapy, PE, CHDF, and LT. We retrospectively evaluated the medical records of five 9606 (male, 2; female, 3) diagnosed with diseaseD006527 along with severe ALF. In cases 1, 2, and 3, complete recovery from ALF was noted without LT. In case 4, initial recovery from ALF was noted without LT; however, ALF worsened owing to diseaseD006470 from the esophageal varix. Thus, the 9606 eventually needed LT. In case 5, recovery from ALF was noted with LT. All cases, except case 2, showed ALF with maximum PELD/MELD scores >=26 and NWISs >= 11, and had indications for LT. In cases of severe ALF with grade I or II diseaseD001927, we recommend evaluations of the effects of chemicalD015032 and chelator treatments while preparing for LT, as the condition may not improve without LT, and pediatricians or physicians can ask transplant surgeons to perform LT urgently if required.
29579829		diseaseD003643 Analysis of diseaseD017114 in Uruguay.BACKGROUND: diseaseD017114 (diseaseD017114) is a syndrome with high diseaseD003643. OBJECTIVE: Describe characteristics and outcomes of 9606 with diseaseD017114 in Uruguay, and identify factors associated with diseaseD003643. METHODS: A retrospective analysis of 33 9606 with diseaseD017114 was performed between 2009 and 2017. RESULTS: The 9606' median age was 43 years, and 64% were 9606. Average Model for End-Stage Liver Disease (MELD) score at admission was 33. The median referral time to the liver transplant (LT) center was 7 days. The most common etiologies were diseaseD014777 (27%), indeterminate (21%), autoimmune (18%), and diseaseD006527 (15%). Overall diseaseD003643 was 52% (71% of transplanted and 46% of nontransplanted 9606). Dead 9606 had higher referral time (10 vs 4 days, P = .008), higher MELD scores at admission (37 vs 28) and highest achieved MELD scores (42 vs 29; P < .001), and higher diseaseD001927 grade III to IV (94% vs 25%, P < .001) than survivors. 9606 without LT criteria (n = 4) had lower MELD score at admission (25 vs 34, P = .001) and highest achieved MELD score (27 vs 37, P = .008) compared with the others. 9606 with LT criteria but contraindications (n = 7) had higher MELD scores at admission (38 vs 31, P = .02), highest achieved MELD scores (41 vs 34, P = .03), and longer referral time (10 days) than those without contraindications (3.5 days) or those without LT criteria (7.5 days, P = .02). Twenty-two 9606 were listed; LT was performed in 7, with a median time on waiting list of 6 days. CONCLUSIONS: diseaseD017114 in Uruguay has high diseaseD003643 associated with delayed referral to the LT center, MELD score, and diseaseD001927. The long waiting times to transplantation might influence diseaseD003643.
31377039		diseaseC531816 with diseaseD004401 and Frequent diseaseC537863: A diseaseD009358.
37936530		Outcome of pediatric living donor liver transplant: Experience from Pakistan; a resource limited setting.INTRODUCTION: Liver transplantation (LT) has emerged as a lifesaving modality for many diseaseD008107 in children. Pediatric LT is an established treatment in the Western world but is relatively a new procedure in resource-limited countries like Pakistan. The study aims to highlight the outcomes and survival of pediatric recipients from the first pediatric liver transplant center in Pakistan. METHOD: A retrospective analysis of pediatric LT was done from 2012 to 2019. The study was conducted in the Hepatobiliary and liver transplant department of Shifa International Hospital (SIH), Islamabad. A detailed analysis for indications for pediatric LT, survival, and complications was done. RESULTS: Forty-five patients under 18 years of age underwent Living donor liver transplant (LDLT) in SIH. Median age was 9 years and M:F of 2:1. diseaseD008107 followed by diseaseD006527 were the two most common indications of LT. The majority of patients had diseaseD008107 34 (75%) while 11 (24%) had diseaseD017114. The right lobe graft was the most common type of graft 19 (42.2%). Thirty days, 1-year, 3-year, and 5-year survival was 77.8%, 75.6%, 73.3%, and 60.6% respectively. Mortality was highest in patients with diseaseD001656 4 (33%). Causes of diseaseD003643 included diseaseD011655, diseaseD018805, surgical complications, and diseaseD058186. Mean survival was 88.850 months (+-7.899) (CI 73.369-104.331). CONCLUSION: Pediatric LDLT has offered disease-free survival for patients. Survival can improve further with nutritional rehabilitation and anticipation and management of post-operative complications.
28861905		Treatable inherited rare movement disorders.There are many rare diseaseD009069, and new ones are described every year. Because they are not well recognized, they often go undiagnosed for long periods of time. However, early diagnosis is becoming increasingly important. Rapid advances in our understanding of the biological mechanisms responsible for many rare disorders have enabled the development of specific treatments for some of them. Well-known historical examples include diseaseD006527 and diseaseC538007, for which specific and highly effective treatments have life-altering effects. In recent years, similarly specific and effective treatments have been developed for more than 30 rare diseaseD013132. These treatments include specific medications, dietary changes, avoidance or management of certain triggers, enzyme replacement therapy, and others. This list of treatable rare diseaseD009069 is likely to grow during the next few years because a number of additional promising treatments are actively being developed or evaluated in clinical trials.   2017 International diseaseD009069 Society.
28516971		Salivary biomarkers and proteomics: future diagnostic and clinical utilities.Saliva testing is a non-invasive and inexpensive test that can serve as a source of information useful for diagnosis of disease. As we enter the era of genomic technologies and -omic research, collection of saliva has increased. Recent proteomic platforms have analysed the 9606 salivary proteome and characterised about 3000 differentially expressed proteins and peptides: in saliva, more than 90% of proteins in weight are derived from the secretion of three couples of "major" glands; all the other components are derived from minor glands, gingival crevicular fluid, mucosal exudates and oral microflora. The most common aim of proteomic analysis is to discriminate between physiological and pathological conditions. A proteomic protocol to analyze the whole saliva proteome is not currently available. It is possible distinguish two type of proteomic platforms: top-down proteomics investigates intact naturally-occurring structure of a protein under examination; bottom-up proteomics analyses peptide fragments after pre-digestion (typically with trypsin). Because of this heterogeneity, many different biomarkers may be proposed for the same pathology. The salivary proteome has been characterised in several diseases: diseaseD000077195 and diseaseD007972, diseaseD000092122 diseaseD012859 and other diseaseD001327 such as diseaseD020083, diseaseD012559 and diseaseD001714, and diseaseD030342 like diseaseD004314 and diseaseD006527. The results of research reported herein suggest that in the near future 9606 saliva will be a relevant diagnostic fluid for clinical diagnosis and prognosis.
28495941		diseaseD001284 and diseaseD054972 in diseaseD006527.BACKGROUND AND PURPOSE: The diseaseD010302 index helps in differentiating diseaseD013494 from diseaseD010300 and diseaseD019578. diseaseC564676 is common in neurologic diseaseD006527, but there is no prior study evaluating the diseaseD010302 index and its indices in diseaseD006527. We report the diseaseD010302 index and its indices in diseaseD006527 and correlate these changes with clinical severity and diseaseD054972. MATERIALS AND METHODS: Thirteen individuals with neurologic diseaseD006527 were included, and their clinical details, including neurologic severity, diseaseD012021, and location of signal changes on MR imaging, were noted. The 3D BRAVO T1 sequence was used for measurement of the diseaseD010302 index and its indices. The diseaseD010302 index and its indices were also obtained in 6 age- and sex-matched controls. The morphometric parameters in diseaseD006527 were compared with those in with healthy controls and among the 9606 with and without diseaseD012021. RESULTS: The midbrain area was reduced in 9606 with diseaseD006527 compared with controls (112.08 +- 27.94 versus 171.95 +- 23.66 mm2, P = .002). The 9606 with an diseaseD012021 had an increased diseaseD010302 index and pons-to-midbrain ratio compared with controls, whereas these parameters were equivalent in 9606 with normal diseaseD054972 and controls. The 9606 with diseaseD012021 had more severe illness, evidenced by higher Burke-Fahn-Marsden scores (51.0 +- 32.27 versus 13.75 +- 12.37, P = .04) and neurologic severity grades (2.57 +- 0.53 versus 1.67 +- 0.82, P = .04). CONCLUSIONS: An increase in the diseaseD010302 index in diseaseD006527 is mainly due to diseaseD020295 and it correlates with neurologic severity and diseaseD012021.
36422847		Plugged percutaneous liver biopsy using Tru-cut needle and coils: A retrospective study.BACKGROUND: Plugged percutaneous liver biopsy, though has been in use for many years, is being used more frequently in 9606 in whom percutaneous liver biopsy is contraindicated due to proven or probable diseaseD006470 tendencies. We report our experience with this procedure, its indications, efficacy, and complications in Indian population over 2 years. METHODS: A retrospective study of 127 consecutive 9606 who had undergone plug liver biopsy from April 2017 to May 2019 was done from the database maintained in our department. The indications, technical success, complications, and impact of histological diagnosis on the management of those 9606 were evaluated. RESULTS: A total of 127 biopsies were performed of which 68 were males and 59 were females, aged between 7 and 73 years. No procedures were abandoned; however, 13 cases needed ultrasonography (USG) guidance because of small size of the liver or presence of right perihepatic fluid. Out of 127 biopsies, none of the samples was inadequate and yielded adequate tissue for histopathological diagnosis. Seven 9606 required repeat study only because underlying diseaseD008107 was suspected clinically and the previous biopsy report had turned out to be normal. Histopathological examination in our study showed diseaseD019693 in 61, diseaseD000094724 changes either 10407 (10407) or 11103 (11103) related in 40, diseaseD006504 in 3, diseaseD002779 in 2, and diseaseD006527 in 2 9606. The remaining 19 were normal. Complications occurred in 3 9606 - diseaseD005402, diseaseD011030, and inadequate coiling causing mild diseaseD006465. CONCLUSION: Percutaneous liver biopsy followed by plugging of the tract with coils is a safe, easy, and effective method in 9606 with underlying diseaseD006470 tendencies, minimal diseaseD001201, and small liver.
29325220	Positive_Correlation|chemicalD001654|diseaseD007683; Positive_Correlation|chemicalD001663|diseaseD058186	Profile, risk factors and outcome of diseaseD058186 in paediatric diseaseD065290.BACKGROUND & AIMS: There are no studies on diseaseD058186 in paediatric diseaseD065290. This study was planned with aim to describe the clinical presentation and outcome of diseaseD058186 among paediatric diseaseD065290 9606. METHODS: Data of all children 1-18 years of age presenting with acute diseaseD058625 (Asia pacific association for the study of the liver definition) was reviewed. diseaseD058186 was defined as per diseaseD007674-Improving Global Outcomes guidelines. Poor outcome was defined as diseaseD003643 or need for liver transplant within 3 months of development of diseaseD058186. RESULTS: A total of 84 children with diseaseD065290 were presented to us in the study period. diseaseD058186 developed in 22.6% of 9606 with diseaseD065290. The median duration from diseaseD065290 to development of diseaseD058186 was 4 weeks (Range: 2-10 weeks). The causes of diseaseD058186 were diseaseD006530 (31.6%), diseaseD018805 (31.6%), nephrotoxic drugs (21%), diseaseD003681 (10.5%) and chemicalD001654 related diseaseD007683 in one 9606. On univariate analysis, higher baseline chemicalD001663, higher international normalized ratio, higher paediatric diseaseD058625, presence of diseaseD018746 and presence of spontaneous diseaseD010538 had significant association with presence of diseaseD058186. On logistic regression analysis, presence of diseaseD018746 (adjusted OR: 8.659, 95% CI: 2.18-34.37, P = .002) and higher baseline chemicalD001663 (adjusted OR: 1.07, 95% CI: 1.008-1.135, P = .025) were independently associated with presence of diseaseD058186. Of the 9606 with diseaseD058186, 5(26.3%) survived with native liver, 10(52.6%) diseaseD003643 and 4 (21.1%) underwent liver transplantation. CONCLUSION: diseaseD058186 developed in 22.6% of children with diseaseD065290. chemicalD001663 more than 17.7 mg/dL and presence of diseaseD018746 were high risk factors for diseaseD058186. Development of diseaseD058186 in a child with diseaseD065290 suggests poor outcome and need for early intervention.
31276461		Scheimpflug Imaging of the Danish Cohort of 9606 With diseaseD006527.PURPOSE: The purpose of this study was to investigate the use of anterior segment imaging in diagnosing diseaseD012303 in 9606 with diseaseD006527. METHODS: In a tertiary center for diseaseD006527, 9606 were examined with a Pentacam HR Scheimpflug-based tomography device in addition to conventional slit-lamp examination. The inferior part of the cornea was analyzed using both a built-in densitometry module and ImageJ. RESULTS: Thirty-one 9606 with diseaseD006527 (78% of all Danish 9606) were included, resulting in 83 examinations over a 5-year period. Ten had a manifest Kayser-Fleischer ring in the inferior part of the cornea on at least 1 examination, 5 had other causes of peripheral corneal scatter, and 16 had normal examinations. The built-in densitometry module performed poorly in discriminating between the presence and absence of a Kayser-Fleischer ring. However, analysis of the images in ImageJ and calculation of a normalized signal (peak posterior value/peak anterior value) with a cutoff value set to 1 detected 28 of 31 diseaseD012303 and resulted in 96% sensitivity and 95% specificity. In 12 9606 who underwent 3 or more examinations during the period, changes in the normalized signal seemed to reflect the efficiency of the treatment, although more studies are needed for this conclusion. CONCLUSIONS: ImageJ-based analysis of Pentacam images has a high sensitivity in detecting diseaseD012303 and can be used as a diagnostic procedure for diseaseD006527 and may be a tool to monitor the disease in an objective manner.
28284465	Association|chemicalD000641|diseaseD017093; Association|chemicalD008345|diseaseD017093; Positive_Correlation|chemicalD008345|diseaseD001925; Positive_Correlation|chemicalD000641|diseaseD001925	diseaseD009461 in liver transplant candidates: Pathophysiology and clinical assessment.diseaseD056486, as a consequence of acute diseaseD048550 or severe chronic diseaseD008107 may be associated with various diseaseD009461, which involve both central and peripheral nervous system. Acute and severe hyperammoniemia inducing cellular metabolic alterations, prolonged state of "diseaseD000090862", activation of brain microglia, accumulation of chemicalD008345 and chemicalD000641, and systemic diseaseD007249 are the main causative factors of diseaseD001925 in diseaseD017093. The most widely recognized neurological complications of serious diseaseD017093 include diseaseD006501, diffuse diseaseD001929, diseaseD006527, diseaseD013118, acquired diseaseD006527, diseaseD005355-related diseaseD010302 and diseaseD003711. diseaseD009461 affecting liver transplant candidates while in the waiting list may not only significantly influence preoperative morbidity and even mortality, but also represent important predictive factors for post-transplant neurological manifestations. Careful pre-transplant neurological evaluation is essential to define severity and distribution of the diseaseD009422, to identify the abnormalities still responsive to current treatment, and to potentially predict the inherent post-operative prognosis. The preferred specific indices of neurological pre-transplant assessment may vary among centers, however, even with the aid of the current biochemical, neurophysiological, neuropsychological and neuroimaging diagnostic tools, the correct diagnosis and differential diagnosis of various syndromes may be difficult. In this article the relevant pathophysiological and clinical aspects of the most frequent diseaseD010523 affecting liver transplant candidates with acute or advanced chronic diseaseD017093 are briefly reported. The practical diagnostic findings useful for the preoperative assessment and treatment, as well as the expected neurological evolution after liver transplantation are also evaluated.
33159804	Association|chemicalD003300|diseaseD006527; Positive_Correlation|diseaseD009461|variantrs121908000##; Positive_Correlation|diseaseD056486|variantrs121908000##; Association|diseaseD056486|ncbi540; Association|chemicalD003300|diseaseD009358; Association|chemicalD003300|ncbi540; Association|diseaseD006527|ncbi540; Association|diseaseD009461|ncbi540; Association|diseaseD009461|ncbi540; Association|diseaseD056486|ncbi540	diseaseD006527: revision of diagnostic criteria in a clinical series with great genetic homogeneity.BACKGROUND: diseaseD006527 is an autosomal recessive diseaseD009358 of chemicalD003300 metabolism caused by mutations in the ncbi540 gene. An early diagnosis is crucial to prevent evolution of the disease, as implantation of early therapeutic measures fully prevents its symptoms. As population genetics data predict a higher than initially expected prevalence, it was important to define the basic diagnostic tools to approach population screening. METHODS: A highly genetically homogeneous cohort of 70 9606, belonging to 50 unrelated families, has been selected as a framework to analyze all their clinical, biochemical and genetic characteristics, to define the disease in our population, with an estimated prevalence of 1 in 12,369, and determine the most useful features that reach diagnostic value. RESULTS: Serum ncbi1356 below 11.5 mg/dL and cupremia below 60 mug/mL, were the best analytical predictors of the disease in asymptomatic individuals, while cupruria or hepatic chemicalD003300 determination were less powerful. Genetic analysis reached a conclusive diagnosis in all 65 9606 available for complete testing. Of them, 48 were carriers of at least one variantrs121908000## mutant allele, with 24 homozygotes. Nine 9606 carried a promoter deletion mutation, revealing that extended sequencing beyond the ncbi540 gene-coding region is essential. All mutations caused diseaseD056486 since early ages, increasing its severity as diagnosis was delayed, and diseaseD009461 appear. CONCLUSION: Serum ncbi1356 determination followed by genetic screening would reduce costs and favor the prioritization of non-invasive procedures to reach a definitive diagnosis, even for asymptomatic cases.
28435998	Positive_Correlation|diseaseD006527|variantrs121907996##; Association|diseaseD006527|ncbi540; Association|chemicalD003300|diseaseD005355; Association|diseaseD006527|ncbi540	A 6-year-old boy with diseaseD006527-A diagnostic dilemma.A 6-year-old boy presented with 2 months history of progressive diseaseD000007 and diseaseD007565. He was deeply icteric with diseaseD001201, diseaseC535727, diseaseD006932, raised transaminases, and diseaseD001778. Viral markers and slit lamp examination for diseaseD012303 were negative. Serum ncbi1356 and 24-h urinary chemicalD003300 post-D-pencillamine challenge were normal. Anti-smooth muscle antibody was positive 1:20, and liver biopsy showed micronodular diseaseD005355 with abundant Mallory hyaline and stainable chemicalD003300 deposits. The liver histology was indicative of Indian childhood diseaseD005355, whereas the presence of autoantibodies, elevated transaminases, and increased globulin was suggestive of diseaseD019693. Gene studies identified variantrs121907996## mutation in ncbi540 gene, which solved the dilemma and confirmed the diagnosis of diseaseD006527 (diseaseD006527). We report a clinicopathological conference of this boy to highlight the challenges faced by pediatricians in the diagnosis of diseaseD006527.  .
38081365	Negative_Correlation|chemicalC000615411|chemicalC020809; Negative_Correlation|chemicalC020809|diseaseD006527; Association|chemicalD003300|diseaseD006527; Negative_Correlation|chemicalC020809|chemicalD003300	Effects of chemicalC020809 on chemicalD003300 metabolism in healthy volunteers and in 9606 with diseaseD006527.BACKGROUND & AIMS: In diseaseD006527 (diseaseD006527), chemicalD003300 accumulates in the liver and brain causing disease. chemicalC020809 (chemicalC020809) is a potent chemicalD003300 chelator that may be associated with a lower risk of inducing paradoxical neurological worsening than conventional therapy for neurologic diseaseD006527. To better understand the mode of action of chemicalC020809, we investigated its effects on chemicalD003300 absorption and biliary excretion. METHODS: In a double-blind randomized setting, hepatic chemicalC000615411 activity was examined after orally administered chemicalC000615411 by PET/CT in 16 healthy volunteers before and after seven days of chemicalC020809 treatment (15 mg/d) or placebo. Oral chemicalC000615411 was administered one hour after the final chemicalC020809 dose. Changes in hepatic chemicalC000615411 activity reflected changes in intestinal chemicalC000615411 uptake. Additionally, in four 9606 with diseaseD006527, the distribution of chemicalC000615411 in venous blood, liver, gallbladder, kidney, and brain was followed after i.v. chemicalC000615411 dosing for up to 68 hours before and after seven days of chemicalC020809 (15 mg/day), using PET/MRI. Increased gallbladder chemicalC000615411 activity was taken as evidence of increased biliary chemicalC000615411 excretion. RESULTS: In healthy volunteers, chemicalC020809 reduced intestinal chemicalC000615411 uptake by 82% 15 hours after the oral chemicalC000615411 dose. In 9606 with diseaseD006527, gallbladder chemicalC000615411 activity was negligible before and after chemicalC020809, while chemicalC020809 effectively retained chemicalC000615411 in the blood, significantly reduced hepatic chemicalC000615411 activity at all time-points and significantly reduced cerebral chemicalC000615411 activity two hours after the intravenous chemicalC000615411 dose. CONCLUSIONS: While we did not show an increase in biliary excretion of chemicalC000615411 following chemicalC020809 administration, we demonstrated that chemicalC020809 effectively inhibited most intestinal chemicalC000615411 uptake and retained chemicalC000615411 in the blood stream, limiting the exposure of chemicalC000615411 to organs like the liver and the brain. IMPACT AND IMPLICATIONS: chemicalC020809 (chemicalC020809) is an investigational chemicalD003300 chelator being developed for the treatment of diseaseD006527. In animal models of diseaseD006527, chemicalC020809 has been shown to facilitate biliary chemicalD003300 excretion. In the present 9606 study, chemicalC020809 surprisingly did not facilitate biliary chemicalD003300 excretion but instead reduced intestinal chemicalD003300 uptake to a clinically significant degree. Our study builds on our understanding of 9606 chemicalD003300 metabolism and the mechanism of action of chemicalC020809.
31899725		Management of diseaseD006527 Diagnosed in Infancy: An Appraisal of Available Experience to Generate Discussion.Increased access to molecular genetic testing is changing the demographics for diagnosing diseaseD030342 and imposing new challenges for medical management. diseaseD006527 (diseaseD006527), typically diagnosed in older children and adults, can now be detected in utero and in infants (children younger than 24 months, including neonates) via genetic testing. An evidence-based approach to management of these neonates and extremely young children, who are typically asymptomatic, has been hampered by lack of clinical experience. We present a case of an infantile diagnosis of diseaseD006527, review available experience, and discuss current trends in antenatal genetic testing of parents and fetus that may lead to a very early diagnosis of diseaseD006527. Based on physiological and nutritional considerations, we propose an algorithmic approach to management of infantile diseaseD006527 as a starting point for further discussion. Future collaboration amongst specialists is essential to identify evidence-based approaches and best practice for managing treatment of infants with genetically diagnosed diseaseD006527.
31222986	Negative_Correlation|chemicalD009173|diseaseD056648; Cotreatment|chemicalD009173|chemicalD010396; Positive_Correlation|chemicalD010396|diseaseC538458; Comparison|chemicalD010396|chemicalD014266; Negative_Correlation|chemicalD003520|diseaseD006469; Negative_Correlation|chemicalD003520|diseaseD006417; Positive_Correlation|chemicalD010396|diseaseD011507; Positive_Correlation|chemicalD010396|diseaseD056648; Negative_Correlation|chemicalD009173|diseaseD006417; Negative_Correlation|chemicalD003520|diseaseD056648; Negative_Correlation|chemicalD010396|diseaseD006469; Negative_Correlation|chemicalD010396|diseaseD004417; Negative_Correlation|chemicalD014266|diseaseD056648; Negative_Correlation|chemicalD003520|diseaseD006030; Negative_Correlation|chemicalD003520|diseaseD004417; Negative_Correlation|chemicalD009173|diseaseD011507; Positive_Correlation|chemicalD010396|diseaseD006470; Negative_Correlation|chemicalD010396|diseaseD006527; Negative_Correlation|chemicalD009173|diseaseD006470; Positive_Correlation|chemicalD010396|diseaseD005921; Cotreatment|chemicalD003520|chemicalD010396; Negative_Correlation|chemicalD003520|diseaseD011507; Negative_Correlation|chemicalD003520|diseaseD006470; Positive_Correlation|chemicalD010396|diseaseD006417	A Pediatric Case of a chemicalD010396 Induced diseaseD056648 Manifesting a diseaseC538458.chemicalD010396 has been reported to cause diseaseD056648 presenting as rapidly progressive diseaseD005921 or diseaseC538458 mostly in adults. We report a pediatric case of chemicalD010396 induced diseaseD056648 that manifests as a diseaseC538458 with a mild diseaseD006030 manifestation. A 13-year-old girl who has been taking chemicalD010396 for five years under the diagnosis of diseaseD006527 visited the emergency room because of diseaseD006469 and diseaseD004417. She had diffuse diseaseD006470, microscopic diseaseD006417, and diseaseD011507. ncbi4353 ANCA was positive, and a diseaseD006030 biopsy revealed pauci-immune crescentic diseaseD005921. Under the diagnosis of chemicalD010396-induced diseaseD056648, chemicalD010396 was switched to chemicalD014266, and the 9606 was treated with plasmapheresis, glucocorticoid, chemicalD003520, and chemicalD009173. diseaseD006470 improved rapidly followed by the disappearance of the diseaseD006417 and diseaseD011507 five months later.
37634880	Positive_Correlation|diseaseD006527|variantrs769484789##; Positive_Correlation|diseaseD006527|variantrs769484789##; Positive_Correlation|diseaseD017114|variantrs769484789##; Association|diseaseD017114|ncbi540; Positive_Correlation|diseaseD017114|variantrs769484789##; Positive_Correlation|diseaseD006527|variantrs769484789##; Positive_Correlation|diseaseD017114|variantrs769484789##; Association|diseaseD006527|ncbi540	Severe Early-Onset diseaseD006527 Caused by a Common Pathogenic Variant in the Bukharan Jewish Population in Israel.BACKGROUND: diseaseD006527 is caused by pathogenic variants in the ncbi540 gene which encodes a copper-transporting ncbi1769. AIMS: Describe a common founder pathogenic variant among Bukharan Jews and to assess its prevalence, clinical features, and outcome. METHODS: The cohort consisted of patients of Bukharan Jewish descent diagnosed with diseaseD006527 at a tertiary pediatric medical center in 2013-2018. Clinical and genetic data were collected and analyzed. RESULTS: Six patients from 4 unrelated families who were homozygous for the variantrs769484789## p.(variantrs769484789##) pathogenic variant in ncbi540 were identified. Five presented with elevated aminotransferase levels, and one, with diseaseD017114. Mean age at diagnosis was 8.7 years (5-12.5). Serum ncbi1356 level was extremely low in all patients (1.9-7 mg/dL; mean 3.2(. The variant was identified in a heterozygous state in 5/153 Bukharan Jews; 2/33 from our local exome database and 3/120 healthy unrelated Bukharan Jews in another cohort, for an estimated carrier frequency of ~1:30. CONCLUSIONS: We report a common founder pathogenic variant in the ncbi540 gene among Bukharan Jews associated with severe early-onset diseaseD006527. Given the clinical severity, high frequency of the variant, and being a treatable disease, its inclusion in pre-symptomatic screening in the Bukharan Jewish community should be considered. Furthermore, diseaseD006527 should be part of future genetic newborn screening programs in Israel and worldwide, to enable early treatment and prevention of future life-threatening complications.
37074913	Association|chemicalD003300|ncbi540; Association|chemicalD002945|ncbi540; Association|chemicalD003300|diseaseD006527; Association|chemicalD000255|chemicalD003300; Association|chemicalD000255|ncbi540; Association|diseaseD006527|ncbi540; Association|chemicalD003300|chemicalD013455; Association|chemicalD003300|ncbi114785; Association|ncbi114785|ncbi540	Structures of the 9606 diseaseD006527 copper transporter ncbi540The P-type ATPase ncbi540 exports cytosolic chemicalD003300 and plays an essential role in the regulation of cellular chemicalD003300 homeostasis. Mutants of ncbi540 cause diseaseD006527 (diseaseD006527), an diseaseD030342 of chemicalD003300 metabolism. Here, we present cryoelectron microscopy (cryo-EM) structures of 9606 ncbi540 in the E1 state in the apo, the putative chemicalD003300-bound, and the putative chemicalD002945-bound forms. In ncbi540, the N-terminal sixth chemicalD008670-binding domain (ncbi114785) binds at the cytosolic chemicalD003300 entry site of the transmembrane domain (TMD), facilitating the delivery of chemicalD003300 from the ncbi114785 to the TMD. The chemicalD013455-containing residues in the TMD of ncbi540 mark the chemicalD003300 transport pathway. By comparing structures of the E1 state 9606 ncbi540 and E2-Pi state frog ncbi540, we propose the chemicalD000255-driving chemicalD003300 transport model of ncbi540 These structures not only advance our understanding of the mechanisms of ncbi540-mediated chemicalD003300 export but can also guide the development of therapeutics for the treatment of diseaseD006527.
31897936	Negative_Correlation|chemicalD003300|diseaseD006527	diseaseD005124 are associated with diseaseD001284 in diseaseD006527.BACKGROUNDS: This study aims to characterize diseaseD005124 in diseaseD006527 and examine their association with the degree of diseaseD001284. METHODS: Twenty 9606 (10 males, mean age 46.8, SD 8.9 years) with genetically confirmed diseaseD006527 on stable anti-chemicalD003300 treatment and 20 age- and sex-matched healthy subjects were examined. Eye movements, including prosaccade and antisaccade tasks, were evaluated using infrared videooculography. MRI was performed using 1.5 T system, and T2-weighted images were used for the measurement of midbrain and pontine area on mid-sagittal slices. Clinical severity was assessed using the Unified diseaseD006527 Rating Scale (UWDRS). RESULTS: Compared to healthy controls, diseaseD006527 9606 showed prolonged latencies of horizontal prosaccades and hypometry of both horizontal (p = 0.04) and vertical (p = 0.0046) prosaccades. In the antisaccade task, diseaseD006527 9606 showed prolonged latency of both horizontal (p = 0.04) and vertical antisaccades (p = 0.047) and increased error rate of vertical antisaccades (p = 0.04). There is a significant association between midbrain area and horizontal latencies (r = -0.53; p = 0.02) and vertical maximum speed in prosaccades (r = 0.47; p = 0.04). The pons area inversely correlated with horizontal prosaccade and antisaccade latencies (p = 0.007). CONCLUSIONS: We showed diseaseD060825 ocular saccades such as prolonged latencies, hypometry, and increased error rate in antisaccades. The strong association between prolonged latencies of prosaccades and the diseaseD001284 suggests that VOG might serve as a sensitive electrophysiological marker of diseaseD020295 in diseaseD006527.
33754827	Negative_Correlation|chemicalD003300|diseaseD006527	Associations of diseaseC566985 and diseaseD000090463 at MRI with Clinical Severity in diseaseD006527.Background Abnormal findings at brain MRI in 9606 with neurologic diseaseD006527 (diseaseD006527) are characterized by signal intensity changes and diseaseD001284. T2 signal hypointensities and diseaseD001284 are largely irreversible with treatment; their relationship with diseaseD003638 has not been systematically investigated. Purpose To investigate associations of regional diseaseC566985 and chemicalD007501 accumulation at MRI with clinical severity in participants with diseaseD006527 who are undergoing long-term anti-chemicalD003300 treatment. Materials and Methods Participants with diseaseD006527 and controls were compared in a prospective study performed from 2015 to 2019. MRI at 3.0 T included three-dimensional T1-weighted and six-echo multigradient-echo pulse sequences for morphometry and quantitative susceptibility mapping, respectively. Neurologic severity was assessed with the Unified diseaseD006527 Rating Scale (UWDRS). Automated multi-atlas segmentation pipeline with dual contrast (susceptibility and T1) was used for the calculation of volumes and mean susceptibilities in deep gray matter nuclei. Additionally, whole-brain analysis using deformation and surface-based morphometry was performed. Least absolute shrinkage and selection operator regression was used to assess the association of regional volumes and susceptibilities with the UWDRS score. Results Twenty-nine participants with diseaseD006527 (mean age, 47 years +- 9 [standard deviation]; 15 9606) and 26 controls (mean age, 45 years +- 12; 14 9606) were evaluated. Whole-brain analysis demonstrated diseaseD001284 of the deep gray matter nuclei, brainstem, internal capsule, motor cortex and corticospinal pathway, and visual cortex and optic radiation in participants with diseaseD006527 (P < .05 at voxel level, corrected for family-wise error). The UWDRS score was negatively correlated with volumes of putamen (r = -0.63, P < .001), red nucleus (r = -0.58, P = .001), globus pallidus (r = -0.53, P = .003), and substantia nigra (r = -0.50, P = .006) but not with susceptibilities. Only the putaminal volume was identified as a stable factor associated with the UWDRS score (R2 = 0.38, P < .001) using least absolute shrinkage and selection operator regression. Conclusion Individuals with diseaseD006527 (diseaseD006527) had widespread diseaseC566985 most pronounced in the central structures. The putaminal volume was associated with the Unified diseaseD006527 Rating Scale score and can be used as a surrogate imaging marker of clinical severity.   RSNA, 2021 Supplemental material is available for this article. See also the editorial by Du and Bydder in this issue.
31884064		Assessment of the Hallmarks of diseaseD006527 in CT Scan Imaging.INTRODUCTION: Owing to nonspecific clinical symptoms, diseaseD006527 (diseaseD006527) diagnosis is often missed or delayed; hence, many 9606 reach diseaseD058625. When diseaseD005355 takes place, it is difficult to distinguish between diseaseD006527 and other causes of diseaseD005355 by imaging alone. This study outlines abdominal computed tomography (CT) imaging findings that occur more frequently in 9606 with diseaseD006527. MATERIAL AND METHODS: Fifty-seven 9606 with diseaseD006527 who had referred for liver transplantation took part in this study and underwent dynamic liver CT examination before transplantation. Qualitative and quantitative parameters including liver density, contour irregularity, diseaseC537340, diseaseD006984, presence of focal parenchymal lesion, thickness of perihepatic fat layer, periportal thickness, diseaseD008206, and other associated findings were recorded and evaluated. RESULTS: Among these 9606, 85.9% had contour irregularity, 28% had diseaseC537340, and periportal thickening and diseaseD002769 were found in 25.5% and 12.3% of 9606, respectively. diseaseD013163, diseaseD008206, and portosystemic shunting were observed in all 9606. Also, hyperdense nodules (>20 mm) and honeycomb pattern were detected in 65.2% and 15.2% of 9606, respectively, in the arterial phase. In the portal phase, these findings were detected only in 13% and 4.3% of 9606. diseaseD006984 was seen only in 12.2% of 9606. CONCLUSION: diseaseD006527-associated diseaseD005355 has many CT imaging findings, although most of them are nonspecific. Some findings, such as hyperdense nodules and honeycomb pattern in non-contrast-enhanced CT scan and arterial phase of triphasic CT scan with lack of diseaseD006984 of caudate lobes, are hallmarks of diseaseD006527.
30836904		Evaluation of diseaseD008107 and Its Severity in Children Referred for Liver Transplant: a Single-Center Report From Nemazee Hospital of Shiraz.OBJECTIVES: Liver transplant has been used as a curative approach for children with diseaseD058625. Here, we describe the underlying causes for pediatric liver transplant performed at the Shiraz Organ Transplantation Center, Nemazee Hospital, Shiraz, Iran. MATERIALS AND METHODS: In this cross-sectional descriptive study, children < 18 years old who were candidates for liver transplant from 2007 to 2010 at the Shiraz Organ Transplantation Center were included. 9606 were evaluated for their underlying diseases leading to diseaseD017093. Disease severity was assessed and compared with Pediatric diseaseD058625 model and the Model for diseaseD058625 scores. RESULTS: Of 107 9606, 60.8% were males and 39.2% were females. The mean age was 11.6 +- 4.9 years. Thirteen 9606 (12.5%) were < 2 years old, 26 (24%) were 2 to 6 years old, 33 (30.8%) were 6 to 12 years old, and 35 (32.7%) were 12 to 18 years old. diseaseD008107 comprised diseaseD001656 (27.1%), diseaseC562577 (21.5%), diseaseD005355 (13.1%), diseaseC535932 (11.2%), diseaseD006527 (9.3%), diseaseD020176 (7.4%), diseaseC536394 (4.7%), diseaseC562378 (3.7%), and diseaseD016767 (1.9%). diseaseD007565 (83.2%), diseaseD001201 (57%), and diseaseD004932 (43%) were the most common clinical findings. Mean serum direct chemicalD001663, total chemicalD001663, international normalized ratio, and serum chemicalD003404 values were 3.6 +- 0.8 mg/dL, 9.3 +- 9.1 mg/dL, 2.1 +- 1.1, and 0.6 +- 0.2 mg/dL, respectively. The mean Pediatric diseaseD058625 score in children < 12 years old was 11.4 +- 9.1. The mean Model for diseaseD008107 score in children > 12 years old was 13.7 +- 5.9. There were no differences in scores among sex, age groups, or different etiologies. CONCLUSIONS: Scores for disease severity were not significantly different with regard to different causes of underlying diseases for liver transplant in Iranian children.
33057522	Association|chemicalD003300|diseaseD006527; Negative_Correlation|chemicalD014266|diseaseD006527; Negative_Correlation|chemicalD010396|diseaseD006527; Association|diseaseD006527|ncbi540; Association|chemicalD003300|diseaseD030342; Association|diseaseD006527|ncbi12870; Association|chemicalD003300|diseaseD056486; Association|chemicalD003300|ncbi540	The blood chemicalD003300 isotopic composition is a prognostic indicator of the diseaseD056486 in diseaseD006527.diseaseD006527 (diseaseD006527) is an diseaseD030342 of chemicalD003300 (chemicalD003300) metabolism. The gene responsible for diseaseD006527, ncbi540, is involved in the cellular transport of chemicalD003300, and mutations in the ncbi540 gene induce accumulation of chemicalD003300 in the liver and ultimately in the brain. In a pilot study, the natural variations of chemicalD003300 stable isotope ratios (65Cu/63Cu) in the serum of diseaseD006527 9606 have been shown to differ from that of healthy controls. In the present study, we challenged these first results by measuring the 65Cu/63Cu ratios in the blood of treated (n = 25), naive 9606 (n = 11) and age matched healthy controls (n = 75). The results show that naive 9606 and healthy controls exhibit undistinguishable 65Cu/63Cu ratios, implying that the chemicalD003300 isotopic ratio cannot serve as a reliable diagnostic biomarker. The type of treatment (chemicalD010396 vs. chemicalD014266) does not affect the 65Cu/63Cu ratios in diseaseD006527 9606, which remain constant regardless of the type and duration of the treatment. In addition, the 65Cu/63Cu ratios do not vary in naive 9606 after the onset of the treatment. However, the 65Cu/63Cu ratios decrease with the degree of diseaseD008103 and the gradient of the phenotypic presentation, i.e. presymptomatic, hepatic and neurologic. To get insights into the mechanisms at work, we study the effects of the progress of the diseaseD006527 on the organism by measuring the chemicalD003300 concentrations and the 65Cu/63Cu ratios in the liver, feces and plasma of 12 and 45 week old ncbi11979-/- 10090. The evolution of the 65Cu/63Cu ratios is marked by a decrease in all tissues. The results show that 63Cu accumulates in the liver preferentially to 65Cu due to the preferential cellular entry of 63Cu and the impairment of the 63Cu exit by ncbi12870. The hepatic accumulation of monovalent 63Cu+ is likely to fuel the production of free radicals, which is potentially an explanation of the pathogenicity of diseaseD006527. Altogether, the results suggest that the blood 65Cu/63Cu ratio recapitulates diseaseD006527 progression and is a potential prognostic biomarker of diseaseD006527.
36524887	Association|chemicalD003300|diseaseD017093; Association|chemicalD003300|diseaseD006527	Does Liver Transplant Improve Neurological Symptoms in diseaseD006527? Report of 24 Cases.OBJECTIVES: diseaseD006527 is an diseaseD030342 that results in chemicalD003300 accumulation in the tissues with diseaseD017093. Orthotopic liver transplant is one of the treatments of choice for this disease. The aim of this study was to compare the neurological symptoms, before and after orthotopic livertransplant, of 9606 with diseaseD008103 due to diseaseD006527, who represent a special group of 9606 with diseaseD017093. MATERIALS AND METHODS: Between 2007 and 2020, there were 24 9606 with diseaseD006527 resistant to medical treatment who underwent deceased donor orthotopic livertransplant and were followed up for 1 year, 5 years, and 10 years for evaluation with neurological scoring systems. 9606 were also evaluated for diseaseD011183 and survival. RESULTS: Of the 24 9606 evaluated, there were 13 (54.2%) female 9606 and 11 (45.8%) male 9606, and the mean age was 34 years (range, 14-57 years). One of the 9606 diseaseD003643 from early diseaseD019106 diseaseD018805. After orthotopic livertransplant, disease scores returned to normal in 16 9606 and improved in the remaining 9606. Before transplant, all 9606 required help in their daily activities. After transplant, there were significant improvements in some symptoms, and the 9606 became more independent in their daily lives. CONCLUSIONS: Our study shows that orthotopic liver transplant provides significant improvement in neurological symptoms and quality of life in 9606 with diseaseD006527.
28060027		Advantages of Anterior Segment Optical Coherence Tomography Evaluation of the diseaseD012303 in diseaseD006527.PURPOSE: To present anterior segment optical coherence tomography (AS-OCT) findings of the Kayser-Fleischer (KF) ring in diseaseD006527 (diseaseD006527) and to discuss the potential advantages of evaluating the KF ring by AS-OCT. METHODS: This is a retrospective case series of 7 9606 with diseaseD006527 with KF rings seen in our institute during the study period (August 2015 to June 2016). All 9606 underwent slit-lamp examination of the cornea and AS-OCT (Optovue RTVue Premier). In 2 9606, the length of the KF ring was measured using the gray scale of AS-OCT. RESULTS: The KF ring on the gray scale of AS-OCT was visualized as a hyperreflective deep corneal layer at the level of Descemet membrane in all eyes. The OCT color scale revealed the KF ring as a greenish, greenish-yellow, yellow, or yellow-orange band. The gray scale of ASchemicalC051883 could easily measure the length of the KF ring in 9606 6 and 7. CONCLUSIONS: AS-OCT is an alternative method of evaluating the KF ring in diseaseD006527, which can be used in combination with slit-lamp examination. The KF ring can be easily measured using the gray scale of ASchemicalC051883. Further studies are required to study the potential advantages of AS-OCT including assessing the density of the KF ring, as a tool to assess response to treatment in diseaseD006527, in differentiating the KF ring of diseaseD006527 from diseaseC535468 in other situations and pigmented corneal rings in non-diseaseD008107.
29961769		Population genomics in South East Asia captures unexpectedly high carrier frequency for treatable diseaseD030342.PURPOSE: Genomic studies have demonstrated the necessity of ethnicity-specific population data to ascertain variant pathogenicity for disease diagnosis and treatment. This study examined the carrier prevalence of treatable diseaseD030342 (diseaseD030342), where early diagnosis of at-risk offspring can significantly improve clinical outcomes. METHODS: Existing exome/ genome sequencing data of 831 Singaporeans were aggregated and examined for disease causing variants in 104 genes associated with 80 diseaseD030342. RESULTS: Among the 831 Singaporean participants, genomic variant filtering and analysis identified 1 in 18 individuals (6%) to be carriers amongst one of 13 diseaseD030342. diseaseC538053 and diseaseD006527 had the highest carrier frequency of 1 in 41, and 1 in 103 individuals, respectively. The pathogenic variants associated with diseaseC538053 were 24 times more prevalent in our local cohorts when compared to Western cohorts. CONCLUSION: This study demonstrates the value of a population specific genomic database to determine true disease prevalence and has enabled the discovery of carrier frequencies of treatable genetic conditions specific to South East Asian populations, which are currently underestimated in existing data sources. This study framework can be adapted to other population groups and expanded to multiple genetic conditions to inform health policies directing precision medicine.
38171926		Liver-directed gene therapy for diseaseD030342.Gene therapy clinical trials are rapidly expanding for diseaseD030342 whilst two gene therapy products have now been approved for liver based diseaseD009358. Liver-directed gene therapy has recently become an option for treatment of diseaseD006467 and is likely to become one of the favoured therapeutic strategies for diseaseD030342 in the near future. In this review, we present the different gene therapy vectors and strategies for liver-targeting, including gene editing. We highlight the current development of viral and nonviral gene therapy for a number of diseaseD030342 including diseaseD056806, diseaseD000092124, diseaseD003414, diseaseD006527, diseaseC538655, diseaseD010661 and diseaseD008375. We describe the main limitations and open questions for further gene therapy development: immunogenicity, diseaseD018746, genotoxicity, gene therapy administration in a diseaseD017093. The follow-up of a constantly growing number of gene therapy treated 9606 allows better understanding of its benefits and limitations and provides strategies to design safer and more efficacious treatments. Undoubtedly, liver-targeting gene therapy offers a promising avenue for innovative therapies with an unprecedented potential to address the unmet needs of 9606 suffering from diseaseD030342.
31421978	Association|diseaseD006527|ncbi1356; Association|diseaseD006527|ncbi540; Positive_Correlation|chemicalD003300|diseaseD006527	diseaseD006527.diseaseD006527 (diseaseD006527) is an diseaseD020739. The resultant defective handling of chemicalD003300 results in toxic effects on the hepatocytes and increased chemicalD003300 in the circulation. chemicalD003300 accumulates in other organ sites especially the central nervous system. diseaseD006527 occurs worldwide, usually between 5 and 35 years; a wider age range is now recognized. Clinical presentations are diverse and include combinations of hepatic, neurological, ophthalmic and diseaseD001523 manifestations. diseaseD000014 such as serum ncbi1356 and 24-h urinary chemicalD003300 excretion are important for the diagnosis but are not always abnormal in diseaseD006527. They can overlap with non-diseaseD006527 causes. 9606 may present with diseaseD009461 or combinations thereof. Approx. 50% of diseaseD006527 9606 present with diseaseD008107. Liver presentation is variable: asymptomatic abnormal liver tests, diseaseD006521 picture, diseaseD005355, and diseaseD017114. Similarly, the histology has several different patterns: mild nonspecific changes, diseaseD005234 or diseaseD005234, diseaseD006521, and diseaseD017114 with submassive or massive diseaseD009336. None of these are specific for diseaseD006527. Aids to the histologic diagnosis include special stains for chemicalD003300 and copper associated protein, and chemicalD003300 concentration in liver tissue. The biopsy is performed in the context of the clinical algorithms for the diagnosis of diseaseD006527 put forth by the clinical hepatology organizations such as the European Association for the Study of diseaseD008107 and the American Association for the Study of diseaseD008107. The discovery of the responsible gene ncbi540 has made the molecular diagnosis feasible through genetic testing and sequencing of the gene.
28602929	Association|diseaseD020786|ncbi11235; Association|diseaseD020786|ncbi83605; Association|diseaseD006527|ncbi540	Hereditary diseaseD020786 Associated with diseaseD006527 and disease151900.We report on a 9606 with 2 diseaseD030342-symptomatic diseaseC536610 (diseaseC536610) and diseaseD006527. Genetic analysis revealed single nucleotide polymorphisms in genes ncbi83605 and ncbi11235, associated with diseaseD020786, and homozygote mutation in the ncbi540 gene, responsible for diseaseD006527. diseaseC536610 were symptomatic in 3 generations. The 9606 also had disease151900, which is suggested to be a diseaseD011125. In recent years there has been an increasing amount of publications linking diseaseC536610 with other pathology, predominantly with diseaseC535700. The present study is the description of an unusual association between 2 independent diseaseD030342 of confirmed genetic origin-a combination that has not been described previously.
36343759		Botulinum toxin type A treatment of four cases of diseaseD006527 with diseaseD004421: A prospective study.Botulinum toxin type A (BoNT-A) has been recommended in various diseaseD009461 as a useful tool for alleviating diseaseD004421. In diseaseD006527 (diseaseD006527) 9606 with diseaseD004421, BoNT-A injection can be used as a treatment modality when conventional treatment is ineffective for alleviating symptoms. The purpose of this study was to thoroughly evaluate the efficacy of BoNT-A injection in treating diseaseD006527 complicated by diseaseD004421. The efficacy of these injections was assessed by clinical scales, surface electromyography (EMG), and gait analysis. A comparative analysis of all gait parameters, EMG parameters, and clinical scales revealed a significant increase in velocity, decrease in integrated EMG (iEMG), and improvement in modified Ashworth scale (MAS), Burke Fahn Marsden (BFM), and activities of daily living (ADL) scores (all P < 0.05). Overall, our findings indicated that BoNT-A injection led to marked relief of symptoms in 9606 with diseaseD006527 with diseaseD004421.
29381936	Association|variant#540#c.2790_2792del|variantrs121907994##; Association|variantrs121907994##|diseaseD006527; Association|variant#540#c.2790_2792del|diseaseD006527; Positive_Correlation|variantrs121907994##|diseaseD010003; Positive_Correlation|variant#540#c.2790_2792del|diseaseD010003; Association|diseaseD006527|ncbi540; Association|diseaseD006527|ncbi540; Association|diseaseD010003|ncbi540	Genotype and clinical course in 2 Chinese Han siblings with diseaseD006527 presenting with isolated disabling diseaseD010003: A case report.RATIONALE: diseaseD010003 (diseaseD010003) is a rare condition in diseaseD006527 (diseaseD006527). Particularly, when diseaseD010003 is the only complaint of a diseaseD006527 9606 for a long time, there would be misdiagnosis or missed diagnosis and then treatment delay. 9606 CONCERNS AND DIAGNOSIS: Two Chinese Han siblings were diagnosed as diseaseD006527 by corneal K-F rings, laboratory test, and mutation analysis. They presented with isolated diseaseD010003 during the first 2 decades or more of their disease course, and were of missed diagnosis during that long time. The older affected sib became disabled due to his severe diseaseD010003 when he was as young as 38 years old. Two compound heterozygous pathogenic variants variant#540#c.2790_2792del and variantrs121907994## were revealed in the ncbi540 gene through targeted next-generation sequencing (NGS). LESSONS: Adolescent-onset diseaseD010003 could be the only complaint of diseaseD006527 individual for at least 2 decades. Long delay in the treatment of diseaseD006527's diseaseD010003 could lead to disability in early adulthood. Detailed physical examination, special biochemical test, and genotyping through targeted NGS should greatly reduce diagnosis delay in atypical diseaseD006527 9606 with isolated diseaseD010003 phenotype.
30829235		diseaseD006527: Copper in the eye.
32398360		Liver transplant for neurologic diseaseD006527: Hope or fallacy?
29979436	Association|chemicalD003300|diseaseD006527; Association|diseaseD006527|ncbi1356	Familial screening of children with diseaseD006527: Necessity of screening in previous generation and screening methods.diseaseD006527 (diseaseD006527) is an diseaseD030342 associated with chemicalD003300 metabolism. Early diagnosis and therapy can result in good prognosis of diseaseD006527. Thus, it is highly recommended to perform familial screening. In this study, we aimed to investigate the range of familial screening of children with diseaseD006527 and determine the appropriate screening methods.We enrolled 20 children with diseaseD006527 and 50 family members of each of these 9606 (40 parents and 10 siblings). All the subjects underwent a physical examination, Kayser-Fleischer (K-F) rings in the cornea, abdominal ultrasonography (Abdl Ur), cranial magnetic resonance imaging (MRI), serum ncbi1356, serum chemicalD003300, 24-hour urine chemicalD003300, blood alanine transaminase (ALT) and aspartate transaminase (AST), and ncbi540 gene.Two new 9606 with presymptomatic diseaseD006527 (1 mother and 1 brother) in 2 families were found by screening. They had no clinical symptoms and K-F rings in corneal. Biochemical examination indicated decreased serum ncbi1356 and serum chemicalD003300 in the mother and decreased serum ncbi1356 in the brother. Gene sequencing revealed compound heterozygous mutations in them. In addition, 48 heterozygous carriers of diseaseD006527 (WHDzc) were found in this study. The levels of ncbi1356 and serum chemicalD003300 in 9606 of diseaseD006527 were significantly less than WHDzc and 24-hour urinary chemicalD003300 were significantly higher than WHDzc (P = .000). The biochemical profiles of diseaseD006527 and WDHzc overlapped in range of 0.8 to 1.5 g/L in ncbi1356, above 9 mumol/L in serum chemicalD003300 and below 100 mug/24 h in urinary chemicalD003300. Gene sequencing showed 2 pathological mutations in all 9606 with diseaseD006527 and 1 pathological mutation in all WDHzc.Not only siblings but also the previous generation of children probands with diseaseD006527 should be screened. Genetic testing should be conducted for the diagnosis of presymptomatic 9606 with diseaseD006527.
28433114	Association|chemicalD003300|diseaseD006527	Hepatic features of diseaseD006527.In diseaseD006527 (diseaseD006527) defective AT7B function leads to biliary chemicalD003300 excretion and pathologic copper accumulation, particularly in liver and brain, where it induces cellular damage. diseaseD008107 most often precedes neurologic or diseaseD001523 manifestations. In most 9606 with diseaseD001523 there is some degree of diseaseD008107 at the time of disease presentation. Hepatic manifestations of diseaseD006527 can be extremely variable. 9606 with clinically asymptomatic diseaseD006527 are often found by family screening or identified on routine laboratory testing. Others may have a clinical picture of diseaseD006521 or of diseaseD058625 with diseaseD005355. A minority present with diseaseD017114, often on the background of advanced diseaseD005355. Complications from diseaseD008107 may be related to diseaseD006975 and concomitant diseaseD008107 may accelerate the course of diseaseD008107. diseaseD006528 may occur in 9606 with diseaseD006527, most commonly when diseaseD005355 and diseaseD007249 are present. The prognosis of 9606 with diseaseD006527 is excellent, especially for those without diseaseD005355 at the time of diagnosis, but requires timely initiation of appropriate therapy specific for diseaseD006527 and for the 9606's diseaseD008107 independent of diseaseD006527.
28536976	Association|chemicalD003300|ncbi24387; Association|chemicalD003300|ncbi25402; Positive_Correlation|chemicalD018698|diseaseD005911; Positive_Correlation|chemicalD018698|diseaseD007859; Positive_Correlation|chemicalD003300|diseaseD007859	diseaseD007859 Following chemicalD003300 diseaseD064420: Biochemical and Immunohistochemical Basis.The prototype disease of diseaseD064420 in 9606 is diseaseD006527, and diseaseD003072 is the presenting symptom of it. There is no study correlating chemicalD003300-induced excitotoxicity, apoptosis, and astrocytic reaction with diseaseD008569. We report excitotoxicity, apoptosis, and astrocytic reaction of the hippocampus and frontal cortex with diseaseD008569 in 10116 model of Cu toxicity. Thirty-six 10116 were divided into group I (control) and group II (100 mg/kgBwt/day chemicalD019327 orally). Y-maze was performed for memory and learning at 0, 30, 60, and 90 days. Frontal and hippocampal free chemicalD003300 concentration, oxidative stress markers [chemicalD005978 (chemicalD005978), total antioxidant diseaseD064420 (TAC), and chemicalD008315 (chemicalD008315)], and chemicalD018698 were measured by atomic absorption spectroscopy, spectrophotometry, and ELISA, respectively. N-methyl-D-aspartate receptors (NMDARs) ncbi24408, ncbi24409, and ncbi24410 were done by real-time polymerase chain reaction. Immunohistochemistry for ncbi25402 and ncbi24387 (ncbi24387) were done and quantified using the ImageJ software. The chemicalD018698 level in hippocampus was increased, and NMDAR expression was decreased at 30, 60, and 90 days in group II compared to group I. In the frontal cortex, chemicalD018698 was increased at 90 days, but NMDARs were not significantly different in group II compared to group I. ncbi25402 and ncbi24387 expressions were also higher in group II compared to group I, and these changes were more marked in hippocampus than frontal cortex. These changes correlated with respective free tissue chemicalD003300, oxidative stress, and Y-maze attention score. Cu toxicity induces apoptosis and diseaseD005911 of the hippocampus and frontal cortex through direct or chemicalD018698 and oxidative stress pathways, and results in diseaseD007859.
29723692		A Learning Collaborative Approach Increases Specificity of Diagnosis of diseaseD017114 in Pediatric 9606.BACKGROUND & AIMS: Many pediatric 9606 with diseaseD017114 (diseaseD017114) do not receive a specific diagnosis (such as diseaseD006561 or diseaseD006527 or diseaseC536560 defects)-they are left with an indeterminate diagnosis and are more likely to undergo liver transplantation, which is contraindicated for some disorders. Strategies to facilitate complete diagnostic testing should increase identification of specific diseaseD008107 and might reduce liver transplantation. We investigated whether performing recommended age-specific diagnostic tests (AS-DTs) at the time of hospital admission reduces the percentage PALFs with an indeterminate diagnosis. METHODS: We performed a multinational observational cohort study of 658 diseaseD017114 participants in the United States and Canada, enrolled at 10 medical centers, during 3 study phases from December 1999 through December 2014. A learning collaborative approach was used to implement AS-DT using an electronic medical record admission order set at hospital admission in phase 3 of the study. Data from 10 study sites participating in all 3 phases were compared before (phases 1 and 2) and after (phase 3) diagnostic test recommendations were inserted into electronic medical record order sets. RESULTS: The percentage of subjects with an indeterminate diagnosis decreased significantly between phases 1-2 (48.0%) and phase 3 (to 30.8%) (P = .0003). The 21-day cumulative incidence rates for liver transplantation were significantly different among phase 1 (34.6%), phase 2 (31.9%), and phase 3 (20.2%) (P = .030). The 21-day cumulative incidence rates for diseaseD003643 did not differ significantly among phase 1 (17.9%), phase 2 (11.9%), and phase 3 (11.3%) (P = .20). CONCLUSIONS: In a multinational study of children with diseaseD017114, we found that incorporating diagnostic test recommendations into electronic medical record order sets accessed at time of admission reduced the percentage with an indeterminate diagnosis that may have reduced liver transplants without increasing mortality. Widespread use of this approach could significantly enhance care of diseaseD017114 in children.
28732478	Association|chemicalD003300|diseaseD006527; Association|chemicalD003300|diseaseD030342	Comparative assessment of clinical rating scales in diseaseD006527.BACKGROUND: diseaseD006527 (diseaseD006527) is an diseaseD030342 of chemicalD003300 metabolism resulting in multifaceted diseaseD001523. The objective of the study was to comparatively assess two clinical rating scales for diseaseD006527, the Unified diseaseD006527 Rating Scale (UWDRS) and the Global Assessment Scale for diseaseD006527 (GAS for diseaseD006527), and to test the feasibility of the 9606 reported part of the UWDRS neurological subscale (termed the "minimal UWDRS"). METHODS: In this prospective, monocentric, cross-sectional study, 65 9606 (median age 35 [range: 15-62] years; 33 female, 32 male) with treated diseaseD006527 were scored according to the two rating scales. RESULTS: The UWDRS neurological subscore correlated with the GAS for diseaseD006527 Tier 2 score (r = 0.80; p < 0.001). Correlations of the UWDRS hepatic subscore and the GAS for diseaseD006527 Tier 1 score with both the Model for diseaseD058625 (MELD) score (r = 0.44/r = 0.28; p < 0.001/p = 0.027) and the Child-Pugh score (r = 0.32/r = 0.12; p = 0.015/p = 0.376) were weak. The "minimal UWDRS" score significantly correlated with the UWDRS total score (r = 0.86), the UWDRS neurological subscore (r = 0.89), and the GAS for diseaseD006527 Tier 2 score (r = 0.86). CONCLUSIONS: The UWDRS diseaseD001523 subscales and the GAS for diseaseD006527 Tier 2 score are valuable tools for the clinical assessment of diseaseD006527 9606. The "minimal UWDRS" is a practical prescreening tool outside scientific trials.
28719006	Association|chemicalD003300|diseaseD006527	Relative exchangeable chemicalD003300: A valuable tool for the diagnosis of diseaseD006527.BACKGROUND & AIMS: Measuring of the relative exchangeable chemicalD003300 seems to be a promising tool for the diagnosis of diseaseD006527. The aim of our study is to determine the performance of REC for the diagnosis of diseaseD006527 in a population of 9606 with chronic diseaseD008107. METHODS: Measuring of exchangeable serum diseaseC535468 levels and relative exchangeable chemicalD003300 was performed in a group of diseaseD006527 9606 at diagnosis or at clinical deterioration because of non-compliance (group 1, n=9), a group of stable diseaseD006527 9606 (group 2, n=40), and two groups of 9606 (adult and paediatric) followed for non-diseaseD008107 (group 3, n=103 and group 4, n=49 respectively). RESULTS: Exchangeable serum chemicalD003300 (N: 0.6-1.1 mumol/L) was significantly higher in group 1 (mean 2.2+-0.7 mumol/L) compared to the other three groups: group 2=0.9+-0.4 mumol/L, group 3=1.2+-0.4 mumol/L, group 4=1.1+-0.3 mumol/L (P<0.05). Relative exchangeable chemicalD003300 was significantly higher in diseaseD006527 9606 group 1 and 2 (mean 52.6% and 43.8%) compared to 9606 suffering from other diseaseD008107 (mean 7.1% and 5.9%) (P<0.05). CONCLUSIONS: Our study confirms that the determination of relative exchangeable chemicalD003300 is a highly valuable tool for the diagnosis of diseaseD006527.
31161407	Association|chemicalD003300|diseaseC565846	diseaseC565846: is abnormal chemicalD003300 metabolism a primary cause of this disease?diseaseC565846 (diseaseC565846) is characterized by marked chemicalD003300 deposition, Mallory-Denk body (MDB) formation and severe diseaseD056486. Although the characteristics are apparently different from diseaseD006527, large amounts of chemicalD003300 accumulate in the liver of the 9606. We extensively treated a 9606 with diseaseC565846 to reduce the body chemicalD003300, however, the 9606 needed liver transplantation. Previous liver biopsy revealed high chemicalD003300 content. But extirpated liver contained an extremely small amount of chemicalD003300, although MDBs and severe diseaseD007249 remained. These phenomena suggest abnormal chemicalD003300 metabolism is not the principle cause of diseaseC565846 but some other abnormality must exist.
30359967	Association|chemicalD001663|diseaseD017093; Positive_Correlation|chemicalD003300|diseaseD017093; Negative_Correlation|chemicalD003300|diseaseD006461; Association|chemicalD001663|diseaseD006461	Plasmapheresis Combined with Continuous Plasma Filtration Adsorption Rescues Severe diseaseD017114 in diseaseD006527 before Liver Transplantation.diseaseD001752 (diseaseD006461 and diseaseD017114 [ALF] in diseaseD006527) is fatal and almost all 9606 ultimately need a timely liver transplantation to save their lives. How to safely pass the critical period to liver transplantation is still a big challenge to doctors especially to pediatricians facing more difficult situations in blood purification. Here, we report about a 7-year-old child (weight 21 kg) presenting with severe diseaseD006461 and impending ALF that made a rapid recovery with prompt initiation of plasmapheresis combined with continuous plasma filtration adsorption (CPFA) and chelation therapy. Rapidly efficient removal of chemicalD003300, chemicalD001663, and albumin-binding toxins by hybrid blood purification alleviated diseaseD006461 and diseaseD017093 and successfully bridged the 9606 over the critical period to late liver transplantation. Moreover, a review of the literature was performed examining the use of plasmapheresis, molecular adsorbent recirculation system, single-pass albumin dialysis, and continuous veno-venous hemodiafiltration in diseaseD006527. The experience of our case points to that plasmapheresis combined with CPFA treatment can improve clinical symptoms and bridge children over through diseaseD001752 to late live transplantation, and CPFA treatment is feasible and safe in children weighing more than 20 kg.
34866098	Association|chemicalD019345|diseaseD064420; Positive_Correlation|chemicalD019345|diseaseD014077; Association|chemicalC002313|chemicalD003300; Negative_Correlation|chemicalD019345|diseaseD006527; Positive_Correlation|chemicalD019345|diseaseD018442; Association|chemicalD003300|diseaseD064420; Positive_Correlation|chemicalD003300|diseaseD018442; Positive_Correlation|chemicalD003300|diseaseD014077	Lustrous White diseaseD014077 Surrounded by an diseaseD018442: A Novel Endoscopic Finding of diseaseD013272 in 9606 with diseaseD006527.diseaseD006527 is an diseaseD020739. We herein report a novel endoscopic finding in three 9606 with diseaseD006527. These 9606 underwent upper endoscopy due to diseaseD012817 or during follow-up. In each case, endoscopy revealed lustrous white diseaseD014077 surrounded by an diseaseD018442 in the greater curvature of the gastric body. A biopsy of the lesions showed chemicalC002313-positive tissue, indicating chemicalD003300 deposition, in the interstitial stroma and fundic glands of the mucosa. All 9606 had been receiving treatment with chemicalD019345. These endoscopic findings might have been related to the diseaseD064420 of the accumulated chemicalD003300 and chemicalD019345.
38317346		Challenges faced in establishing a pediatric liver transplant program in a lower-middle-income country with free healthcare service.BACKGROUND: Liver transplant is the cure for children with diseaseD017093. Sri Lanka is a lower-middle-income country with a predominant free, state health system. Pediatric liver transplant program in Sri Lanka is still in the budding state where the initial experience of the program is yet to be documented. METHODS: A retrospective review was performed including the clinical characteristics of all pediatric liver transplant recipients of Colombo North Centre for diseaseD008107 since the inception of the program from June 2020 to May 2023. RESULTS: There were 14 PLT performed in 3 years. The median recipient age and weight were 8 years (6 months-15 years) and 23.3 kg (6.4-49.2), respectively. The majority were boys (64%). All were from low-income backgrounds. Indications for LT were diseaseD017114 (5/14), decompensated diseaseD008107 (5/14), and diseaseD065290 (4/14). Underlying diseaseD008107 were diseaseD006527 (6/14), diseaseD008107 (3/14), diseaseD001656 (2/14) and progressive diseaseC535935 (1/14), and unknown etiology (2/14). The majority were living donor liver transplants (86%). Of the living donors, 42% (5/12) were Buddhist priests. There were three immediate diseaseD003643 and two late diseaseD003643. The 3-month survival was 78%, and overall survival was 64%. Living donor transplants carried a higher success rate (92%) compared to diseased donor transplants (0%; 2/2). CONCLUSIONS: Initial experience of pediatric liver transplant program of Sri Lanka is promising despite being established in a free healthcare system amidst the crisis circumstances.
28433103		Liver transplantation for diseaseD006527.Liver transplantation (LT) is a life-saving and curative treatment for diseaseD006527 (diseaseD006527), providing restoration of function of the liver and mitigation of diseaseD006975. Indications for LT in 9606 with diseaseD006527 include diseaseD017114 or diseaseD058625 not treatable by medical therapy. LT is also used to treat diseaseD006528 when it develops in 9606 with diseaseD006527 when diseaseD009369 resection is not feasible. LT solely for diseaseD009461 diseaseD001523 diseaseD006527 remains controversial. Living liver donation as well as cadaveric orthotopic and auxiliary LT are options for transplantation for diseaseD006527. Outcomes for LT for diseaseD006527 are excellent, and supportive measures while awaiting transplantation help bridge the 9606 to a more successful outcome. Future hepatocyte or stem cell transplantation may augment or supplant current LT for diseaseD006527.
33070579		Comment on "A rare case of diseaseD006527 associated with diseaseD002543".
30706949	Negative_Correlation|diseaseD056486|ncbi540; Association|chemicalD003300|ncbi540; Association|diseaseD006527|ncbi540; Association|chemicalD003300|diseaseD006527	Liver Expression of a ncbi540 Gene Results in Long-Term Restoration of chemicalD003300 Homeostasis in a diseaseD006527 Model in 10090.Gene therapy with an adeno-associated vector (AAV) serotype 8 encoding the 9606 ATPase copper-transporting beta polypeptide (ncbi540) complementary DNA (cDNA; 372030-ncbi540) is able to provide long-term chemicalD003300 metabolism correction in 6-week-old male diseaseD006527 (diseaseD006527) 10090. However, the size of the genome (5.2 kilobases [kb]) surpasses the optimal packaging capacity of the vector, which resulted in low-yield production; in addition, further analyses in diseaseD006527 female 10090 and in animals with a more advanced disease revealed reduced therapeutic efficacy, as compared to younger males. To improve efficacy of the treatment, an optimized shorter AAV vector was generated, in which four out of six chemicalD008670-binding domains (MBDs) were deleted from the ncbi540 coding sequence, giving rise to the ncbi540 protein (Delta57-486-ncbi540). In contrast to 372030-ncbi540, 372030-ncbi540 could be produced at high titers and was able to restore chemicalD003300 homeostasis in 6- and 12-week-old male and female diseaseD006527 10090. In addition, a recently developed synthetic AAV vector, AAVAnc80, carrying the ncbi540 gene was similarly effective at preventing diseaseD056486, restoring chemicalD003300 homeostasis, and improving survival 1 year after treatment. Transduction of approximately 20% of hepatocytes was sufficient to normalize chemicalD003300 homeostasis, suggesting that corrected hepatocytes are acting as a sink to eliminate excess of chemicalD003300. Importantly, administration of AAVAnc80-ncbi540 was safe in healthy 10090 and did not result in diseaseC535468. Conclusion: In summary, gene therapy using an optimized therapeutic cassette in different AAV systems provides long-term correction of chemicalD003300 metabolism regardless of sex or stage of disease in a clinically relevant diseaseD006527 10090 model. These results pave the way for the implementation of gene therapy in diseaseD006527 9606.
30635331		MR Imaging of the Brain in diseaseD006527.BACKGROUND AND PURPOSE: diseaseD006527 is an diseaseD030342 characterized by a diseaseC535468 that causes damage to many organs, especially the brain. Few studies report the relationships between these diseaseD009461 and MR imaging of the brain. Therefore, we investigated the correlation of diseaseD001927 in 9606 with diseaseD006527 with their clinical symptoms, age of onset, and lag time to diagnosis. MATERIALS AND METHODS: A cohort of 364 9606 was recruited in China between January 2003 and December 2017. Age of onset, lag time until diagnosis, and diseaseD009461 were recorded, and cranial MR imaging was performed. 9606 were divided into groups within each of these factors for correlation analysis with the MR imaging brain scans. RESULTS: Abnormal signals in the MR imaging brain scans were seen in all 364 cases. Affected regions included the putamen, pons, midbrain, and thalamus, while the medulla and occipital lobe were unaffected. The putamen was the most frequently damaged brain region in this study. With the age of onset younger than 10 years, cranial MR imaging scans showed only impairment in the putamen. 9606 with a longer lag time before diagnosis were more likely to have impairment in the pons, midbrain, and cortex. Among diseaseD009461 of diseaseD006527, diseaseD004422 is associated with the midbrain and cortex, and diseaseC567034 is related to the caudate nucleus. CONCLUSIONS: Abnormalities in the putamen, pons, midbrain, and thalamus are part of the neuroimaging spectrum of diseaseD006527. There is a significant correlation between the site of diseaseD001930 and diagnosis lag time.
32043565	Association|diseaseD018981|ncbi84317; Association|diseaseD006527|ncbi540; Association|diseaseD006527|ncbi84317	Genetics of diseaseD006527 and diseaseD006527 in a clinical series from eastern Spain.diseaseD006527 (diseaseD006527) is an diseaseD030342 caused by ncbi540 mutations. Subjects with only one mutation may show clinical signs and individuals with biallelic changes may remain asymptomatic. We aimed to achieve a conclusive genetic diagnosis for 34 9606 clinically diagnosed of diseaseD006527. Genetic analysis comprised from analysis of exons to WES (whole exome sequencing), including promoter, introns, UTRs (untranslated regions), besides of study of large deletions/duplications by MLPA (multiplex ligation-dependent probe amplification). Biallelic ncbi540 mutations were identified in 30 9606, so that four 9606 were analyzed using WES. Two affected siblings resulted to be compound heterozygous for mutations in ncbi84317, which is involved in a form of diseaseD018981. In sum, the majority of 9606 with a diseaseD006527 phenotype carry ncbi540 mutations. However, if genetic diagnosis is not achieved, additional genes should be considered because other disorders may mimic diseaseD006527.
33663358		diseaseD065290 in Children: A Single-Center Experience.OBJECTIVES: diseaseD065290 and its outcomes have not yet been evaluated in detail in children. We aimed to evaluate the etiology, diseaseD000208 events, and prognostic factors of diseaseD065290 in children. MATERIALS AND METHODS: Pediatric 9606 (age 2-18 years) diagnosed with diseaseD065290 between April 2014 and April 2020 were evaluated retrospectively. diseaseD065290 was defined as the presence of diseaseD000208 diseaseD056486 in previously diagnosed or undiagnosed diseaseD008107 causing diseaseD007565 (total serum chemicalD001663 >=5 mg/dL) and diseaseD001778 (international normalized ratio of >=2.0) and clinical and/or radiological diseaseD001201 and/or diseaseD006501 within 4 weeks. diseaseD065290 Research Consortium and diseaseD058625-Sequential diseaseD009102 Assessment scores were calculated for 9606 at first admission and at end of day 5 or before liver transplant. RESULTS: Our study included 29 9606. Underlying diseaseD008107 were mostly diseaseD019693 (51.72%) and diseaseD006527 (27.58%), with flare-ups of these diseases also the most common diseaseD000208 events (48.28% and 27.58%, respectively). Seven 9606 (24.14%) received liver transplants. At first admission, diseaseD065290 Research Consortium and diseaseD058625-Sequential diseaseD009102 Assessment cut-off scores to predict liver transplant were 7.5 and 6.5; at end of day 5 or before transplant, cut-off scores were 8.5 and 7.5, respectively. The 8.5 cut-off score on day 5 was the most specific and sensitive to predict liver transplant. International normalized ratio cut-off of 3.04 predicted transplant requirement with maximum sensitivity and specificity. CONCLUSIONS: diseaseD006527 and diseaseD019693 were the most common underlying chronic and diseaseD000208 events of diseaseD065290 in children. Although an diseaseD065290 Research Consortium score >= 8.5 best predicted liver transplant, for 9606 with scores >= 7.5 and being followed in a nontransplant center, 9606 referral to a transplant center is appropriate.
30888628		diseaseD065290 score: best predictor of outcome in children and adolescents with decompensated diseaseD006527.BACKGROUND AND AIMS: Doubts have been raised about efficacy of New Wilson's index (NWI) in predicting Liver Transplant (LT) or mortality in decompensated diseaseD006527 (diseaseD006527) 9606. APASL diseaseD065290 Research Consortium (AARC) has introduced a new score (diseaseD065290) which has not been studied in children. METHODS: Data of all pediatric diseaseD006527 cases were prospectively collected and analyzed. Cox regression and Area Under Receiver Operative Curve (AUROC) analyses were used to identify best predictive score for mortality at 90 days. RESULTS: Sixty-six confirmed cases of decompensated diseaseD006527, 39 (59%) improved on medical management and 27 (41%) either diseaseD003643 (20) or were transplanted (7). Among those with NWI >= 11 (42/66 cases) 19 survived versus those with NWI < 11 (24/66), 4 diseaseD003643. NWI (HR 1.23, 95% CI 1.07-1.42, p = 0.005), diseaseD065290 (HR 1.66, 95% CI 1.34-2.05, p = 0.000) and diseaseD058625-Sequential Organ diseaseD051437 Assessment score also known as CLIF-SOFA (HR 1.31, 95% CI 1.13-1.50, p = 0.000) were all significantly associated with diseaseD003643 on univariate Cox regression analysis. On comparative evaluation of the predictive scores in the present cohort, the highest positive (6.02) and lowest negative (0.09) likelihood ratios as well as highest accuracy (87.88%) revealed diseaseD065290 as the best predictor of mortality. diseaseD065290 had the best predictability with AUROC of 0.939 and the minimum standard error of 0.027. For every unit increase in diseaseD065290 score, there is likelihood of 66% increase in 90 day mortality. The optimal cutoff for the diseaseD065290 score to predict mortality was 11 or more. CONCLUSION: diseaseD065290 is the best score for the prediction of mortality at 90 days in decompensated diseaseD006527 cases.
33070580		Response to comment on "A rare case of diseaseD006527 associated with diseaseD002543".
32401363		Diagnostic Performance of Ultrasound Elastography and Serologic diseaseD005355 Indices for Evaluation of diseaseD056486 in diseaseD006527.OBJECTIVES: To investigate the diagnostic value of transient elastography (TE), 2-dimensional (2D) shear wave elastography (SWE), and the serologic diseaseD005355 indices aspartate transaminase-to-platelet ratio index (APRI) and diseaseD005355 (diseaseD005355) score for diseaseD006527 (diseaseD006527). METHODS: We retrospectively identified 9606 with a diagnosis of diseaseD006527 who underwent TE and 2D SWE on the same day. Their APRI and diseaseD005355 scores were calculated. diseaseD056486 was classified into 5 clinical categories (I-V) based on the laboratory findings, hepatic morphologic characteristics on ultrasound (US) imaging, and clinical symptoms of diseaseD005355: I, normal (n = 17); II, only biochemical abnormality (n = 15); III, altered hepatic morphologic characteristics (n = 10); IV, compensated diseaseD008103 (n = 3); and V, decompensated diseaseD008103 (n = 0). We compared the area under the receiver operating characteristic curve (AUROC) data for TE, 2D SWE, the APRI, and the diseaseD005355 score. A combined assessment of the serologic markers and US elastography was performed, and the AUROCs of the combinations were compared. RESULTS: Forty-five 9606 were included in the study (median age, 16.0 years; range, 3-35 years). Transient elastography, 2D SWE, and APRI were comparable in distinguishing the clinical categories (AUROC, 0.799-0.928). The diseaseD005355 score showed lower diagnostic value in distinguishing clinical category I from the other categories (AUROC, 0.647). Combining the serologic markers and US elastography significantly increased the AUROC value of the diseaseD005355 score (with TE and 2D SWE, P = .01 and .02). CONCLUSIONS: Transient elastography and 2D SWE showed excellent diagnostic accuracy for differentiating the clinical categories of diseaseD056486. The APRI showed better diagnostic performance than the diseaseD005355 score. The assessment of hepatic manifestations in diseaseD006527 can be improved by combining US elastography with serologic indices.
33785637		Alternative Etiologies of diseaseD008107 in 9606 With Suspected diseaseD065626.OBJECTIVES: To determine the prevalence of alternative causes of diseaseD008107 in a cohort of youth with diseaseD050177 and diseaseD009765 undergoing evaluation for suspected diseaseD065626 (diseaseD065626). METHODS: Multicenter, retrospective cohort study of 9606 aged <=18 years with diseaseD050177 and diseaseD009765 and evidence of elevated serum aminotransferases and/or diseaseD005234 on imaging, referred for suspected diseaseD065626 to Cincinnati 9606's Hospital Medical Center (2009-2017) or Yale New Haven 9606's Hospital (2012-2017). Testing was performed to exclude the following: diseaseD019693 (diseaseD019693), diseaseD006527, diseaseD014777 (diseaseD019694), diseaseD013959, diseaseD002446, diseaseD019896, and diseaseD006432. RESULTS: A total of 900 9606 with diseaseD050177 and diseaseD009765 (63% boys, 26% Hispanic ethnicity) were referred, with a median age of 13 years (range: 2-18). Most had severe diseaseD009765 (n = 666; 76%) with a median BMI z score of 2.45 (interquartile range [IQR]: 2.2-2.7). Median alanine aminotransferase level at presentation was 64 U/L (IQR: 42-95). A clinically indicated liver biopsy was performed in 358 9606 (40%) at a median of 6 months (IQR: 1-14) post initial visit; of those, 46% had confirmed diseaseD065626. Positive autoantibodies were observed in 13% of the cohort, but none met criteria for diseaseD019693. Only 19 (2%) were found to have other causes of diseaseD008107, with no cases of diseaseD014777 or diseaseD006527 detected. CONCLUSIONS: In a large, multicenter cohort, the vast majority of 9606 with diseaseD050177 and diseaseD009765 with presumed or confirmed diseaseD065626 tested negative for other causes of diseaseD008107. In contrast to a previous pediatric report, no 9606 was diagnosed with diseaseD019693.
34435331	Association|chemicalD018698|diseaseD019954; Positive_Correlation|chemicalD018698|diseaseD006527	Neuropsychiatric diseaseD012877 of diseaseD006527: Correlation with MRI and Glutamate Excitotoxicity.This study aims to identify neuropsychiatric diseaseD012877 in neurological diseaseD006527 (diseaseD006527), and their correlation with MRI changes and glutamate excitotoxicity. Forty-three consecutive 9606 with diseaseD006527 from a tertiary care teaching hospital were evaluated prospectively who fulfilled the inclusion criteria. The neuropsychiatric evaluation was done using Neuropsychiatric Inventory (NPI) battery that assesses 12 domains including diseaseD063726, diseaseD006212, diseaseD011595/diseaseD010554, diseaseD019052/diseaseD003866, diseaseD001007, euphoria, apathy, diseaseD057180, diseaseD001523, diseaseD002869, diseaseD001068, and diseaseD053206 behavior. Cranial MRI was done using a 3 T machine, and locations of signal changes were noted including the total number of MRI lesions. Serum chemicalD018698 level was measured by a fluorescence microplate reader. Abnormal NPI in various domains and total NPI scores were correlated with MRI lesions, serum and urinary chemicalD003300, and chemicalD018698 level. The median age of the 9606 was 16 years. Forty-one (48.8%) 9606 had diseaseD003072 and 37 (86%) had diseaseD009069. diseaseD019954 was detected in all-commonest being diseaseD011595 (90.7%) followed by diseaseD001068 (81.4%), elation (74.4%), diseaseD001523 (69.8%), diseaseD001007 (67.4%), diseaseD003866 (65.1%), apathy (44.2%), night time diseaseD001523 (32.6%), diseaseD002869 (20.9%), diseaseD063726 (16.3%), and diseaseD006212 (18.6%). The diseaseD013786 was associated with diseaseD003866, globus pallidus with diseaseD003866 and diseaseD001007, caudate with diseaseD001007 and diseaseD011595, brainstem with diseaseD001523, and frontal cortex with apathy. Serum chemicalD018698 level was higher in diseaseD006527. NPI sum score correlated with MRI load and chemicalD018698 level. Varying severity of diseaseD019954 are common in the 9606 with diseaseD006527 and correlate with the location of MRI lesion and chemicalD018698 level.
32544364	Negative_Correlation|chemicalD014266|diseaseD009765; Negative_Correlation|chemicalD014266|diseaseD015430; Negative_Correlation|chemicalD013095|diseaseD009765; Negative_Correlation|chemicalD011073|diseaseD009765; Association|chemicalD014266|ncbi20229; Negative_Correlation|chemicalD014266|diseaseD006527	chemicalD014266 (chemicalD014266): a caloric restriction mimetic with a new mode of action.Caloric restriction mimetics (CRMs) are nontoxic macroautophagy/autophagy enhancers that act through the stimulation of cytoplasmic protein deacetylation reactions. Thus far, three functional classes of CRMs have been described: inhibitors of acetyltransferases (such as chemicalD013095), inhibitors of chemicalD000105 (AcCoA) synthesis (such as chemicalC007999) and activators of deacetylases/sirtuins (such as chemicalD000077185). chemicalD014266 (also called chemicalD014266, abbreviated chemicalD014266) is a synthetic chemicalD011073 with resemblance in its structure to chemicalD013095, a natural chemicalD011073 reputed for its pro-autophagic, anti-diseaseD009765 and anti-aging effects. chemicalD014266, which is approved for the treatment of diseaseD006527, has no effects on the longevity of 10090, yet does induce autophagy and reduces diseaseD015430 in 10090 fed a high-fat diet (HFD). Mechanistically, these effects of chemicalD014266 involve an increased activity of the chemicalD014266-metabolizing enzyme, ncbi20229 (ncbi20229). ncbi20229 overactivation ultimately results in the depletion of intracellular AcCoA with a consequent de-acetylation of cytoplasmic proteins and induction of autophagy. Accordingly, chemicalD014266 fails to induce autophagy or to control HFD-induced diseaseD015430 in ncbi20229-deficient 10090. Altogether, these findings indicate that chemicalD014266 induces autophagy through a novel mode of action, namely, by the activation of an AcCoA-depleting enzyme.
34908013		Re-evaluation of diseaseC536883 Index in Children With Acutely Decompensated Hepatic diseaseD006527.OBJECTIVES: Liver transplantation (LT) in diseaseD006527 (diseaseD006527) is a life-saving option for 9606 presenting with diseaseD017093 and diseaseD001927. 9606 without diseaseD001927 can avoid LT and treated successfully with chelation therapy. It is essential to predict the risk of fatal outcomes where LT is required. We aim to critically analyse the validity of the diseaseD006527 Index prospectively from a cohort of diseaseD006527 9606 managed at our institution. METHODS: diseaseD006527 Index and other clinical data from 2005 to 2018, recorded prospectively as part of clinical management, were analysed. RESULTS: Over 13-year period, 52 children with diseaseD006527 (29 boys) with median age at diagnosis of 11.69 (range 3.92-17.26) years were studied. Of these, 17 were diagnosed as part of family screening, 17 presented with diseaseD056486, and 18 with diseaseD017114 (diseaseD017114) as per PALF definition. 9606 presented with diseaseD056486 and in the pre-symptomatic group had diseaseD006527 Index <11, and none of them required LT. diseaseD006527 Index is still a good predictor for LT in diseaseD006527 9606 with diseaseD017114, providing a sensitivity of 80%, specificity of 100%, positive-predictive, and negative-predictive value of 100% and 80%, respectively. 9606 presented with an index of 8-10 also required LT at median duration of 58 days (IQR 48-135 days). CONCLUSIONS: diseaseD006527 9606 presenting with diseaseD017114 who had an index of >=11 do require LT. Children with a diseaseD006527 Index of 8 to 10 within the first 2 months of admission require close monitoring as LT may become necessary.
35255304	Association|diseaseD003865|ncbi2670; Association|diseaseD000067877|ncbi2670; Association|diseaseD009471|ncbi2670; Association|diseaseD001249|ncbi2670; Association|diseaseD000086382|ncbi2670; Association|diseaseD016883|ncbi2670; Association|diseaseD000544|ncbi2670; Association|diseaseD057174|ncbi2670; Association|diseaseD005909|ncbi2670; Association|diseaseD020521|ncbi2670; Association|diseaseD019636|ncbi2670; Association|diseaseD006527|ncbi2670; Association|diseaseD010300|ncbi2670; Association|diseaseD013119|ncbi2670; Association|diseaseD004827|ncbi2670; Association|diseaseD005621|ncbi2670; Association|diseaseD012559|ncbi2670; Association|diseaseD020271|ncbi2670; Association|diseaseD009103|ncbi2670; Association|diseaseD009461|ncbi2670	Serum ncbi2670 is a body fluid biomarker: A valuable prognostic for diseaseD020271 - A systematic review.Astrocytes are the most abundant cell type in the 9606 central nervous system, and they play an important role in the regulation of neuronal physiology. In diseaseD009461, astrocyte disintegration leads to the release of ncbi2670 (ncbi2670) from tissue into the bloodstream. Elevated serum levels of ncbi2670 can serve as blood biomarkers, and a useful prognostic tool to facilitate the early diagnosis of several diseaseD020271 ranging from diseaseD020521 to diseaseD019636. This systematic review synthesizes studies published between January 2012 and September 2021 that used ncbi2670 as a potential blood biomarker to detect diseaseD009461. The following electronic databases were accessed: MEDLINE, Scopus, and Web of Science. In all the databases, the following search strategy was used:  ncbi2670  OR  ncbi2670  AND  neurological  OR  neurodegenerative  AND  plasma  OR  serum . The initial search identified 1152 articles. After the exclusion criteria were applied, 48 publications that reported ncbi2670 levels in diseaseD009461 were identified. A total of16 different diseaseD009461 that have plasmatic ncbi2670 levels as a possible biomarker for the disease were described in the articles, being: diseaseD009103, diseaseD057174, diseaseD000544, diseaseD010300, diseaseD000086382, diseaseD004827, diseaseD006527, diseaseD016883, diseaseD012559, diseaseD000067877, diseaseD003865, diseaseD005909, diseaseD013119, diseaseD001249, diseaseD009471 and diseaseD005621. Our review shows an association between ncbi2670 levels and the disease being studied, suggesting that elevated ncbi2670 levels are a potentially valuable diagnostic biomarker in the evaluation of different diseaseD020271.
37347440		Pediatric diseaseD065290.diseaseD065290 (diseaseD065290) is characterized by an acute hepatic insult happening in a 9606 with underlying diseaseD005355 with compromised hepatic reserve leading to development of systemic diseaseD007249, diseaseD018805, and diseaseD009102 resulting in poor outcome in majority. While Asia Pacific Association for Study of diseaseD008107 (APASL) emphasizes on early diagnosis before development of diseaseD009102, European Association for Study of diseaseD008107 (EASL) mandates the presence of diseaseD009102 to define diseaseD065290. There is a lack of consensus definition of pediatric diseaseD065290 although recent APASL guidelines have tried to address the issue. While diseaseD006527 (diseaseD006527) and diseaseD019693 (diseaseD019693) are the most common cause of underlying diseaseD005355 in children, acute diseaseD014777 and flares of diseaseD006527 and diseaseD019693 are the commonest acute precipitating events. Poor outcomes [diseaseD003643 and liver transplantation (LT)] ranging from 19 to 59% have been reported. Prognosis in pediatric diseaseD065290 is usually better than that in adults due to greater proportion of treatable etiologies, lesser diseaseD009102, comorbidities and better hepatic reserves. APASL diseaseD065290 Research Consortium (AARC) score more than or equal to 11 is predictive of poor 28-90 d mortality. Treatment of pediatric diseaseD065290 relies mainly on prompt diagnosis and medical management of a potentially treatable etiology of underlying diseaseD005355. Bridging therapies, especially high volume plasma exchange can be initiated early as a bridge to LT or native liver recovery. Those with no improvement in 4-7 d should undergo LT before development of diseaseD018805 or diseaseD009102.
32726213		A Rare diseaseD010494 with Complete Separation between the Visceral and Parietal Pericardium: A Case Report.BACKGROUND: diseaseD010493 is the most common form of diseaseD008476, while diseaseD010494 is challenging in diagnosis and is easily overlooked. CASE REPORT: A 30-year-old female presented with diseaseD000007 and mild diseaseD004487 for 3 months. The 9606 was initially suspected of having diseaseD005355 caused by diseaseD006527. Following liver biopsy and multiple investigation, thickened, calcified pericardium was detected by echocardiography and chest computed tomography. The 9606 was finally diagnosed with diseaseD010494 and received pericardiectomy. Intraoperatively, we found that the heart was entirely constricted by the thickened and calcified visceral pericardium, which was completely separated from the parietal pericardium. The 9606 received successful pericardiectomy and had relief of symptoms after surgery. CONCLUSION: 9606 with diseaseD010494 may present with symptoms similar to that of diseaseD008107, which makes it difficult and complicated for diagnosis. This case highlights the importance of comprehensive preoperative evaluation and maintaining clinical suspicion of diseaseD010493 in 9606 with features of elevated systemic venous pressure. In addition, diseaseD010494 with complete separation between visceral and parietal pericardium has seldom been reported.
32398357		Liver transplantation as a rescue therapy for severe neurologic forms of diseaseD006527.OBJECTIVE: To evaluate the effect of liver transplantation (LT) in 9606 with diseaseD006527 (diseaseD006527) with severe neurologic worsening resistant to active chelation. METHODS: French 9606 with diseaseD006527 who underwent LT for pure neurologic indication were retrospectively studied. Before LT and at the last follow-up, diseaseD009422 was evaluated with the Unified diseaseD006527 Rating Scale (UWDRS) score, disability with the modified Rankin Scale (mRS) score, and hepatic function with the Model for diseaseD058625 score, together with the presence of a Kayser-Fleischer ring (KFR), brain MRI scores, and copper balance. The survival rate and disability at the last follow-up were the coprimary outcomes; evolution of KFR and brain MRI were the secondary outcomes. Prognosis factors were further assessed. RESULTS: Eighteen 9606 had LT. All were highly dependent before LT (median mRS score 5). diseaseD009461 were severe (median UWDRS score 105), dominated by diseaseD004421 and diseaseD010302. The cumulated survival rate was 88.8% at 1 year and 72.2% at 3 and 5 years. At the last follow-up, 14 9606 were alive. Their mRS and UWDRS scores improved (p < 0.0001 and p = 0.0003). Eight 9606 had a major improvement (78% decrease of the UWDRS score), 4 a moderate one (41% decrease), and 2 a stable status. KFR and brain MRI scores improved (p = 0.0007). Severe diseaseD018805 (p = 0.011) and intensive care unit admission (p = 0.001) before LT were significantly associated with diseaseD003643. CONCLUSIONS: LT is a rescue therapeutic option that should be carefully discussed in selected 9606 with diseaseD006527 resistant to anticopper therapies (chelators or zinc salts) as it might allow 9606 to gain physical independency with a reasonable risk. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for 9606 with diseaseD006527 with severe neurologic worsening resistant to active pharmacologic therapy, LT might decrease diseaseD009422.
37565896	Association|diseaseD013927|ncbi5054	diseaseD065666 secondary to superior mesenteric diseaseD012170 in a patient with diseaseD008103: A case report.RATIONALE: diseaseD065666 due to diseaseD013478 is a rare yet potentially life-threatening emergency. Our case report explores this condition in the context of a patient with diseaseD008103 due to diseaseD006527. We specifically highlight the complex derangement of the coagulative balance in diseaseD008103. PATIENT CONCERNS: A 34-year-old female with diseaseD006527-related diseaseD005355 presented with intractable diseaseD015746, diseaseD009325, and diseaseD014839 that showed no response to antispasmodic medication. DIAGNOSES: A contrast-enhanced abdominal computed tomography scan and Doppler ultrasound confirmed an intraluminal filling defect in the SMV, leading to the diagnosis of diseaseD013478. INTERVENTIONS: Prompt anticoagulation, intravenous fluids, and an antibiotic were initiated. Surgical consultation recommended conservative therapy with close monitoring. OUTCOMES: Over the following 2 days, the patient's condition improved considerably, with almost complete resolution of her symptoms. Genetic testing identified a 4G/4G homozygous genotype of the ncbi5054 gene, associated with a higher risk of diseaseD013927 in the vessels of internal organs. After 2 months of sustained anticoagulant therapy, a follow-up contrast-enhanced computed tomography scan revealed near-complete recanalization of the SMV, and the patient remained symptom-free. LESSONS: This case underscores the importance of early detection and treatment of diseaseD065666 in patients with diseaseD008103, as well as the potential role of genetic factors in diseaseD013927.
31653639	Association|diseaseD006527|ncbi1356; Positive_Correlation|chemicalD000438|diseaseD008107; Positive_Correlation|chemicalD000438|diseaseD058186	diseaseD006527: a diagnostic challenge in a 9606 with diseaseD008108.A 32-year-old man with diseaseD008104 presented with worsening diseaseD000007 and diseaseD007565. He was diagnosed with diseaseD005355 2 years prior after a hospitalisation for diseaseD017114, during which diseaseD014777, diseaseD001327 and metabolic workup was unrevealing. Heavy chemicalD000438 consumption was his only obvious risk factor for diseaseD008107, so his decompensation was attributed to chemicalD000438. At the present time, he was admitted with diseaseD065290 and diseaseD058186. The severity of his presentation and the disproportionately mild elevation in alkaline phosphatase relative to his hyperbilirubinaemia prompted repeating a ncbi1356 level, which, though previously normal, was now low, and eventually led to a diagnosis of diseaseD006527 (diseaseD006527) with concomitant diseaseD008108. Clinicians must recognise limitations in ncbi1356 and chemicalD003300 levels when screening for diseaseD006527 and maintain suspicion for diseaseD006527 in young 9606, even if there is an already established aetiology of diseaseD008107.
30861190	Positive_Correlation|chemicalD010396|diseaseD006417; Positive_Correlation|chemicalD010396|diseaseD051437; Positive_Correlation|chemicalD010396|diseaseC536480; Positive_Correlation|chemicalD010396|diseaseD053565; Negative_Correlation|chemicalD010396|diseaseD006527	diseaseC536480 in children and adolescents with diseaseD006527 before and during treatment with chemicalD010396.BACKGROUND AND AIM: diseaseD007674 can occur at any time point during the course of diseaseD006527 (diseaseD006527). We aimed to fill a literature gap in this respect by studying diseaseC536480 in children and adolescents with diseaseD006527. METHODS: This study included 60 children with diseaseD006527 presenting to the Pediatric Hepatology Unit, Cairo University. The following data were retrieved from the 9606' files including age, sex, liver function tests, serum ncbi1356, 24-h urinary chemicalD003300, serum chemicalD003404, blood chemicalC530477, urinalysis, urinary ncbi213/chemicalD003404 ratio, urinary chemicalD002118/chemicalD003404 ratio, urinary ncbi3135, liver and renal biopsy results when available. RESULTS: All studied cases had no symptoms related to diseaseC565423. Microscopic diseaseD006417 was detected in 11% and 12% at baseline and within 5 years of therapy, respectively. Moderate microalbuminuria was detected in 34%, 50%, and 33% at baseline, within 5 years and > 5 years after therapy, respectively. diseaseD053565 was detected in 23% at baseline, 34% in those 9606 treated for up to 5 years and 37.5% > 5 years of therapy. Age and international normalized ratio were significantly higher in 9606 with high chemicalD002118/chemicalD003404 ratio compared with those with normal values at initial evaluation. Frequency of elevated urinary ncbi3135 was 36%, 36%, and 37% in 9606 at baseline, up to 5 years and > 5 years of therapy, respectively. CONCLUSION: Asymptomatic diseaseC536480 are present in 9606 with diseaseD006527 at any time point of the disease and during treatment with chemicalD010396. They have to be searched for, as early intervention may prevent progression to diseaseD051437.
33316133		diseaseD019636 in Hepatic and Neurologic diseaseD006527.Clinical presentation of diseaseD006527 (diseaseD006527) includes hepatic and neurologic manifestations. This study compares subcortical brain regions by magnetic resonance imaging in 9606 with diseaseD006527 and without diseaseD009461. Distinct diseaseD001284 affecting the basal ganglia, accumbens, and hippocampus was present in neurological diseaseD006527. diseaseD002526 was observed in hepatic diseaseD006527 without diseaseD009461.
30701819		The first experience of non-interferon therapy of diseaseD006526 in 9606 with diseaseD006527.In the article we present three clinical observations demonstrating that diseaseD006526 in 9606 with remission of diseaseD006527 causes an recrudescence of the disease, in one of the observations - decompensation of diseaseD008103. In this study we first describe on the successful treatment of diseaseD006526 with direct antiviral drugs in 9606 with diseaseD006527. Establishment of all factors of diseaseD056486 and successful treatment (elimination of the virus, adequate lifelong medical treatment) allow to expect a favorable prognosis in 9606 with a combination of diseaseD006527 and diseaseD006526.
31474637	Negative_Correlation|chemicalD019345|diseaseD006527; Negative_Correlation|chemicalD003300|chemicalD010396; Negative_Correlation|chemicalD019345|diseaseD008107; Negative_Correlation|chemicalD003300|chemicalD019345; Negative_Correlation|chemicalD014266|diseaseD009461; Negative_Correlation|chemicalD003300|chemicalD014266; Comparison|chemicalD014266|chemicalD019345	[Diagnosis and treatment of diseaseD006527 in Japan].diseaseD006527 is an diseaseD030342 based on diseaseD008661. The chemicalD003300 accumulates in the liver, brain, cornea, kidney, and other organs. This disease should be considered any individual with diseaseD008107 except infant, any 9606 older than teenage with neurological (especially for extra pyramidal signs) or diseaseD001523 with or without diseaseD008107 and sibling of diseaseD006527 9606. Typically, a combination of low serum ceruloplasmine levels and high levels of urinary chemicalD003300 contents is sufficient to establish a diagnosis. As other diagnostic tests, measurement of hepatic chemicalD003300 content and ncbi540 gene analysis are available. The key strategy of treatment is to reduce the amount of chemicalD003300 in the liver and other tissues by administering both chemicalD003300-chelating agents, such as chemicalD010396 or chemicalD014266, and/or chemicalD019345. The author recommend chemicalD019345 monotherapy for mild to moderate diseaseD008107, chemicalD014266 mono therapy for mild to moderate diseaseD009461 and combination therapy of chemicalD014266 and chemicalD019345 for sever diseaseD009461.
30936772	Negative_Correlation|chemicalD003300|diseaseD009069; Association|chemicalD003300|diseaseD006527; Association|diseaseD006527|ncbi1356	diseaseD006527: case series on a diagnostic and therapeutic emergency.diseaseD006527 is a rare diseaseD030342 causing pathologic deposition of chemicalD003300 in the liver, brain, cornea, kidney, and cardiac muscles. Presented are two cases of diseaseD006527 with progressive diseaseD009069 and Kayser-Fleischer rings with low serum chemicalD003300, low ncbi1356, and increased 24-hour urine chemicalD003300 against a background of normal transaminases. Cranial imaging revealed symmetric diseaseD001480 in T2/FLAIR. More often than not, these cases go unnoticed and misdiagnosed because of its rarity and varied presentation. Extensive workup is necessary to confirm the diagnosis. As for management, the earlier the intervention is initiated, the better prognosis would be for recovery. There are several treatment options which should be tailored to every 9606 with diseaseD006527. diseaseD006527 is considered as a diseaseC535468; immediate diagnostic evaluation and early treatment initiation is a must.
32739840		Atypical brain MRI in neurological diseaseD006527.
30558096	Negative_Correlation|chemicalD019287|diseaseD016115; Negative_Correlation|chemicalD014494|diseaseD014202; Positive_Correlation|diseaseD016115|variant#540#p.R299H; Positive_Correlation|diseaseD016115|variantrs28942074##; Positive_Correlation|diseaseD016115|variantrs121907990##; Positive_Correlation|diseaseD006527|variantrs121907990##; Positive_Correlation|chemicalD003300|diseaseD056486; Negative_Correlation|chemicalD019287|diseaseD014202; Positive_Correlation|diseaseD006527|variantrs28942074##; Association|diseaseD006527|ncbi540; Negative_Correlation|chemicalD010396|diseaseD014202; Negative_Correlation|chemicalD010396|diseaseD006527; Association|diseaseD016115|ncbi540; Association|diseaseD006527|ncbi540	A case report: Co-occurrence of diseaseD006527 and diseaseD016115 in a Chinese 9606.RATIONALE: Both diseaseD006527 (diseaseD006527) and diseaseD016115 (diseaseD016115) are rare diseaseD030342 that are caused by mutations on chromosome 13 and chromosome 11, respectively. Here, we report on a 9606 with coexisting diseaseD006527 and diseaseD016115, initially presenting episodes of diseaseD014202. 9606 CONCERNS: diseaseD006527 is a disorder of diseaseC535468. The main sites of chemicalD003300 accumulation are the liver and the brain, resulting in diseaseD056486. diseaseD016115 is a disorder of chemicalD008543 biosynthesis, characterized by a generalized reduction in pigmentation of the eyes (oculo-), skin (-cutaneous), and hair. DIAGNOSIS: The diagnosis of diseaseD006527 was confirmed by neurological symptoms, metabolism tests, and MRI scans. Interestingly, the 9606 also had very light skin color, blond hair and eyebrows, and dark brown eyelashes and irises. Because the association of dermatologic signs in diseaseD006527 has rarely been reported, diseaseD016115 was highly suspected based on these clinical findings. Genetic analysis was subsequently conducted, and the results revealed the p. (variantrs28942074##) mutation in 1 allele and the p. (variantrs121907990##) mutation in the other allele of the ncbi540 gene, confirming the diagnosis of diseaseD006527; the variant#540#p.D456fsX) mutation in 1 allele and the p. (variant#540#p.R299H) mutation in the other allele of the TYR gene, confirming the diagnosis of diseaseD016115. The family history was positive for diseaseD006527 with a 14-year-old younger brother also being diagnosed with it. Her parents are negative for diseaseD016115 and diseaseD006527. INTERVENTIONS: chemicalD014494 (DMPS) was given during hospitalization. chemicalD010396 and chemicalD019287 treatment was initiated after discharge for long-term control. OUTCOMES: Postural and diseaseD014202 disappeared, and other symptoms and signs markedly improved after treatment. LESSONS: In this study, we reported on the first case of a child who simultaneously presented diseaseD006527 and diseaseD016115, bringing up the possibility of a presumable link between these 2 rare diseases.
31416725	Association|chemicalD005947|diseaseD019636; Association|chemicalD005947|diseaseD004827	Positron Emission Tomography in Pediatric diseaseD019636.Application of molecular neuroimaging using positron emission tomographic techniques to assess pediatric diseaseD019636 has been limited, unlike in adults where positron emission tomography has contributed to clinical diagnosis, monitoring of diseaseD019636 progression, and assessment of novel therapeutic approaches. Yet, there is a huge unexplored potential of molecular imaging to improve our understanding of the pathophysiology of diseaseD019636 in children and provide radiological biomarkers that can be applied clinically. The obstacles in performing PET scans on children include sedation, radiation exposure, and access but, as will be illustrated, these barriers can be easily overcome. This review summarizes findings from PET studies that have been performed over the past three decades on children with various diseaseD019636, including the diseaseD009472, juvenile diseaseD006816, diseaseD006527, diseaseD052556, diseaseD004831, diseaseD004421, diseaseD028361, diseaseD008661, diseaseD016464, diseaseD003711, diseaseD015518, diseaseD009358, glucose transporter Glut 1 deficiency, and diseaseD007926. Because positron emission tomographic scans have often been clinically useful and have contributed to the management of these disorders, we suggest that the time has come for chemicalD005947 metabolism positron emission tomographic scans to be reimbursed by insurance carriers for children with diseaseD019636, and not restricted only to diseaseD004827 surgery evaluation.
29528784	Positive_Correlation|chemicalD010396|diseaseD017093; Negative_Correlation|chemicalD010396|diseaseD009422	diseaseD006527 and diseaseD008181: is it coincidence or a true association?A 12-year-old girl born to third-degree consanguineous parents presented with recurrent episodes of haematuria for 8 months in association with diseaseD009916 for 20 days. There was no diseaseD007565, diseaseD006529 or diseaseD009461 at presentation. An older brother had died following diseaseD007565 at 10 years of age. Urinalysis showed multiple diseaseD012010 without diseaseD011507 and there was diseaseC536227, diseaseD013921 and diseaseD052456 (23 g/L). diseaseC565169 was low and anti-nuclear antibodies and anti-double-stranded DNA antibodies were strongly positive by immunofluorescence. diseaseD008180 (diseaseD008180) was considered but the severe diseaseD052456 was unexplained. During the pre-renal biopsy work-up, a deranged diseaseD001778 profile with raised transaminases prompted evaluation for diseaseD008107 which culminated in the diagnosis of diseaseD006527. Treatment with chemicalD010396 and immunosuppressants was initiated, but there was diseaseD009422 on Day 30 of admission and she died owing to worsening diseaseD017093 on the Day 41. Post-mortem liver biopsy demonstrated diseaseD005355 and post-mortem renal biopsy showed features of diseaseD008181. diseaseC538437 and diseaseD001327 have been reported in diseaseD006527 and there are anecdotal reports of an association of diseaseD008180 with diseaseD006527. However, this case is unique in that diseaseD008181 was the presenting manifestation before diseaseD006527 was diagnosed. The underlying pathophysiological mechanisms of this association requires further research.
36096368	Association|diseaseD006527|ncbi540; Association|diseaseD008107|ncbi540	ncbi540 Genotype and diseaseD008107 Treatment Outcomes in diseaseD006527: Worse Survival With Loss-of-Function Variants.BACKGROUND AND AIMS: Although a good genotype-phenotype correlation has not been established in diseaseD006527 (diseaseD006527), 9606 with loss-of-function (LOF) ncbi540 variants demonstrate different clinical and biochemical characteristics. We aim to describe long-term treatment outcomes in the diseaseD008107 (diseaseD008107) phenotype and evaluate an association with LOF variants. METHODS: This was a single-center retrospective review of diseaseD006527 9606 with at least 1 variant in ncbi540 Demographic, biochemical, genetic, and clinical parameters were obtained. The composite clinical endpoint of liver transplantation or diseaseD003643 was used for probands with diseaseD008107 phenotype on chelators. RESULTS: Of 117 9606 with diseaseD006527: 71 had diseaseD008107, 27 had diseaseD017114 requiring urgent liver transplantation, and 19 were diagnosed through family screening. Median age at diagnosis was 13.1 (interquartile range, 9.7-17.6) years. In total, 91 variants in ncbi540 were identified in the study population. At least 1 LOF variant was present in 60 (51.3%) 9606. During median follow-up of 10.7 (interquartile range, 6.7-18.9) years, 10 (14.1%) of the probands with diseaseD008107 reached the composite endpoint. There was a worse transplant-free survival for 9606 prescribed chelation therapy in 9606 with at least 1 LOF variant (P = .03). CONCLUSIONS: 9606 with diseaseD006527 and diseaseD008107 phenotype on chelators, who have at least 1 LOF variant in ncbi540, have a worse prognosis during long-term follow up. This subgroup of 9606 requires close monitoring for signs of progressive diseaseD008107. Sequencing of ncbi540 may be used in the diagnosis of diseaseD006527, and in addition, it may provide useful prognostic information for 9606 with diseaseD006527.
34439909	Association|chemicalD013654|diseaseD006527; Association|chemicalD003300|diseaseD006527; Association|chemicalD001216|diseaseD006527; Association|diseaseD006527|ncbi540; Association|chemicalD018698|diseaseD006527; Association|chemicalD003300|ncbi1356; Association|chemicalD003300|ncbi540	Diagnosis of diseaseD006527 and Its Phenotypes by Using Artificial Intelligence.diseaseD006527 is caused by ncbi540 variants disrupting chemicalD003300 efflux resulting in excessive chemicalD003300 accumulation mainly in liver and brain. The diagnosis of diseaseD006527 is challenged by its variable clinical course, onset, morbidity, and ncbi540 variant type. Currently it is diagnosed by a combination of clinical symptoms/signs, aberrant chemicalD003300 metabolism parameters (e.g., low ncbi1356 serum levels and high urinary and hepatic chemicalD003300 concentrations), and genetic evidence of ncbi540 mutations when available. As early diagnosis and treatment are key to favorable outcomes, it is critical to identify subjects before the onset of overtly detrimental clinical manifestations. To this end, we sought to improve diseaseD006527 diagnosis using artificial neural network algorithms (part of artificial intelligence) by integrating available clinical and molecular parameters. Surprisingly, diseaseD006527 diagnosis was based on plasma levels of chemicalD018698, chemicalD001216, chemicalD013654, and Fischer's ratio. As these amino acids are linked to the chemicalD014508-Krebs' cycles, our study not only underscores the central role of hepatic mitochondria in diseaseD006527 pathology but also that most diseaseD006527 9606 have underlying diseaseD008107. Our study provides novel evidence that artificial intelligence utilized for integrated analysis for diseaseD006527 may result in earlier diagnosis and mechanistically relevant treatments for 9606 with diseaseD006527.
34162411	Positive_Correlation|chemicalD003300|diseaseD006331; Association|chemicalD003300|diseaseD006333; Association|chemicalD003300|diseaseD056486; Association|chemicalD003300|diseaseD006527	The impact of diseaseD006527 on myocardial tissue and function: a cardiovascular magnetic resonance study.BACKGROUND: Systemic effects of altered serum chemicalD003300 processing in diseaseD006527 (diseaseD006527) might induce myocardial chemicalD003300 deposition and consequently diseaseD006331 and structural remodeling. This study sought to investigate the prevalence, manifestation and predictors of diseaseD000014 in diseaseD006527 9606. METHODS: We prospectively enrolled diseaseD006527 9606 and an age-matched group of healthy individuals. We applied cardiovascular magnetic resonance (CMR) to analyze myocardial function, strain, and tissue characteristics. A subgroup analysis of diseaseD006527 9606 with predominant neurological (diseaseD006527-neuro+) or diseaseD056486 manifestation only (diseaseD006527-neuro-) was performed. RESULTS: Seventy-six 9606 (37 years (27-49), 47% 9606) with known diseaseD006527 and 76 age-matched healthy control subjects were studied. The prevalence of diseaseD001281 in diseaseD006527 9606 was 5% and the prevalence of symptomatic diseaseD006333 was 2.6%. Compared to healthy controls, 9606 with diseaseD006527 had a reduced left ventricular global circumferential strain (LV-GCS), and also showed abnormalities consistent with global and regional diseaseD005355. diseaseD006527-neuro+ 9606 presented with more severe structural remodeling and functional impairment when compared to diseaseD006527-neuro- 9606. CONCLUSIONS: In a large cohort, diseaseD006527 was not linked to a distinct cardiac phenotype except CMR indexes of diseaseD005355. More research is warranted to assess the prognostic implications of these findings. TRIAL REGISTRATION: This trial is registered at the local institutional ethics committee (S-188/2018).
31898387		Non-invasive diagnosis of diseaseD005355 and long-term disease monitoring by transient elastography in 9606 with diseaseD006527.BACKGROUND & AIMS: The value of liver stiffness measurement (LSM) by transient elastography (TE) for non-invasive diseaseD005355 staging and disease monitoring has not been established in 9606 with diseaseD006527 (diseaseD006527). METHODS: Liver stiffness measurement by TE and non-invasive diseaseD005355 scores (APRI, FIB-4) were analysed from 188 diseaseD006527 9606 with liver biopsy (LBX). Longitudinal LSM was performed in 128 (68.1%) 9606. RESULTS: One hundred and eighty-eight 9606 (mean age: 35 +- 14 years, 54.8% 9606; 27.1% with histological diseaseD005355) were studied. Forty-four[23.4%] 9606 were recently diagnosed with diseaseD006527, while 144[76.6%] were previously diagnosed (>1 year between LBX and LSM). Overall, LSM (11.3 vs 6.1 kPa, P < .001), APRI (0.72 vs 0.38, P < .001) and FIB-4 (1.54 vs 0.89, P < .001) were higher in diseaseD000094724 than in non-diseaseD000094724 9606. This was even more pronounced in recently diagnosed 9606 (35.2 kPa vs 6.4 kPa, P < .001). Accuracy for diagnosing diseaseD005355 at an LSM cut-off >=9.9 kPa was better in recently diagnosed (PPV: 74%, NPV: 100%) vs previously diagnosed (PPV: 53%, NPV: 82%) 9606. Recently diagnosed 9606 had higher Area Under the Curve (AUC) for APRI (0.79 vs 0.61) and FIB-4 (0.84 vs 0.65) than previously diagnosed 9606. At APRI <1.5 and FIB-4 <3.25 diseaseD005355 was ruled out with a specificity of 93% and 95% respectively. During a median follow-up of 46 (24-66) months, only 5.9% (5/85) of non-diseaseD000094724 diseaseD006527 9606 showed progression to diseaseD000094724 LSM values, while 30.8% (4/13) of diseaseD000094724 diseaseD006527 9606 showed LSM suggestive of diseaseD005355 regression. CONCLUSION: TE-based LSM >=9.9 kPa accurately identifies diseaseD005355 in diseaseD006527 9606. Next to TE-LSM <9.9 kPa, APRI <1.5 and FIB-4 <3.25 values assist to non-invasively rule out diseaseD005355. LSM remains stable in most non-diseaseD000094724 9606 on diseaseD006527 therapy, while one-third of diseaseD000094724 9606 present clinically relevant decreases in LSM.
37184248	Negative_Correlation|chemicalC000615411|diseaseD009369; Association|chemicalD003300|diseaseD006527; Association|chemicalD003300|diseaseD007706; Negative_Correlation|chemicalC000615411|diseaseD006527; Association|chemicalD003300|diseaseC535468; Negative_Correlation|chemicalC000615411|diseaseD020521	Positron Emission Tomography Using chemicalC000615411 as a Tracer for the Study of Copper-Related Disorders.chemicalD003300 is an essential trace element, functioning in catalysis and signaling in biological systems. Radiolabeled chemicalD003300 has been used for decades in studying basic 9606 and animal chemicalD003300 metabolism and diseaseC535468, such as diseaseD006527 (diseaseD006527) and diseaseD007706. A recent addition to this toolkit is chemicalC000615411 (chemicalC000615411) positron emission tomography (PET), combining the accurate anatomical imaging of modern computed tomography (CT) or magnetic resonance imaging (MRI) scanners with the biodistribution of the chemicalC000615411 PET tracer signal. This allows the in vivo tracking of chemicalD003300 fluxes and kinetics, thereby directly visualizing 9606 and animal chemicalD003300 organ traffic and metabolism. Consequently, chemicalC000615411 PET is well-suited for evaluating clinical and preclinical treatment effects and has already demonstrated the ability to diagnose diseaseD006527 accurately. Furthermore, chemicalC000615411 PET/CT studies have proven valuable in other scientific areas like diseaseD009369 and diseaseD020521 research. The present article shows how to perform chemicalC000615411 PET/CT or PET/MR in 9606. Procedures for chemicalC000615411 handling, 9606 preparation, and scanner setup are demonstrated here.
32314442		Retrospective analysis of long-term outcome 10 years after liver transplantation for diseaseD006527: experience over three decades.We evaluated long-term outcomes for 9606 with diseaseD006527 (diseaseD006527) after liver transplantation (LT) and searched for risk factors for poor survival. Retrospective analysis of UNOS/OPTN data identified 156 pediatric and 515 adult cases of LT for diseaseD006527 between 1987 and 2016. Comparison cases were 10 442 pediatric and 104 874 adult non-diseaseD006527 transplant recipients. Survival was calculated using Kaplan-Meier analysis. Recipient, donor, and surgical variables were compared by Cox regression. Survival rates 3, 5, and 10 years after LT for adult diseaseD006527 9606 (87.5%, 85.4%, and 80.5%, respectively) were significantly higher than those for non-diseaseD006527 9606 (P < 0.001); survival rates for pediatric diseaseD006527 9606 (90.5%, 89.7%, and 86.5%, respectively) did not differ significantly from non-diseaseD006527 9606. Graft survival in adult and pediatric 9606 followed similar trends. Regression analysis identified older age, female gender, and use of life support at the time of transplant as risk factors for decreased survival for adults with diseaseD006527, and younger age, male gender, diseaseD009765, and high serum chemicalD003404 at the time of transplant as risk factors for poor survival in pediatric recipients with diseaseD006527. Presentation with diseaseD017114 was not associated with survival in diseaseD006527 9606. No donor characteristic predicted poor survival. Long-term 9606 and graft survival after LT is excellent for both adult and pediatric diseaseD006527 9606.
33197948	Negative_Correlation|chemicalD014266|diseaseD006527	[Retrospective cross-sectional study based on nationwide data of drug prescriptions and contractional data of 9606 offices regarding diseaseD006527].INTRODUCTION:  In this article, the prevalence of the diseaseD006527 in Germany is determined. This is based on nationwide data of drug prescriptions and contractional data of 9606 offices. The prevalence is set in ratio to the found prevalence of prescriptions in Germany. METHOD:  The descriptive evaluation is based on the database of the Central Research Institute of Ambulatory Health Care (Zi) in Germany. Additionally, data of the Federal Office of Statistics regarding inpatient treatment are available. RESULTS:  It can be seen that there is a notable difference between the prevalence of 9606 undergoing therapy and the 9606 with verified diagnoses. In total, prevalence is increasing. The incidence on hand and the given dynamic of the 9606 population could indicate that, possibly, there is an increased rate of misdiagnosis in the first year of diagnosis. According to data, the hepatic form is the more often diagnosed form. The 9606 genetic diagnostic increases, on average, are most distinct. ATTRIBUTES:  diseaseD006527, Prevalence, Incidence, chemicalD014266, Trientintetrahydrochlorid, D-Penicillamin, Zinc acetat, Zinc.
32844772	Association|chemicalD003300|diseaseD006527	Transient Elastography to Represent Hepatic chemicalD003300 Accumulation in diseaseD006527.
28433104	Positive_Correlation|chemicalD000438|diseaseD056486	diseaseD006527: symptomatic liver therapy.diseaseD006527 leads to symptomatic diseaseD008107 or diseaseD008103. Strict adherence to decoppering agents is essential in these 9606. Secondary prevention of additional diseaseD056486 by avoidance of other toxic substances (e.g., chemicalD000438, drugs) and sufficient calorie intake is recommended. Routine examinations in diseaseD000094724 9606 include screening for signs of diseaseD006975 (diseaseD014648), development of diseaseD001201, and diseaseD006501. Where diseaseD014648 are present, primary or secondary preventive interventions may include treatment with nonselective beta-blockers or variceal ligation, similar to the approach in 9606 with diseaseD008103 due to other etiologies. For 9606 presenting with diseaseD001201, diuretics are the treatment of choice. Spontaneous diseaseD010538 can be diagnosed by paracentesis and should be treated with antibiotics. diseaseD008103 can also lead to accumulation of neurotoxins causing diseaseD006501. It is characterized by unspecific diseaseD001523 and is treated with laxatives and nonresorbable antibiotics. The best prophylaxis is regular defecation. 9606 with diseaseD008103 are susceptible for diseaseD001424 of any cause and diseaseD018805 is one of the leading causes of diseaseD003643 in these 9606. In advanced stages of diseaseD005355 diseaseD007674 is a common feature. The diseaseD006530 shows a high mortality. Where diseaseD006527 9606 have decompensated diseaseD008103, liver transplantation should be evaluated.
37204330		Factors affecting activities of daily living among 9606 with diseaseD006527.diseaseD006527 (diseaseD006527) is a diseaseC535468 with various manifestations and can be treated with oral medication. This study examined the factors related to decline in activities of daily living (ADL) in 9606 with diseaseD006527 as research in this area remains limited. We enrolled 308 9606 with diseaseD006527, including 9606 who participated in a national survey and those who sought cares at the Department of Pediatrics, Toho University Ohashi Medical Center, from 2016 to 2017. We analyzed the association between diseaseD020773 and factors including age at diagnosis, period from diagnosis to survey, diseaseD056486, diseaseD009461, and diseaseD001523 presentation at diagnosis. The relative risks (RRs) for diseaseD020773 were estimated for each factor using multivariate modified Poisson regression analysis. Overall, 97 out of 308 (31.5%) 9606 experienced diseaseD020773. After adjusting for explanatory variables, regression analysis revealed that factors significantly associated with diseaseD020773 were a period of >=20 years from diagnosis to survey (adjusted RR = 2.34, 95% CI: 1.47-3.74), diseaseD056486 with diseaseD013163 (adjusted RR = 2.57, 95% CI: 1.26-5.24), mild diseaseD009461 (adjusted RR = 3.20, 95% CI: 1.96-5.23), and severe diseaseD009461 (adjusted RR = 3.63, 95% CI: 2.28-5.77). diseaseD009461, diseaseD056486 with diseaseD013163, and a period of 20 years from diagnosis to survey are associated with diseaseD020773. Thus, careful assessment of 9606 for these factors is necessary, and these findings may guide future efforts to improve 9606 prognosis. diseaseD009461, diseaseD056486 with diseaseD013163, and a period of 20 years from diagnosis to survey are associated with a decline in activities of daily living in 9606 with diseaseD006527. AA and NS conceived the study. AA, KA, and YN developed the statistical analysis plan and conducted statistical analyses. All authors contributed to the interpretation of the results. AA drafted the original manuscript. NS supervised the implementation of the study. All authors reviewed the manuscript draft and revised it critically for intellectual content. All authors approved the final version of the manuscript to be published. Norikazu Shimizu received an honorarium from Alexion Pharmaceuticals, Inc. This research was supported by AMED under Grant Number JP20ek0109482h0001. The study protocol was approved by the Ethics Committee of the Faculty of Medicine, Toho University(No. A20054). The protocols of the study were disclosed on the institutions' websites or other places, such as bulletin boards, and provisions to opt-out were presented. Therefore, written consent was not obtained. Our manuscript has no associated data. Not applicable. This article is protected by copyright. All rights reserved.
30059866	Association|chemicalD002244|chemicalD008687	Application of chemicalD002244 sensors for potentiometric determination of copper(II) in chemicalD014867 and biological fluids of diseaseD006527 9606. Studying the surface reaction using SEM, EDX, IR and DFT.The performance characteristics of a new selective and sensitive modified screen printed electrode (MSPE; electrode I) and chemicalD002244 paste electrode (MCPE; electrode II) based on 2-N, N-dimethylcarbamimidoyl (chemicalD008687) as modifier for the potentiometric determination of copper (II) in chemicalD014867 sample, serum and urine samples of diseaseD006527 9606 have been optimized. The chemical reaction which happens between Cu (II) and the modifier on the surface of the sensors was investigated with scanning electron microscope (SEM), energy dispersive X-ray analysis (EDX), IR spectra measurement and computational calculations at DFT/B3LYP. The sensors showed perfect potentiometric response for Cu (II) over concentration range of 1.0 x 10-6 - 1.0 x 10-2 and 1.0 x 10-6 - 5.0 x 10-2 mol L-1 with a detection limit of 1.0 x 10-6 mol L-1with divalent slope value 30.2 and 31.8 mV decade-1 over the pH range of 2-6 for MCPE and MSPE, respectively. MSPE was stable with repeatable potential over period of 37 days and exhibits fast response time of 6 and 10 s for MSPE and MCPE, respectively. Also, these sensors exhibited good selectivity towards Cu(II) with respect to other chemicalD008670 ions and have higher antibacterial activity against 1280 as Gram-positive bacteria and 562 as Gram-negative bacteria. The obtained results using the sensors were in agreement with those obtained using the reported method.
28679132		Comment on Advantages of Anterior Segment Optical Coherence Tomography Evaluation of the diseaseD012303 in diseaseD006527.
31269566		[Clinical characteristics of 9606 with delayed diseaseD006527].Objective: To evaluate the clinical manifestations, metal metabolism, imaging characteristics and treatment response in 9606 with delayed diseaseD006527 (diseaseD006527). Methods: 9606 with untreated diseaseD006527 (40 with delayed onset and 40 with non-delayed onset) were enrolled. Twenty healthy people were included as normal controls. All 9606 were evaluated with modified Young scale neural symptom scores, grade of Child liver function and mental symptoms rating scale, magnetic resonance imaging (MRI) scan, magnetic sensitive imaging (susceptibility weighted imaging, SWI), metal metabolism. Corrected phase (CP) was measured at SWI. After 2 week treatment, neurologic symptoms, liver function, and metal metabolism were reviewed. Results: The total score of diseaseD009461 in diseaseD006527 9606 with delayed onset was lower than that of non-delayed onset (13.00+-6.87 vs. 21.13+-5.53, P=0.033). The scores of SCL-90 and HAMA diseaseD003866 scales in 9606 with delayed onset were lower than those of non-delayed onset. On T(2) weighted imaging, areas including substantia nigra and thalamus, the caudate nucleus, globus pallidus, putamen presented high signal rate in 9606 with delated onset than those with non-delayed (P=0.022, 0.037, 0.022, 0.037, 0.029 respectively). The SWI CP values of cangbai sphere and shell nucleus in 9606 with delayed onset were lower than those with non-delayed onset. 9606 with delayed onset had higher urinary chemicalD003300 than those with non-delayed onset before and after treatment (P=0.040, 0.036). After treatment, the score of diseaseD014202 and gait in 9606 with delayed onset was decreased (P=0.037, 0.044), while as the occurrence of diseaseD009461 was increased by 10%, and the liver function level in 9606 with delayed diseaseD006527 was decreased in 3 cases. Conclusions: The brain of diseaseD006527 9606 with delayed onset is mainly composed of metal deposits, however the cell damage is not apparent. Clinical symptoms are characterized by significant diseaseD017093, but relatively mild diseaseD001523. 9606 with delayed diseaseD006527 have higher urinary chemicalD003300 excretion than those with non-delayed diseaseD006527. Chelating agents improves the diseaseD009461 in 9606 with delayed onset.
36459990	Association|chemicalD003300|diseaseD030342; Association|chemicalD003300|diseaseD006527	An Update on the Future of diseaseD006527 Management.The recognition of diseaseD006527 (diseaseD006527) has progressed over the last century from a diseaseD009461 associated with diseaseD008107 to the understanding that diseaseD006527 is a rare diseaseD030342 of chemicalD003300 metabolism. Due to diseaseD006527's myriad manifestations, its rarity, and its broad range of symptoms, differential diagnosis may be challenging, leading to delays in treatment initiation. This Neuroscience Commentary reviews diagnostic acumen and the latest updates in the field, including key clinical data and novel therapies in late-stage development, all of which ensure optimal management of diseaseD006527 in the coming years.
31728073	Positive_Correlation|variant#5244#c.833+1G>T|diseaseC535935; Positive_Correlation|chemicalD003300|diseaseD002779; Positive_Correlation|variant#5244#c.1798T>A|diseaseC535935; Association|diseaseD006509|ncbi5244; Association|diseaseC535935|ncbi5244	diseaseD006509 mimicking morbus diseaseD006527: A potential diagnostic pitfall.INTRODUCTION: diseaseC535935 (diseaseC535935) is a rare diseaseD008107 caused by genetic diseaseD006509 (diseaseD006509), a hepatocanalicular floppase translocating chemicalD010743 from the inner to the outer leaflet of the canalicular membrane chemicalD008055 bilayer. diseaseC535935 is characterised by production of hydrophilic bile with lithogenic properties which is harmful to the hepatobiliary epithelia. diseaseD002779 in some 9606 may be accompanied by excessive accumulation of chemicalD003300 in the liver and by increased urinary chemicalD003300 excretion, the findings mimicking diseaseD006527 (diseaseD006527). METHODS AND RESULTS: We report an 11 y/o male 9606 with diseaseD006130, mild diseaseC537512 and chronic diseaseD008107, initially diagnosed and treated as diseaseD006527. Whereas genetic testing for diseaseD006527 was negative, further molecular and histopathological analysis revealed two novel mutations (variant#5244#c.833+1G>T and variant#5244#c.1798T>A) in diseaseD006509 and complete absence of the diseaseD006509/ncbi5244 protein in the liver, determining diseaseC535935 as the correct diagnosis. CONCLUSION: diseaseC535935 and diseaseD006527 display pleomorphic and sometimes overlapping clinical and laboratory features, which may pose a differential diagnostic problem. Since the 9606 management in diseaseD006527 and diseaseC535935 differs significantly, an early and accurate diagnosis is crucial for optimising of therapeutic approach and prevention of possible complications.
30635971	Association|chemicalD003300|diseaseD006527	Anterior segment optical coherence tomography (AS-OCT) as a new method of detecting chemicalD003300 deposits forming the Kayser-Fleischer ring in 9606 with diseaseD006527.PURPOSE: Kayser-Fleischer ring pathognomonic for diseaseD006527 (diseaseD006527) is formed of corneal chemicalD003300 deposits present predominantly within the anterior chamber angle at the Schwalbe's line. The slit-lamp assessment commonly used as a standard of care cannot detect them early enough, as the angle view is obscured by the corneal limbus. The aim of the research was to evaluate the anterior segment optical coherence tomography (AS-OCT), as objective diagnostic assessment of chemicalD003300 deposits forming KF ring in 9606 with diseaseD006527. METHODS: Twenty-nine subjects (17 9606) and twenty-nine controls (14 9606) were enrolled and underwent slit lamp and AS-OCT assessment. RESULTS: Kayser-Fleischer ring was not detected - either with a slit lamp or with AS-OCT - in any of the controls. Fifteen subjects presenting without KF ring at a slit-lamp examination were found to have a KF ring when examined with AS-OCT (p < 0.001), which confirms improved accuracy of AS-OCT, as compared to the slit-lamp examination. CONCLUSION: Our results support AS-OCT as a diagnostic procedure to offer better objectivity and accuracy as compared to a slit-lamp examination, both at the diagnostic stage and when monitoring changes in KF ring during medical therapy to assess its efficacy and 9606 compliance.
28433112		diseaseD006527 - diseaseD017093.The liver in diseaseD006527 may demonstrate a wide range of damage patterns. Some 9606 may present almost no detectable microscopic pathology, while others display lesions consistent with diseaseD017114 or diseaseD017114. Most liver biopsy specimens show moderate to severe diseaseD005234, variable degree of portal and/or lobular diseaseD007249, and diseaseD005355 eventually progressing to diseaseD005355. Additional findings include diseaseD006528 and ballooning, Mallory hyaline bodies, diseaseD006528, and glycogenation of periportal hepatocytic nuclei. None of the above lesions are specific for diseaseD006527 and should be interpreted in a wider medical context and particular clinical setting. The main message concerning diseaseD017093 is that diseaseD006527 may be microscopically misinterpreted as many other diseaseD008107, including diseaseD014777, diseaseD000437/diseaseD065626, diseaseD056486, cryptogenic diseaseD005355, diseaseD008107, and many others. The possibility of diseaseD006527 should be considered in all 9606, especially young ones presenting unexplained diseaseD008107 with many variable patterns of microscopic liver involvement.
28433098	Association|chemicalD003300|diseaseD006527; Association|diseaseD006527|ncbi540; Association|diseaseD006527|ncbi7033; Association|diseaseD006527|ncbi1769	diseaseD006527 in children.diseaseD006527 (diseaseD006527) is an diseaseD030342 mainly of hepatocellular chemicalD003300 disposition, due to dysfunction of the Wilson ATPase, a ncbi7033 encoded by the gene ncbi540 In children, as in older age brackets, clinical diseaseD004194 is highly diverse. Although diseaseD056486 is the common presentation in children/adolescents, neurologic, diseaseD001523, and hematologic clinical presentations do occur. Very young children may have clinically evident diseaseD008107 due to diseaseD006527. Early diagnosis, preferably when the child/adolescent is asymptomatic, is most likely to result in near-normal longevity with generally good health so long as the 9606 tolerates effective medication, is adherent to the lifelong treatment regimen, and has consistent access to the medication. Apart from a lively index of clinical suspicion on the part of physicians, biochemical tests including liver tests, serum ncbi1356, and basal 24-hour urinary chemicalD003300 excretion and genotype determination are key to diagnosis. Oral chelation treatment remains central to medical management, although zinc appears to be an attractive option for the presymptomatic child. Pediatric 9606 presenting with Wilsonian diseaseD017114 must be differentiated from those with decompensated diseaseD005355, since the latter may respond to intensive medical interventions and not require liver transplantation. Recently identified diseaseD006527 disorders reveal important aspects of diseaseD006527 pathogenesis.
33763932		Biopsy-proven diseaseD008103 in young children: A 10-year cohort study.Young children with diseaseD008103 have a significantly high risk of mortality. However, there are few studies regarding early childhood-onset diseaseD005355. This study aims to explore the causes, clinical findings and prognosis of biopsy-proven diseaseD005355 in infants, toddlers and preschoolers. We enroled young children with biopsy-proven diseaseD005355 from January 2010. Till January 2020, the study has been going on for 10 years. A total of 139 diseaseD000094724 children were enrolled, including 87 boys and 52 girls. The median age at initially histological diagnosis of diseaseD005355 was 2 years old (range: 1 month-6 years). Sixty-two 9606 reported yellowish discoloration of sclera and/or skin as an initial symptom. Ninety-three 9606 had definite aetiologies while 46 had indeterminate causes. Among the confirmed cases, 31 had diseaseD006509, accounting for 33.3%. Subsequently, diseaseD006008 was diagnosed in 16 cases and diseaseD006527 in 14 cases. In these 9606 with diseaseD006509, nine finally achieved hepatitis B surface antigen (HBsAg) loss (29.0%) after effective antiviral therapy during the follow-up. Logistic regression revealed that baseline alanine aminotransferase (odds ratio 1.008, p = 0.028) was the independent predictor of HBsAg loss. Furthermore, one 9606 who underwent second biopsies showed histological reverse. diseaseD006509 is an important cause of paediatric diseaseD005355 in our study. The pathogenesis of HBV-related diseaseD005355 in early childhood deserves further studies.
28452067		Zinc monotherapy for young children with presymptomatic diseaseD006527: A multicenter study in Japan.BACKGROUND AND AIM: Few studies of zinc monotherapy for presymptomatic diseaseD006527 have focused on young children. We therefore evaluated long-term efficacy and safety of zinc monotherapy for such children and established benchmarks for maintenance therapy. METHODS: We retrospectively and prospectively examined children under 10 years old with presymptomatic diseaseD006527 who received zinc monotherapy from time of diagnosis at 12 participating pediatric centers in Japan. RESULTS: Twenty-four 9606 met entry criteria. Aspartate aminotransferase and alanine aminotransferase decreased significantly beginning 1 month after initiation of treatment and usually remained under 50 U/L from 1 to 8 years of treatment. Twenty four-hour urinary chemicalD003300 decreased significantly at 6 months and usually remained under 75 mug/day and between 1 and 3 mug/kg/day for the remainder of the study. All 9606 continued to take zinc, and none became symptomatic. In 9606 under 6 years old who received 50 mg/day of zinc as an initial dose, aspartate aminotransferase and alanine aminotransferase significantly decreased at 1 month after initiation of treatment, as did ncbi2678 and 24-h urinary chemicalD003300 at 6 months. CONCLUSIONS: To our knowledge, this is the first multicenter study of zinc monotherapy for young children with presymptomatic diseaseD006527. Such monotherapy proved highly effective and safe. Maintaining normal transaminase values (or values under 50 U/L when normalization is difficult) and 24-h urinary chemicalD003300 excretion between 1 and 3 mug/kg/day and under 75 mug/day is a reasonable goal. An initial dose of 50 mg/day is appropriate for 9606 under 6 years old.
38306527	Association|diseaseD006527|ncbi540	A rare presentation of diseaseD006527 with diseaseD009461 symptoms: Case report and genetic analysis.RATIONALE: diseaseD006527 is a rare diseaseD030342 primarily associated with diseaseD056486 symptoms; however, its unique diseaseD009461 presentation remains a subject of interest in the medical literature. This case report contributes to existing knowledge by highlighting the unusual manifestation of diseaseD006527 with significant diseaseD009461 symptoms. 9606 CONCERNS: The 9606, pseudonym John Smith, presented with prominent diseaseD009461 symptoms, including diseaseD014202, diseaseD004421, and diseaseD001523 manifestations. Clinical findings corroborated diseaseC535468 in the brain, prompting a thorough diagnostic investigation. DIAGNOSES: Genetic analysis revealed two ncbi540 mutations, confirming the primary diagnosis of diseaseD006527. This case underscores the importance of recognizing atypical diseaseD009461 presentations in the context of this rare diseaseD030342. INTERVENTIONS: Chelation therapy, initiated promptly upon diagnosis, targeted diseaseC535468 overload. The intervention led to notable improvements in diseaseD009461 symptoms and diseaseD001523 manifestations. The dosage and duration of treatment were adjusted based on regular monitoring. OUTCOMES: Regular follow-up revealed a positive trajectory, with reduced diseaseD014202 and improved overall well-being. Genetic testing, coupled with clinical assessments, contributed to monitoring treatment efficacy and optimizing therapeutic interventions. LESSONS: The main takeaway lessons from this case include the significance of a comprehensive diagnostic approach, personalized therapeutic interventions, and the imperative to acknowledge the diverse clinical spectrum of diseaseD006527. Early recognition and tailored treatment contribute to favorable outcomes in cases with atypical diseaseD009461 presentations.
32281751	Positive_Correlation|chemicalD003300|diseaseD012640; Negative_Correlation|chemicalD003300|diseaseD006527; Negative_Correlation|chemicalD003300|diseaseD004829	Clinical features and outcome of diseaseD006527 with diseaseD004829 in Chinese 9606.OBJECTIVE: diseaseD004829 is rarely reported in 9606 with diseaseD006527 (diseaseD006527) and lacks experience in clinical practice. We aim to provide better experience for the diagnosis and treatment for diseaseD006527 9606 with diseaseD004827 in the future. METHODS: A retrospective study was performed in 13 Chinese diseaseD006527 9606 with diseaseD004829. Each 9606 was diagnosed with diseaseD006527 by clinical evaluation and genetic screening. 9606 were given small doses of antiepileptic drugs (AEDs), followed by chemicalD003300-chelation therapy when the diseaseD012640 stabilized. Clinical manifestations, brain imaging changes, and treatment and outcome after a long-term follow-up were analyzed. RESULTS: Four out of 13 (30.8%) 9606 stopped taking chemicalD003300-chelation drugs for more than 1 year before they were admitted for diseaseD004827. The incidence of diseaseD004827 of diseaseD006527 9606 in our cohort is 1.43% (13/910), lower than those (4.5%-5.9%) in other populations. After the attack of diseaseD004827, frontal lobes were the most common abnormalities (13/13, 100%) in 9606, followed by brain stem (8/13, 61.5%) and thalamus (7/13, 53.8%). After a long-term follow-up, brain imaging and clinical manifestations of 8 (8/9, 88.9%) diseaseD006527 9606 were significantly improved. CONCLUSIONS: We firstly described diseaseD006527 9606 with diseaseD004829 in the Chinese population. diseaseD006527 9606 with aggravation of diseaseD001523 are prone to occur diseaseD004827; thus, brain MRI should be performed regularly in those 9606. diseaseD054220 in brain MRI is a warning sign of diseaseD004827. Irregular use of chemicalD003300-chelation drugs and excessive chemicalD003300 deposition in the brain may be the cause of diseaseD012640. Long-term standardized treatment for diseaseD006527 can effectively prevent the extensive diseaseD001925 and reduce the incidence of diseaseD004827 in diseaseD006527 9606.
28260463	Association|chemicalD003300|diseaseD006527	Auxiliary Partial Orthotopic Living Liver Transplant for diseaseD006527.diseaseD006527 is a diseaseD030342 involving chemicalD003300 metabolism disturbances that result in chemicalD003300 accumulations, especially in the liver and brain. diseaseD006527 can be treated with pharmacologic agents, such as chelators that induce urinary excretion of chemicalD003300 or zinc salts that inhibit chemicalD003300 absorption in the digestive tract. Liver transplant is the only treatment option for diseaseD006527 when diseaseD017093 has occurred. In some 9606, that is, in those with Child-Pugh A score, diseaseD020271 can be seen without diseaseD017093. Our recommendation is for these 9606 to have auxiliary partial orthotopic liver transplant. Here, we present a 36-year-old male 9606 with diseaseD020271 associated with diseaseD006527 who had successful related living-donor auxiliary partial orthotopic liver transplant using a left lobe. The 9606, as a result of diseaseD009461 that included diseaseD014202 walking and speaking problems and low serum ncbi1356 level of 7 mg/dL, was diagnosed with diseaseD006527, and a liver biopsy was performed. diseaseD002908 activity was 4/18, and the 9606 received chelation treatment. His hepatic functions were normal. The donor was the 9606's 57-year-old father whose liver function tests were also normal. The graft-to-recipient weight ratio was 1% using a left lobe graft. After transplant, serum ncbi1356 levels on day 15 and month 1 were 14 and 19 mg/dL. At month 1, liver function tests were normal. Doppler ultrasonography showed normal vascular flow of the native liver and the graft. The 9606's diseaseD009461 were progressively reduced. Progressive diseaseD009422 with no diseaseD048550 is considered a suitable indication for auxiliary partial orthotopic liver transplant; this procedure is suggested before the diseaseD017093 symptoms of diseaseD006527 occur.
30384011	Negative_Correlation|chemicalD013859|diseaseD007706; Negative_Correlation|chemicalD006639|diseaseD006527; Negative_Correlation|chemicalD014266|diseaseD006527; Negative_Correlation|chemicalD003300|diseaseD007706; Negative_Correlation|chemicalD008063|diseaseD007706; Negative_Correlation|chemicalD006639|diseaseD007706; Negative_Correlation|chemicalC020809|diseaseD006527; Negative_Correlation|chemicalD003300|chemicalD006639; Association|chemicalD003300|diseaseD006527; Association|chemicalD003300|diseaseC566858; Association|chemicalD003300|diseaseD030342; Negative_Correlation|chemicalD003300|chemicalD013859; Negative_Correlation|chemicalD003300|chemicalD008063	Chelating principles in diseaseD006527: Choosing the right compounds in the right combinations at the right time.Dysregulation of chemicalD003300 homeostasis in 9606 is primarily found in two diseaseD030342 of chemicalD003300 transport, diseaseD006527, which show symptoms of diseaseC566858, respectively. However, both diseases are diseaseD006527 despite completely opposite clinical pictures. Clinically, diseaseD007706 is characterized by diseaseC535468 secondary to poor loading of chemicalD003300-requiring enzymes although sufficient body chemicalD003300. chemicalD003300 accumulates in non-hepatic tissues, but is deficient in blood, liver, and brain. In contrast, diseaseD006527 is characterized by symptoms of diseaseC535468 secondary to accumulation of chemicalD003300 in several organs most notably brain and liver, and a saturated blood chemicalD003300 pool. It is a challenge to correct chemicalD003300 dyshomeostasis in either disease though chemicalD003300 depletion in diseaseD007706 is most challenging. Both diseases are caused by defective chemicalD003300 export from distinct cells, and we seek to give new angles and guidelines to improve treatment of these two complementary diseases. Therapy of diseaseD007706 with chemicalD003300-chemicalD006639, chemicalD013859, nitrilotriacetate or chemicalD008063 is discussed. In diseaseD006527 combination of a hydrophilic chelator e.g. chemicalD014266 or dimercaptosuccinate with a brain shuttle e.g. chemicalC020809 or lipoate, is discussed. New chelating principles for chemicalD003300 removal or delivery are outlined.
35042319	Association|ncbi1356|ncbi540; Bind|chemicalD003300|ncbi1356; Association|diseaseD006527|ncbi540; Association|chemicalD003300|ncbi540	diseaseD006527 in children and young adults - State of the art.diseaseD006527 (diseaseD006527) is an diseaseD030342 caused by mutations of the ncbi540 gene, with a reported prevalence of 1:30,000-50,000. ncbi540 encodes an enzyme called transmembrane copper-transporting ATPase, which is essential for chemicalD003300 incorporation into ncbi1356 and for chemicalD003300 excretion into the bile. A lack or dysfunction of this enzyme results in a progressive accumulation of chemicalD003300 in several organs, especially in the liver, the nervous system, corneas, kidneys, and heart. Children with diseaseD006527 can present with asymptomatic diseaseD008107, diseaseD005355, or diseaseD017114, with or without diseaseD001523. Approximately 20%-30% of diseaseD006527 9606 present with ALF, while most of the other 9606 have chronic progressive diseaseD056486 or diseaseD005355 if untreated. Although genetic testing has become a more important diagnostic tool for diseaseD006527, the diagnosis remains based on both clinical features and laboratory investigations. The aims of treatment are to reduce chemicalD003300 levels and prevent its accumulation in the liver and other organs, especially in the central nervous system. Liver transplantation in diseaseD006527 is a life-saving option for 9606 presenting with diseaseD017093 and diseaseD001927. For diseaseD006527 9606 treated with chelating agents, adherence to the therapy is essential for long-term success. In this review, we also address specific issues in young adults as compared to children.
33879678	Positive_Correlation|diseaseD006527|variant#540#p.E1382X; Positive_Correlation|variant#540#c.4144G>T|diseaseD006527; Positive_Correlation|diseaseD006527|variant#540#c.4144G>T; Association|diseaseD006527|ncbi540; Positive_Correlation|diseaseD006527|variant#540#c.1448_1455del; Positive_Correlation|diseaseD006527|variant#540#p.R483SfsX19; Positive_Correlation|variant#540#c.1448_1455del|diseaseD006527; Association|diseaseD006527|ncbi540	Identification of mutations in the ncbi540 gene in 14 diseaseD006527 children: Case series.INTRODUCTION: diseaseD006527 (diseaseD006527) is an diseaseD030342 caused by mutations in the ncbi540 gene (ncbi540). diseaseD006527 can cause fatal diseaseD009461 if not diagnosed and treated. OBJECTIVE: To analyze the disease-causing mutations of 14 Chinese diseaseD006527 children, 11 of whom are diagnosed with diseaseD008107, 2 with diseaseD009410 and 1 with both diseaseD009461. METHODS: All ncbi540 coding regions were analyzed by Sanger sequencing. Single nucleotide polymorphisms (SNPs) functional impacts were assessed by combining the results of four bioinformatics tools (Poly-phen-2, SIFT, PANTHER-PSEP and PhD-SNPs) in an index that reflects the combined probability (cPdel) of an amino acid change to be deleterious to the protein function. RESULTS: Two novel variants involved in diseaseD006527 development, variant#540#c.1448_1455del (variant#540#p.R483SfsX19) and variant#540#c.4144G>T (variant#540#p.E1382X), and 11 previously reported mutations were detected. Both new variants result in shortened and dysfunctional ncbi540 proteins. cPdel score suggests that SNPs may be deleterious to the ncbi540 functionality. CONCLUSIONS: This study enriches the library of the ncbi540 mutations that lead to diseaseD006527 and can be used as a basis for genetic counseling, for diseaseD006527 prevention and clinical and prenatal diagnosis. Those SNPs that are believed to be harmless to ncbi540 protein may be involved in the pathogenesis of diseaseD006527.
34923539		Case Report: diseaseD058437 in an Acutely Anemic 9606.SIGNIFICANCE: The Valsalva maneuver is known to cause pre-diseaseD012166, which have a predilection to affect the macula. Certain conditions may increase the risk of developing diseaseD058437 including diseaseD000740. Knowing these associations can aid in uncovering underlying systemic conditions for which a 9606 may not otherwise be aware. PURPOSE: This case report reviews the presentation of diseaseD058437 and the impacts of acute diseaseD000740 on retinal findings. Recommendations for management are also reviewed and reported. CASE REPORT: A 30-year-old Hispanic man presented to the emergency department for progressing diseaseD018908 over the previous month. He had a history of diseaseD019966 and had not been eating for the previous month except for water intake. He was diagnosed with unconjugated diseaseD006932, diseaseD000740, diseaseD013921, diseaseD019851, diseaseD007008, and hypomagnesia and admitted to the intensive care unit for treatment and observation. He was referred to the eye clinic to be examined for diseaseD012303 because of concern for diseaseD006527. On ophthalmological examination, the 9606 had diseaseD015354 in both eyes attributed to bilateral subinternal limiting membrane macular diseaseD006470 likely due to Valsalva, with acute diseaseD000740 and diseaseD013921 as contributing factors. The 9606 was referred to a retinal specialist, and observation was recommended with follow-up in 3 months. The 9606, unfortunately, never followed up despite multiple attempts to reschedule. CONCLUSIONS: 9606 history and the common location of diseaseD012166 aid in diagnosing diseaseD058437. In this case, the 9606 had a known history of acute diseaseD000740 and diseaseD013921 with a recent history of straining. diseaseD000740, among other systemic conditions, can increase the risk of developing diseaseD058437 after a Valsalva maneuver. Although diseaseD058437 can occur in healthy 9606 without underlying conditions, it is important to rule out other conditions that might present with diseaseD012166 or that may increase the risk of diseaseD058437.
31083157	Negative_Correlation|chemicalD000077143|diseaseD009369; Negative_Correlation|chemicalD017239|diseaseD064726; Negative_Correlation|chemicalD003520|diseaseD064726; Negative_Correlation|chemicalD015251|diseaseD064726; Negative_Correlation|chemicalD017239|diseaseD006527; Negative_Correlation|chemicalD000077143|diseaseD064726; Cotreatment|chemicalD000077143|chemicalD015251; Negative_Correlation|chemicalD017239|diseaseD056486; Negative_Correlation|chemicalD003520|diseaseD009369; Cotreatment|chemicalD000077143|chemicalD003520; Negative_Correlation|chemicalD017239|diseaseD005355	diseaseD001943 in a 9606 with diseaseD006527: A case report.RATIONALE: diseaseD006527 (diseaseD006527) is an diseaseD030342 in which the 9606 usually has a reduced risk of developing diseaseD009369. In particular, with the exception of diseaseD006528 and diseaseD018281, the incidence of diseaseD009369 is significantly lower in diseaseD006527 9606 compared with the general population. This case study presents a rare case of diseaseD006527 complicated with diseaseD001943. 9606 CONCERNS: A 40-year-old 9606 who was diagnosed with diseaseD006527 at 25 years of age found a diseaseC536531 in her left breast. She has a family history of diseaseD009369. DIAGNOSES: Ultrasound and mammography results were highly suggestive of a diseaseD009369. After core needle biopsy, it was confirmed that she had diseaseD001943. INTERVENTIONS: A modified radical mastectomy was performed for the left breast. As the diseaseD009369 was defined as a stage IIa diseaseD064726, the 9606 would have been recommended chemicalD015251/chemicalD003520 + chemicalD000077143 for 8 cycles if diseaseD006527 was not a comorbidity. As the 9606 had diseaseD005355 and diseaseD056486, she was given chemicalD017239 weekly for 6 cycles instead. OUTCOMES: The 9606 showed good tolerance, and has not had a recurrence in 2 years. LESSONS: We reviewed the literature for studies of 9606 with diseaseD006527 complicated with diseaseD009369, and to our knowledge, this is the first report on diseaseD006527 complicated with diseaseD001943. The 9606 received chemotherapy even with diseaseD017093, which suggests that 9606 with diseaseD006527 can be safely treated with chemicalD017239 chemotherapy under close surveillance.
28573989		Evaluation of diseaseD012303 in diseaseD006527 by anterior segment optical coherence tomography.PURPOSE: The purpose of the study is to present anterior segment optical coherence tomography (AS-OCT) as an alternative method of evaluating Kayser-Fleischer (KF) ring in diseaseD006527 (diseaseD006527) not only by ophthalmologists but also by other clinicians dealing with diseaseD006527. MATERIALS AND METHODS: This was a retrospective case series of six diseaseD006527 9606 with KF ring. Evaluation of KF ring was done by naked eye examination using torch light, slit lamp biomicroscopy (SL), and AS-OCT. SL examination was done using a narrow slit of the superior cornea. AS-OCT was done using the Optovue RTvue PremierTM device (Fremont, CA, USA). RESULTS: AS-OCT revealed KF ring as an intense hyperreflective band at the level of Descemet membrane (DM). Color scale of AS-OCT showed KF ring as greenish/greenish yellow/orange yellow/yellowish/red band. Validation of AS-OCT findings was done by second ophthalmologist, medical gastroenterologist, surgical gastroenterologist, and neurophysician. After seeing the first observation, they could identify the AS-OCT features in all pictures with ease. CONCLUSIONS: This is the first observation of KF ring in diseaseD006527 on ASchemicalC051883. On AS-OCT, KF ring is visualized as intense hyperreflectivity at the level of DM in the peripheral cornea. Further, studies are needed to evaluate the usefulness of AS-OCT in diseaseD006527 management.
32228506	Positive_Correlation|diseaseD002805|variantrs1800562##; Association|chemicalD014807|ncbi5741; Positive_Correlation|diseaseD006432|variantrs1800562##; Association|diseaseD006432|ncbi3077; Association|chemicalD007501|diseaseD006432; Association|diseaseD002805|ncbi3077; Association|diseaseD006432|ncbi3077	diseaseC536275 in a 9606 with diseaseD006432.BACKGROUND: Detection of brain-MRI T2/T2* gradient echo images (T2*GRE)-hypointensity can be compatible with diseaseD000090463 and leads to a differential diagnosis work-up including diseaseD019636 with diseaseC548080 (diseaseD006211) and diseaseD006527. Idiopathic or secondary diseaseC536275 can be also associated with diseaseC538190 and brain-MRI T2/T2*GRE-hypointensity. diseaseD006432 (diseaseD006432), characterized by systemic chemicalD007501 loading, usually does not involve the CNS, and only sporadic cases of diseaseD009461 or brain-MRI T2/T2*GRE-hypointensity have been reported. CASE PRESENTATION: A 59-year-old man came to our observation after a diagnosis of diseaseD006432 carried out in another hospital 2 years before. First-level genetic test had revealed a homozygous ncbi3077 variantrs1800562## (variantrs1800562##) mutation compatible with the diagnosis of HFE-related diseaseD006432, thus phlebotomy treatment was started. The 9606 had a history of diseaseD024821, diseaseD003924, diseaseD013967 and severe diseaseD002805. Brain-MRI showed the presence of bilateral T2*GRE hypointensities within globus pallidus, substantia nigra, dentate nucleus and left pulvinar that were considered expression of diseaseD012806. No diseaseD009461 or family history of diseaseD020271 were reported. Neurological examination revealed only mild right-sided diseaseD009127. chemicalD014807-ncbi5741 axis, measurements of serum ncbi1356 and chemicalD003300, and urinary chemicalD003300 were within the normal range. A brain computed tomography (CT) was performed to better characterize the suspected and unexplained diseaseC548080. On the CT images, the hypointense regions in the brain MRI were hyperdense. DNA sequence analysis of genes associated with diseaseC536275 and diseaseD006211 was negative. CONCLUSIONS: This report highlights the importance of brain CT-scan in ambiguous cases of suspected diseaseD012806, and suggests that diseaseD006432 9606 with a severe phenotype, and likely associated with diseaseD002805, may display also diseaseC536275. Further studies are needed to confirm this hypothesis. So far, we can speculate that chemicalD007501 and chemicalD002118 homeostasis could be reciprocally connected within the basal ganglia.
37996345		Efficacy of therapeutic plasma exchange in pediatric cases of diseaseD017114 as an extracorporeal liver support system.BACKGROUND: diseaseD017114 in the pediatric population is often accompanied by deranged metabolism, severe diseaseD001927 and diseaseD001778. A liver transplant is the most viable option for the management of such patients. Therapeutic plasma exchange (TPE) is helpful in improving the liver biochemistry profile, thereby, increasing their likelihood of undergoing a liver transplant METHOD: The study was conducted over a period of 3 years (January 2018 to December 2021). Indications mainly consisted of ALF with diseaseD006501, worsening liver parameters in spite of medical management, and candidacy for undergoing a liver transplant. Plasma exchange was performed daily or alternatively until the patient recovered, succumbed, or was stable enough to undergo a transplant. Biochemical parameters serum chemicalD001663, ALT, AST serum chemicalD000641 serum chemicalD014508, serum chemicalD003404 were recorded before and after TPE sessions. RESULTS: The study group comprised 14 patients of which a total of 28 TPE was performed. There were a total of 5 cases of cryptogenic ALF, 4 of diseaseD006527, 2 cases each of diseaseD007239-related ALF and diseaseD019693, and a single case of drug-induced diseaseD056486. A total of 5 out of 14 patients underwent a liver transplant and amongst the 9 who did not undergo a transplant, 4 patients expired due to diseaseD012772; the remaining 5 were discharged in a stable condition following TPE sessions. The disease-free survival was 78.9% and the transplant-free survival was 35.71%. CONCLUSION: TPE plays a crucial role in improving the biochemistry profile of the liver in children with diseaseD017093.
31920114	Negative_Correlation|chemicalD003300|chemicalD014266; Comparison|chemicalD010396|chemicalD014266; Positive_Correlation|chemicalD010396|diseaseD058186; Negative_Correlation|chemicalD003300|diseaseD006527; Negative_Correlation|chemicalD003300|chemicalD010396; Negative_Correlation|chemicalD010396|diseaseD006527; Negative_Correlation|chemicalD014266|diseaseD006527	Switching Pharmacological Treatment in diseaseD006527: Case Report and Recommendations.Background. Available treatments for diseaseD006527 (diseaseD006527) prevent longterm complications of diseaseC535468 accumulation. Current anti-chemicalD003300 agents include zinc salts, chemicalD010396, and chemicalD014266. 9606 with diseaseD006527 may switch between the agents for a number of reasons. Due to the different mechanisms of action between the copper chelators and zinc salts, transitioning could require a period of overlap and increased monitoring. There are no large studies that investigate the best transition strategies between agents. In this article, we review the treatments for diseaseD006527 and how to monitor for treatment efficacy. Case Summary. The 9606 had been diagnosed with diseaseD006527 for over 20 years prior to establishing care in our Hepatology Clinic. During his initial course, he was transitioned from chemicalD010396 to zinc due to evidence suggesting chemicalD010396 had greater adverse effects in the long term. Later, he was switched to chemicalD014266. His liver enzymes and 24-hour urine chemicalD003300 were monitored. During these years, he intermittently had some financial hardship, requiring him to be on chemicalD010396 rather than chemicalD014266. He also had developed diseaseD058186. Overall, his diseaseD008107 remained under control and he never had signs of decompensated diseaseD005355, but had fluctuations of liver enzymes over the years. Conclusion. Anti-chemicalD003300 treatment for diseaseD006527 has to be tailored to medication side effects profile, 9606's chronic and emerging comorbidities, as well as costs. Transitioning regimens is often challenging, and it requires closer monitoring, with no predictors of response.
33541020	Association|chemicalD003300|diseaseD006527; Association|diseaseD006527|ncbi540; Association|diseaseC535468|ncbi540	[Research progress in gene therapy for diseaseD006527].diseaseD006527 (diseaseD006527) is a kind of inherited single-gene diseaseD030342 in which mutations in the ncbi540 gene cause diseaseC535468. Drug therapy is currently the main treatment method for diseaseD006527. Liver transplantation should be considered for poor drug response or diseaseD017114. However, it faces problems such as medication adherence, adverse reactions and shortage of liver source. Gene therapy in diseaseD006527 may permanently correct abnormal chemicalD003300 metabolism, which is why it is the focus of current research. This article summarizes the research progress of diseaseD006527 around gene therapy vectors and CRISPR/Cas9 gene editing system.
31152642	Positive_Correlation|chemicalD016572|diseaseD016393; Negative_Correlation|chemicalD000069283|diseaseD016393; Negative_Correlation|chemicalD016572|diseaseD008223	Remission of Late-Onset Post-Liver Transplantation diseaseD008228.We describe the clinical course of a 9606 who developed high-grade diseaseD008223 during immunosuppression treatment with chemicalD016572, following liver transplantation. After anti-neoplastic polychemotherapy treatment, the remission of diseaseD008223 was confirmed and maintained for over four years. The 9606, a 27 year old female had liver transplantation at the age of 17, due to diseaseD017114, caused by non-diagnosed diseaseD006527. Nearly seven years post-transplantation, the 9606 was diagnosed with diseaseD016393 (diseaseD016393), potentially induced by Cephalosporin A therapy. After the treatment with chemicalD000069283 and CHOP therapy (r-CHOP protocol), remission was determined using computer tomography. Remission is maintained to date. A review of reported cases of diseaseD008232 (diseaseD008232) in liver transplanted (LT) 9606 showed that the onset of diseaseD008232 is the highest in the first year after transplantation. In addition, remission rates of diseaseD016393 in LT 9606 are not much elaborated in the literature. It is our opinion that the presented case is rare, both from the aspect of timeline of occurrence of the PTLD and the achieved remission, using chemicalD001120-CHOP protocol.
33662781	Association|chemicalD003300|diseaseD006527	Zinc monotherapy for young 9606 with oligosymptomatic diseaseD006527: A single center, retrospective study.BACKGROUND AND AIMS: Few studies have focused on the treatment failure of zinc monotherapy for oligosymptomatic diseaseD006527 (diseaseD006527) 9606. Therefore, we aimed to evaluate the long-term efficacy of zinc monotherapy in oligosymptomatic 9606 and to analyze the possible factors that may influence the outcome of this treatment. METHODS: We retrospectively reviewed the medical records of oligosymptomatic diseaseD006527 9606 who received zinc monotherapy from the time of diagnosis. Then, the characteristics of 9606 who were treated with zinc monotherapy successfully and those who experienced treatment failure were investigated. RESULTS: Forty oligosymptomatic diseaseD006527 9606 were identified that have received zinc monotherapy as initial treatment, with a median age of 3.83 years at the time of diagnosis. 36 (90%) 9606 had abnormal alanine transaminase/aspartate transaminase levels at baseline. None of the 9606 became symptomatic during zinc monotherapy. 28 (70%, Group 1) 9606 were treated with zinc monotherapy successfully for a median period of 2.4 years. In Group 1, serum aminotransferase levels significantly decreased 6 and 12 months after zinc therapy compared to the baseline levels (P <  0.05). 12 (30%, Group 2) 9606 experienced treatment failure with zinc monotherapy due to uncontrolled serum liver enzyme levels, and chemicalD010396 was combined. The baseline 24-hour urine chemicalD003300 levels before treatment were significantly higher in Group 2 compared to that in Group 1 (182.5 vs 90.92 mug /day, P = 0.018). Comparing the age at onset; ncbi1356, serum chemicalD003300, ALT, and ncbi26503 levels; and proportions of abdominal ultrasonography abnormality at baseline between Group 1 and 2 revealed no statistically significant differences. CONCLUSIONS: We found that high initial 24 -h urinary chemicalD003300 levels may lead to treatment failure of zinc monotherapy in oligosymptomatic diseaseD006527 9606. It might be reasonable to follow up liver function tests more closely during zinc monotherapy and to begin combination treatment with chelators early in 9606 with high level of 24 -h urinary chemicalD003300.
33181595		Evoked Potentials in 9606 With diseaseD006527.INTRODUCTION: diseaseD006527 (diseaseD006527) is an diseaseD020739 presenting with a variety of symptoms but commonly as a diseaseD017093 or diseaseD004194. Abnormal evoked responses are constantly found among 9606 with neurologic manifestations and sometimes in 9606 with hepatic presentation or in presymptomatic siblings. The aim of our study was to assess visual and brainstem auditory evoked potentials (BAEP) in 9606 with various presentation of diseaseD006527. METHODS: Visual evoked potentials (VEP) were performed in 36 diseaseD006527 9606 and BAEP were done in 37 diseaseD006527 9606. RESULTS: Brainstem auditory evoked potentials were normal in 9606 with isolated hepatic presentation, whereas they were abnormal in 93.5% of 9606 with diseaseD009461. There was significant prolongation of the latencies of the III and V waves and of the interpeak III-V and I-V latencies in comparison with the healthy controls (T-test P = 0). Abnormal VEP were observed in 81% of the 9606 including six of seven neurologically asymptomatic 9606. The values of N75, P100, and N145 latencies were significantly longer in all 9606 than in healthy controls (T-test). CONCLUSIONS: The data showed that VEP and BAEP are more frequently abnormal in diseaseD006527 than previously reported. The abnormal VEP and BAEP even without clinical signs and brain diseaseD000014 point to subclinical involvement of visual and auditory pathways caused by diseaseC535468. Because VEP and BAEP are noninvasive and widely available, they should be performed in all patents with diseaseD006527.
30026388	Negative_Correlation|chemicalD003300|chemicalD010396; Negative_Correlation|chemicalD010396|diseaseD006527	Exome sequencing of an adolescent with diseaseD065626 identifies a clinically actionable case of diseaseD006527.Diagnostic whole-exome sequencing has proven highly successful in a range of rare diseases, particularly early-onset genetic conditions. In more common conditions, however, exome sequencing for diagnostic purposes remains the exception. Here we describe a 9606 initially diagnosed with a common, complex diseaseD008107, diseaseD065626 (diseaseD065626), who was determined to have diseaseD006527 (diseaseD006527) upon research-related exome sequencing. The 9606 presented as a 14.5-yr-old adolescent with chronically elevated aminotransferases, normal ncbi1356, and histologic examination consistent with diseaseD065626 with advanced diseaseD005355. He was enrolled in a large longitudinal study of 9606 with diseaseD065626 and was found to have diseaseD006527 by exome sequencing performed 4 yr later. This new diagnosis, confirmed clinically by 24 h urine chemicalD003300 quantification, led to a change in the therapy from lifestyle counseling to directed treatment with chemicalD010396, a chemicalD003300 chelating agent. In this case, the likelihood of making the correct diagnosis and thereby choosing the appropriate treatment was increased by exome sequencing and careful interpretation. This example illustrates the utility of exome sequencing diagnostically in more common conditions not currently considered as targets for genome-wide evaluation and adds to a growing body of evidence that 9606 diagnosed with more common conditions often in fact have rarer genetically determined syndromes that have escaped clinical detection.
29715505	Negative_Correlation|chemicalD000255|chemicalD003300; Association|chemicalD003300|diseaseC564971; Association|chemicalD003300|diseaseD006527; Association|chemicalD017382|diseaseC564971; Association|chemicalD003300|chemicalD013438; Negative_Correlation|chemicalD003300|diseaseD009447; Association|chemicalD013438|diseaseC535468	The exceptional sensitivity of brain diseaseC564971 to chemicalD003300.diseaseD006527 (diseaseD006527) is characterized by a disrupted chemicalD003300 homeostasis resulting in dramatically increased chemicalD003300 levels, mainly in liver and brain. While chemicalD003300 damage to diseaseC564971 is an established feature in diseaseD006527 livers, much less is known about such detrimental chemicalD003300 effects in other organs. We therefore assessed the mitochondrial sensitivity to chemicalD003300 in a tissue specific manner, namely of isolated 10116 liver, kidney, heart, and brain diseaseC564971. Brain diseaseC564971 presented with exceptional chemicalD003300 sensitivity, as evidenced by a comparatively early membrane potential loss, profound structural changes already at low chemicalD003300 dose, and a dose-dependent reduced capacity to produce chemicalD000255. This sensitivity was likely due to a chemicalD003300-dependent attack on free protein chemicalD013438 and due to a decreased chemicalD003300 reactive defense system, as further evidenced in diseaseD009447 0019 cells. In contrast, an increased production of chemicalD017382 was found to be a late-stage event, only occurring in destroyed diseaseC564971. We therefore propose mitochondrial protein chemicalD013438 as major targets of diseaseC535468.
28433099		Other organ diseaseC564676 and clinical aspects of diseaseD006527.diseaseD006527 (diseaseD006527) is a rare diseaseC535468 that presents mainly with diseaseC564678. chemicalD003300 accumulates not only in the liver and brain, but also in other organs. diseaseD017093 can also be the cause of secondary impairment of other tissues. Therefore, the clinical manifestation of diseaseD006527 may be renal, cardiac, skin, osteoarticular, or endocrinologic and include other organ disturbances. diseaseD007674 include diseaseD005198 (e.g., diseaseD000141, diseaseD000608) and diseaseD053040. diseaseD018488 is a common manifestation in 9606 with diseaseD006527. diseaseD006331 may include diseaseD001145, diseaseD009202, and diseaseD001342. Different endocrine system manifestations, such as diseaseD007246 or repeated diseaseD000022, diseaseD006130, and diseaseD007011, are observed. Other important clinical aspects of diseaseD006527 include pancreas diseaseC564676, diseaseD007154, the presence of diseaseD008067, and diseaseD012871. Although other organ diseaseC564676 is not common in diseaseD006527 and usually not severe, delayed diagnosis may lead to irreversible changes in organs and tissues. Therefore, awareness of other possible diseaseD006527 presentations is important in the differential diagnosis of diseaseD006527.
36456202		Reversible Diffusion-Weighted Imaging High Intensity Signal in diseaseD006527.
29806946	Association|chemicalD003300|diseaseD006527; Negative_Correlation|chemicalC020809|diseaseD006527; Negative_Correlation|chemicalC020809|diseaseD056486; Association|chemicalD003300|diseaseC566858	chemicalC020809 - an investigational drug for the treatment of diseaseD006527.INTRODUCTION: diseaseD006527 (diseaseD006527) is a diseaseD030342 in which excess toxic chemicalD003300 accumulates in the liver, brain, and other tissues leading to severe and life-threatening symptoms. diseaseC566858 can be assessed as non-ceruloplasmin-bound chemicalD003300 non-ceruloplasmin-bound chemicalD003300 (NCC) in blood. Current therapies are limited by efficacy, safety concerns, and multiple-daily dosing. Areas covered: This article reviews the literature on chemicalC020809 (chemicalC020809), an oral first-in-class chemicalD003300-protein-binding agent in development for the treatment of diseaseD006527. Expert opinion: In a proof-of-concept phase II trial, once-daily chemicalC020809 over 24 weeks rapidly lowered NCC levels and this was accompanied by improved neurological status without apparent initial drug-induced paradoxical worsening, reduced disability, stable diseaseD056486, with a favorable safety profile. WTX101 directly removes excess chemicalD003300 from intracellular hepatic chemicalD003300 stores and also forms an inert tripartite complex with chemicalD003300 and ncbi213 in the circulation and promotes biliary chemicalD003300 excretion. These mechanisms may explain the rapid biochemical and clinical improvements observed. A phase III trial of chemicalC020809 is ongoing and results are eagerly awaited to confirm if chemicalC020809 can improve the treatment of this devastating disease.
28753182	Negative_Correlation|chemicalD010396|diseaseD006527; Positive_Correlation|diseaseD006527|variant#1356#p.H1069Q; Association|diseaseD006527|ncbi1356	Early Onset of diseaseD006527: Diagnostic Challenges.OBJECTIVES: The aim of the study was to analyze the clinical presentations, diagnosis, and treatment of 9606 ages <=5 years with early onset diseaseD006527 (diseaseD006527). METHODS: Data from 143 pediatric 9606 with diseaseD006527 treated at our center between January 1996 and November 2015 were retrospectively analyzed. RESULTS: A review of the 143 pediatric 9606 with diseaseD006527 identified 21 (10 girls, 11 boys) with first symptoms or abnormal liver function test results at age <=5 years. The diagnosis of diseaseD006527 was confirmed in 8 9606 younger than 5 years. At baseline the mean serum alanine aminotransferase level was 222 U/L and the mean serum aspartate aminotransferase level was 130 U/L. The mean serum ncbi1356 concentration in 16 tested 9606 was <20 mg/dL. Of the 15 9606 who underwent urinary chemicalD003300 excretion testing, 8 had levels between 40 and 100 mug/day, with only 4 having levels >100 mug/day. Liver chemicalD003300 quantification was >250 mug/g dry weight in 16 9606. The most common mutation was variant#1356#p.H1069Q, with compound heterozygosity in 5 9606 and homozygosity in 9. Sixteen 9606 were treated with zinc salts and 5 with chemicalD010396. Both treatments were effective, with no serious side effects observed after 3 to 24 months. CONCLUSIONS: diseaseD006527 can present as early as 2 years of age. Because biochemical tests may be less sensitive in very young children, diagnoses may require a combination of tests. If molecular tests are inconclusive, liver chemicalD003300 content should be measured.
34357516	Association|chemicalD003300|diseaseD006527; Association|chemicalD003300|diseaseD030342; Negative_Correlation|chemicalD014266|diseaseD006527	Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and chemicalD014266 in Healthy Subjects.BACKGROUND AND OBJECTIVE: diseaseD006527 (diseaseD006527) is an diseaseD030342 of chemicalD003300 metabolism. Chelation of excessive chemicalD003300 is recommended but data on the pharmacokinetics of chemicalD014266 are limited. The aim of this study was to compare the pharmacokinetics of a new trientine tetrahydrochloride formulation (TETA 4HCl) with those of an established chemicalD014266 (chemicalD014266 2HCl) salt. METHODS: A randomised single-centre crossover study to evaluate the pharmacokinetics, safety and tolerability of two different oral formulations of chemicalD014266 (TETA 4HCl tablets vs chemicalD014266 2HCl capsules) in 23 healthy adult subjects receiving a single dose equivalent to 600 mg of chemicalD014266 base was performed. RESULTS: Following oral administration, the median time to reach maximum plasma concentration (Tmax) was 2.00 h (TETA 4HCl) and 3.00 h (chemicalD014266 2HCl). The rate (maximum plasma concentration [Cmax]) and extent (area under the plasma concentration-time curve from time zero to infinity [AUC0- ]) of absorption of the active moiety, chemicalD014266, were greater (by approximately 68% and 56%, respectively) for TETA 4HCl than for the chemicalD014266 2HCl formulation. The two formulations presented a similar terminal elimination rate (lambdaz) and a similar terminal half-life (t1/2) for chemicalD014266. Differences between TETA 4HCl and chemicalD014266 2HCl in the levels of the two main mono- and diacetylated metabolites were less than seen for chemicalD014266. For both tested formulations, healthy male volunteers demonstrated higher chemicalD014266 plasma levels but lower mono- and diacetylated metabolite levels compared with females, with no sex differences in terminal half-life (t1/2) observed. Single oral doses of both formulations were safe and well tolerated. CONCLUSIONS: Compared with an identical dose of a chemicalD014266 2HCl formulation, the TETA 4HCl formulation provided more rapid absorption of chemicalD014266 and greater systemic exposure in healthy subjects. Clinical Trials Number EudraCT # 2015-002199-25.
30893721	Negative_Correlation|chemicalC030691|diseaseD006527; Negative_Correlation|chemicalD010396|diseaseD009461; Negative_Correlation|chemicalD010396|diseaseD006527; Negative_Correlation|chemicalD003300|diseaseD006527	[Clinical characteristics of the diseaseD006527 carrier].Objective: To study the clinical symptoms, diseaseC535468 and imaging characteristics of diseaseD006527 (diseaseD006527) carriers and to explore the treatment strategy of diseaseD006527 carriers. Methods: Forty diseaseD006527 carriers, 40 diseaseD006527 9606 and 20 normal controls from the First Affiliated Hospital of Sun Yat-sen University from July 2007 to May 2018 were included. The modified Young scale was used for neural symptom scoring, and 9606 grading of liver function, mental symptoms rating scale, magnetic resonance imaging (MRI) scan, susceptibility weighted imaging (SWI) inspection, metal metabolism tests were also applied to all the included subjects. Corrected phase (CP) was measured by SWI. diseaseD006527 carriers were divided into symptomatic group and asymptomatic group. Symptomatic diseaseD006527 carriers were treated with chemicalD010396 for 2 weeks and chemicalC030691 for 3 months, then their diseaseD009461, liver function grade, metal metabolism index were rechecked. Results: Six diseaseD006527 carriers presented with some clinical symptoms, including 5 with diseaseD009461 and 4 with diseaseD017093. The score of Hamilton diseaseD001007 (HAMA) scale of symptomatic diseaseD006527 carriers was higher than that of normal control group (P=0.021). 85% of carriers had ncbi1356 level less than 0.26 g/L. 80% of carriers had serum chemicalD003300 between normal controls and diseaseD006527 9606. The free chemicalD003300 level of diseaseD006527 carriers was lower than that of diseaseD006527 9606 (P=0.012, 0.019). Urinary chemicalD003300 in symptomatic diseaseD006527 carriers was higher than normal controls (P=0.047). The CP values of thalamus, globus pallidus and putamen in symptomatic diseaseD006527 carriers were lower than those in normal control group. After treatment with chemicalD010396 in symptomatic diseaseD006527 carriers, urinary chemicalD003300 was higher than that before treatment (P=0.036). After treatment, the liver enzymes of symptomatic diseaseD006527 carriers returned to normal, and the score of modified Young scale was lower than before treatment (P=0.031). Conclusions: Mild diseaseC535468 is seen in diseaseD006527 carriers. A few carriers have diseaseD009461 such as diseaseD014202, or diseaseD017093 such as diseaseD056486. Abnormal diseaseC535468 is more serious in symptomatic diseaseD006527 carriers than in asymptomatic diseaseD006527 carriers. Symptomatic diseaseD006527 carriers can be treated with chemicalC030691.
30693797	Association|diseaseD006527|ncbi11979; Association|diseaseD006527|ncbi540; Association|chemicalD003300|diseaseD006527; Association|chemicalD003300|ncbi540	A Gene Therapy Approach to Improve chemicalD003300 Metabolism and Prevent diseaseD056486 in a 10090 Model of diseaseD006527.diseaseD006527 (diseaseD006527), an diseaseD030342 caused by mutations in a copper-transporting P-type ATPase (ncbi11979), causes severe diseaseD056486. This disease is currently treated with the lifelong use of chemicalD003300 chelation therapy, which has side effects and does not fix chemicalD003300 metabolism. Here, we thoroughly characterized a 10090 model of diseaseD006527, the toxic milk 10090, and used the model to test a gene therapy approach for treating diseaseD006527. diseaseD006527 10090 accumulated chemicalD003300 in the liver from birth; severe diseaseC535468 and concurrent diseaseD008107 were evident by 2 months of age. Intravenously administering an adeno-associated viral (AAV) 8 vector expressing a codon-optimized version of the 9606 ncbi540 transgene into 2-month-old diseaseD006527 10090 significantly decreased liver chemicalD003300 levels compared with age-matched, uninjected, diseaseD006527 10090. We also observed a significant dose-dependent decrease in diseaseD008107. Male 10090 injected with 1011 genome copies of AAV8 vector showed only mild histopathological findings with a complete lack of diseaseD008103. Therefore, we conclude that administering gene therapy at the early stages of disease onset is a promising approach for reducing diseaseD056486 and correcting chemicalD003300 metabolism in diseaseD006527.
29050651		[diseaseD009069: An update].diseaseD009069 (diseaseD014202, diseaseD002819, diseaseD004421, diseaseD020323, and diseaseD009207) are related to basal ganglia and/or interconnected brain diseaseD001927 dysfunction. Clinical examination is a key point in order to characterize the abnormal movement and identify associated signs that can guide etiological approach. diseaseD007049 will be systematically ruled out before conducting additional investigations (brain MRI, electrophysiological studies). diseaseD006527, but also other treatable diseaseD008659, and diseaseC538437 will be systematically considered. Therapeutic management is symptomatic and based on specific oral drugs appropriate to each diseaseD009069. In some cases, radiosurgery and deep brain stimulation should be helpful, especially for diseaseD014202 and generalized diseaseD004421.
35706098	Association|chemicalD003300|diseaseD006527	Long-Term Urinary chemicalD003300 Excretion and Exchangeable Copper in Children With diseaseD006527 Under Chelation Therapy.OBJECTIVES: Determining 24-hour urinary chemicalD003300 excretion (UCE) levels is useful for diagnosing diseaseD006527 (diseaseD006527) and for treatment monitoring. Exchangeable copper (ExC) is a novel potential marker, but its long-term changes have never been described in 9606 under chelation therapy. Our aim was to describe the long-term changes in ExC levels compared to UCE levels in symptomatic diseaseD006527 pediatric 9606 under chelation therapy. METHODS: A retrospective, descriptive, and analytical study including all 9606 under 18 years of age, diagnosed between 2006 and 2020, and treated with chelation therapy was conducted at the National Reference Center for diseaseD006527 in Lyon. ncbi1356 levels, serum chemicalD003300, 24 h-UCE, ExC, and liver enzymes at diagnosis and during follow-up were analyzed. RESULTS: Our study included 36 9606, predominantly with hepatic form of diseaseD006527 (n = 31). The median [interquartile range (IQR)] age at diagnosis was 10.5 (8.4-13.1) years, and the median (IQR) follow-up duration was 6.3 (3.3-8.8) years. At diagnosis, the median (IQR) ExC value was 1.01 (0.60-1.52) micromol/L. There was a significant decrease during the first year of chelation treatment ( P = 0.0008), then a stabilization. The median (IQR) ExC values was 0.38 (0.22-0.63) micromol/L at 12-18 months and 0.43 (0.31-0.54) micromol/L at 5 years of chelation treatment ( P = 0.4057). Similarly, there was a significant decrease in 24-hour UCE ( P < 0.001) during the first year of chelation treatment, then a stabilization. CONCLUSIONS: Our study showed a significant decrease in ExC and 24-hour UCE levels during the first year of follow-up; The dynamics of both biomarkers were similar along the follow-up, demonstrating their usefulness in clinical practice for monitoring diseaseD006527.
28987255		Genetic Testing in diseaseD008107: What to Order, in Whom, and When.Genetic causes of diseaseD008107 lead to a wide range of presentations, from mildly abnormal liver tests to diseaseD017114. This article discusses the indications for testing and what to test for diseaseD006432, progressive diseaseC535932, diseaseC535933, diseaseC531854, diseaseD005878, diseaseD019896, and diseaseD006527.
34286869	Positive_Correlation|chemicalD003300|diseaseD006527; Positive_Correlation|chemicalD003300|diseaseD006331	diseaseD006331 in diseaseD006527: Review of the literature and description of three cases of diseaseD003645.diseaseD006527 (diseaseD006527) is a rare genetic condition that results from a build-up of chemicalD003300 in the body. It requires life-long treatment and is mainly characterized by hepatic and neurological features. chemicalD003300 accumulation has been reported to be related to the occurrence of diseaseD006331, although little is known regarding this association. We have conducted a systematic review of the literature to document the association between diseaseD006527 and diseaseD006331. Thirty-two articles were retained. We also described three cases of diseaseD003645. Cardiac manifestations in diseaseD006527 include diseaseD009202 (mainly diseaseD020257, diseaseD006984, and diseaseD018487, and less frequently diseaseD018487), increased levels of troponin, and/or brain natriuretic peptide, electrocardiogram (ECG) abnormalities, and rhythm diseaseD054537, which can be life-threatening. diseaseD054969 has also been reported. The mechanism of diseaseD006331 in diseaseD006527 has not been elucidated. It may be the result of chemicalD003300 accumulation in the heart, and/or it could be due to a toxic effect of chemicalD003300, resulting in the release of free oxygen radicals. 9606 with signs and/or symptoms of diseaseD006331 or who have cardiovascular risk factors should be examined by a cardiologist in addition to being assessed by their interdisciplinary treating team. Furthermore, ECG, cardiac biomarkers, echocardiography, and 24-hours or more of Holter monitoring at the diagnosis and/or during the follow-up of 9606 with diseaseD006527 need to be evaluated. Cardiac magnetic resonance imaging, although not always available, could also be a useful diagnostic tool, allowing assessment of the risk of diseaseD001145 and further guidance of the cardiac workup.
33097693	Association|diseaseD006528|ncbi1499	Prime editing for functional repair in 9606-derived disease models.Prime editing is a recent genome editing technology using fusion proteins of Cas9-nickase and reverse transcriptase, that holds promise to correct the vast majority of diseaseD030342. Here, we develop prime editing for primary adult stem cells grown in organoid culture models. First, we generate precise in-frame deletions in the gene encoding ncbi1499 (ncbi1499) that result in proliferation independent of Wnt-stimuli, mimicking a mechanism of the development of diseaseD006528. Moreover, prime editing functionally recovers disease-causing mutations in intestinal organoids from 9606 with DGAT1-deficiency and liver organoids from a 9606 with diseaseD006527 (ATP7B). Prime editing is as efficient in 3D grown organoids as in 2D grown cell lines and offers greater precision than Cas9-mediated homology directed repair (HDR). Base editing remains more reliable than prime editing but is restricted to a subgroup of pathogenic mutations. Whole-genome sequencing of four prime-edited clonal organoid lines reveals absence of genome-wide off-target effects underscoring therapeutic potential of this versatile and precise gene editing strategy.
32624691		diseaseD005355 in diseaseD006527 is characterized by diseaseD008107, diseaseD007970 and diseaseD013921.Background: 9606 with diseaseD006527 (diseaseD006527) progress to diseaseD005355 at an early age but have good prognoses. This study aimed to delineate hepatic features in diseaseD006527 9606 with or without diseaseD005355. Methods: Medical data were retrospectively collected from 27 July 2015 to 27 June 2018. diseaseD006527 9606 were divided into two groups based on whether or not they progressed to diseaseD005355. Liver function, diseaseD006975 features and hematocytopenia rates were compared between groups. Results: The study enrolled 119 diseaseD006527 9606 with diseaseD005355 and 53 diseaseD006527 9606 without diseaseD005355. There were no differences between groups for liver enzyme levels or incidence rates of diseaseD012303 (all P > 0.05). diseaseD001201 and diseaseD006501 were nearly absent in both groups, and almost all 9606 were Child-Pugh group A. However, diseaseD006527-associated diseaseD000094724 9606 had a higher prothrombin time (beta = 0.908, P = 0.004) and international normalized ratio (beta = 0.089, P = 0.040), wider portal vein diameter (beta = 1.330, P < 0.001), and an increased risk of diseaseD013163/splenectomy (odds ratio [OR] = 4.36, 95% confidence interval [CI]: 2.15-8.84, P < 0.001). Moreover, diseaseD006527-associated diseaseD000094724 9606 have significantly increased risks of diseaseD007970 (OR = 2.30, 95% CI: 1.00-5.25, P = 0.049) and diseaseD013921 (OR = 6.89, 95% CI: 2.01-23.59, P = 0.002). Conclusions: Despite presenting good outcomes, mild diseaseD014947, and good hepatic metabolic function, diseaseD006527-associated diseaseD000094724 9606 show more serious impairment of hepatic synthetic function, wider portal vein diameter, and higher risk of diseaseD013163 due to diseaseD006975.
32181965		Semiquantitative Scale for Assessing diseaseD001927 in diseaseD006527: A Validation Study.BACKGROUND: MRI is a sensitive method for the assessment of diseaseD001927 in diseaseD006527, that is, diseaseC535434, T2 hypointensities, and diseaseD001284, but a validated scoring system for the classification of radiological severity is lacking. The objective of this study was to develop and validate a brain MRI visual rating scale for diseaseD006527. METHODS: The proposed diseaseD006527 brain MRI severity scale consists of acute diseaseD064420 and chronic damage subscores from predefined structures. The former, calculated by summing scores of diseaseC535434 (excluding cavitation), is likely to be partially reversible with treatment. The latter, representing the sum of scores of T2 hypointensities and diseaseC566985, reflects pathology that is not readily reversible. Validation was performed on MRI scans acquired using 1.5T system from 39 diseaseD006527 9606 examined at baseline and after 24 months on anticopper treatment. Intraclass correlation coefficients of 5 ratings from 3 raters were calculated. Temporal evolution of the MRI severity score and its association with clinical severity, assessed using the Unified diseaseD006527 Rating Scale part III, was calculated. RESULTS: Intrarater and interrater agreement were good (r > 0.93; P < 0.001; and r > 0.74; P < 0.001, respectively). In neurologic diseaseD006527 9606, the total MRI severity score improved over 2 years (P = 0.032), mainly because of reduced acute diseaseD064420 (P = 0.0015), whereas the chronic damage score deteriorated (P = 0.035). Unified diseaseD006527 Rating Scale part III score was positively associated with chronic damage and total score at baseline (P = 0.005 and P = 0.003, respectively) and in month 24 (P < 0.001 and P = 0.001, respectively). CONCLUSIONS: The diseaseD006527 brain MRI severity scale is a simple, reliable, and valid instrument that allows semiquantitative assessment of radiological diseaseD006527 severity.   2020 International diseaseD009069 Society.
34047646	Association|chemicalD012834|ncbi1356; Positive_Correlation|chemicalD012834|diseaseD000309; Positive_Correlation|chemicalD012834|diseaseC536004; Association|chemicalD003300|chemicalD012834; Negative_Correlation|chemicalC586932|diseaseC536378	Serum ncbi1356 monitoring in a case of chemicalD012834 intoxication due to intravenous chemicalD012834 infusion.INTRODUCTION: chemicalC586932 packaged as a dietary supplement is readily available online and is thought to be safe. Literature describing its diseaseD064420 in 9606 is scarce. CASE REPORT: A 47-year-old man presented to us for diseaseD020234. He had unremarkable past health except diseaseC536378. He further volunteered a history of receiving chronic oral and intravenous administration of chemicalC586932. We confirmed his plasma chemicalD012834 was 1200-fold elevated, measuring 11990 nmol/L (normal < 10 nmol/L). He had deranged liver function tests, and liver biopsy showed distorted acinar architecture, bridging diseaseD005355 and lymphocytic infiltrate with chemicalD012834 particles clustering along the vascular endothelium and portal venules. Brain magnetic resonance imagining showed features of mineralization over bilateral globus pallidi. There was biochemical evidence of central diseaseD000309, intracellular diseaseD019190 and diseaseC536004 (<0.05 g/L). Gradual clinical and biochemical improvement was noted after chemicalD012834 cessation: his plasma chemicalD012834 dropped to 4800 nmol/L (3 months) and 1650 nmol/L (12 months), and serum ncbi1356 reverted to 0.13 g/L (10 months) and 0.29 g/L (20 months). CONCLUSIONS: The potential effects of chemicalD012834 to liver and chemicalD003300 metabolism were shown in this case. Serum ncbi1356 also serves as a surrogate marker in monitoring chemicalD012834 intoxication.
32745371	Negative_Correlation|chemicalD010396|diseaseD008107; Negative_Correlation|chemicalD010396|diseaseD006527; Negative_Correlation|chemicalD010396|diseaseD058625	Effect of chelation therapy in pediatric diseaseD006527: Liver and endoscopic outcome.BACKGROUND: As there is paucity of exclusive literature on pediatric hepatic diseaseD006527 (diseaseD006527), this study was undertaken to evaluate the efficacy of chelation on hepatocellular function and diseaseD006975 in diseaseD006527. METHODS: diseaseD006527 9606 with >=9 months of follow-up were evaluated for response to chelation therapy in the following categories: (a) complete remission, (b) partial remission (c) progression of disease; (d) diseaseD064420. Pediatric diseaseD058625 (diseaseD058625), Nazar and New diseaseD006527 Index scores were compared. Hemodynamically stable 9606 underwent esophagogastroduodenoscopy (baseline and surveillance) and received prophylaxis (primary or secondary). Endoscopic outcome was assessed at follow-up. RESULTS: Of the 111 diseaseD006527 children (aged 9 [3-15] years; diseaseD058625 score 16 [-11 to 60]), 65 with follow-up of 3.6 (0.8-12) years on chelation (83% chemicalD010396 monotherapy, 17% chemicalD010396 and zinc) were analyzed. 81% had severe disease at presentation. Favorable outcome (complete and or partial remission), progression of disease and diseaseD064420 were seen in 71%, 29% and 10.8%, respectively. Two-thirds had diseaseD004932 which did not show progression. Large diseaseD004932 (16%) were effectively downgraded in 3 (2-6) therapeutic endoscopic sessions. Nazar score and diseaseD058625 score at baseline were independent predictors of outcome with favorable correlation with each other (r = .864, P < .001). diseaseD058625 cutoff 9.45 (AUC: 71%, sensitivity: 87%, specificity: 50%; P = .009) and Nazar score cut off 3.5 (AUC: 68%, sensitivity: 83%, specificity: 50%; P = .02) were associated with poor prognosis. CONCLUSIONS: Despite severe diseaseD008107, the majority of hepatic diseaseD006527 can be managed on chemicalD010396 monotherapy. diseaseD058625 score and Nazar score effectively determine the outcome.
